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TBD 1,3,4-triazabicyclo[4.4.0]dec-5-ene 
TBHP tert-butyl hydroperoxide 
TBME tert-butyl methyl ether 
Tf  trifluoromethanesulfonyl (triflyl) 
TFA  trifluoroacetic acid 
TFAA trifluoroacetic anhydride 
TFE 2,2,2-trifluoroethanol 
THF  tetrahydrofuran 




tR retention time 
Ts  p-toluenesulfonyl (tosyl) 
UV  ultraviolet 
v/v volume to volume 
w  weak 
w/v weight to volume 
X anionic ligand or halide 
λ  wavelength 
µ micro 
 






Enantioselective Synthesis of gem-Disubstituted N-Boc 
Diazaheterocycles via Decarboxylative Asymmetric Allylic Alkylation† 
 
  
1.1   INTRODUCTION AND BACKGROUND 
 
The catalytic decarboxylative allylic alkylation, originally reported by Tsuji and 
Saegusa in 1980,1,2 is a powerful transformation to effect C–C bond formation between 
an enolate precursor and an allyl group (Scheme 1.1A). However, an enantioselective 
version of the reaction was not developed until 2004 by the Tunge and Stoltz groups, who 
reported enantioselective alkylations of acyclic esters and cyclic allyl enol carbonates 
using DACH-Trost ligand and (S)-t-BuPHOX, respectively (Scheme 1.1B & C).3,4 In 
2005, Trost reported a similar carbocyclic system, though using the ANDEN phenyl trost 
ligand to achieve high stereoselectivity.5,6 In an important advance, the Stoltz group in 
2005 reported the DAAA of β-keto allyl esters, which significantly expanded the 
substrate scope of this  
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transformation; such bench stable ketoesters can be alkylated under mild basic conditions  
to afford a variety of decarboxylative alkylation substrates that would normally be 
difficult to access by other means (Scheme 1.1D).7  
 
Scheme. 1.1 Key Developments in Decarboxylative Allylic Alkylation Reactions 
          
Since these fundamental developments in asymmetric decarboxylative alkylation, 
numerous groups have further contributed to the expansion of this methodology to 
encompass a variety of acyclic and cyclic substrates.8,9 Summarized below in Table 1.1 
are some of the many gem-disubstituted cyclic products that our laboratory has 
synthesized utilizing the DAAA reaction, highlighting the incredible versatility of this 






A. Tsuji’s Pd-catalyzed decarboxylative allylic alkylation (1980)X









up to 94% yield














up to 96% yield





D. Stoltz’s Pd-catalyzed DAAA of allyl β-keto esters (2005)X
up to 88% ee
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Table. 1.1 Chiral α-disubstituted carbocycles/lactams accessible by decarboxylative allylic alkylation  
 
Despite the incredibly broad substrate scope of this reaction, there is still room for 
innovation, including novel medicinally relevant cyclic scaffolds, and the next frontier: 
acyclic scaffolds.17 In this chapter, we describe the extension of the DAAA reaction 
toward Boc-protected six-membered diazaheterocycles, including piperazinones and 
tetrahydropyrimidinones. Then, in the accompanying two appendices, we describe the 























































X = CH2, N




Up to 99% yield










reference 11 reference 11 reference 16 reference 14
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1.2   PIPERAZINONE and TETRAHYDROPYRIMIDINONE DAAA 
 Nitrogen containing heterocycles are ubiquitous components of biologically 
active small molecules.18 For instance, piperazine, a representative diazaheterocycle, is 
the third most prevalent heterocycle in small molecule pharmaceuticals18 and can be 
found in bioactive molecules such as the antiviral natural product Herquline A,19 
blockbuster psychiatric drug aripiprazole,20 and the HIV integrase inhibitor 
dolutegravir21,22 (as the oxidized counterpart, piperazin-2-one) (Fig. 1.1). 
 
Fig. 1.1 Representative piperazine and piperazine-2-one pharmaceuticals and natural products. 
 
In the field of medicinal chemistry and fragment-based drug discovery, an 
emerging paradigm to enhance drug-like properties of small molecules involves reducing 
molecular flatness by incorporating chiral centers.23–27 This method of increasing 
molecular complexity can enhance binding affinity and specificity for a target, as 
receptor-ligand binding is often defined by three dimensional contacts.24 Furthermore, 
depending on the chemical composition of the chiral center, other properties such as 
metabolism, aqueous solubility, and cell-penetration may be optimized.23 The prevalence 
of piperazine in bioactive molecules makes it an excellent scaffold upon which to 
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of four carbon atoms in the piperazine ring could dramatically alter physicochemical 
properties (Fig. 1.2). Despite this potential, there are no gem-disubstituted piperazines 
among the current 98 FDA approved piperazine-containing non-natural product derived 
drugs.28 Error! Reference source not found. In contrast, a significant number contain mono-
substituted piperazines, which can be prepared through a variety of strategies,29–39 
including cyclization of chiral precursors, enantioselective hydrogenation of 
pyrazines,32,33 palladium-catalyzed cyclizations,34–36 or asymmetric lithiation.37,38  
 
Fig. 1.2 Advantages of chiral gem-disubstituted piperazines 
 
The dearth of piperazine gem-disubstitution in the pharmacopoeia highlights the 
significant challenge of installing fully substituted chiral centers into diazaheterocycles. 
The state of the art is perhaps best exemplified by the Bode laboratory’s extensive 
development of tin (SnAP) and silicon (SLAP) coupling reagents to generate spiro-
substituted piperazines (Scheme 1.2A).40–42 However, this method is not yet 
enantioselective and involves potentially toxic tin reagents. Other non-enantioselective 
methods to synthesize gem-disubstituted piperazines include [4+2] cycloadditions of 1,2 
diamines with propargyl alcohols developed by Rawal (Scheme 1.2B),34 and the ring 
expansion of oxetane spirocycles by Carreira (Scheme 1.2C).43  
To our knowledge, the only method enabling the highly enantioselective synthesis 
of gem-disubstituted piperazines was published by our group in 2015.15Error! Reference source 









Augmented properties: specificity, metabolism, solublity, permeability
Absent in all 98 FDA-approved piperazine containing drugs6
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Scheme. 1.2 Existing approaches for gem-disubstituted piperazines and piperazinones 
 
 
palladium-catalyzed decarboxylative asymmetric allylic alkylation reaction to synthesize 
chiral α,α-disubstituted N4-benzylated piperazin-2-ones (Scheme 1.2D). These piperazin-
2-ones could then be reduced into desirable chiral gem-disubstituted piperazines. 
However, we encountered two issues during the course of our attempts to utilize this 
method to synthesize disubstituted piperazines for medicinal chemistry purposes: first, 









Cu(OTf)2 (10 mol %)












R8Pd2(dba)3 (5 mol %)
(S)-(CF3)3-t-BuPHOX (12.5 mol %)
PhMe (0.014 M)




R9 = Bn or PMB




D. Decarboxylative Asymmetric Allylic Alkylation (Stoltz 2015)
R8 = Me, Et, iBu, Bn, CH2OBn, 
Up to 96% ee
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Up to 20:1 dr
Currently not enantioselective
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synthesis via nucleophilic side reactions, leading to low yields of products. As a result, 
we failed to synthesize many desired substrates via standard enolate functionalization of 
the dicarbonyl precursor.  Instead, we resorted to a low-yielding 5-step convergent 
sequence beginning from an amino acid (Scheme 1.3A). As a result, our substrate scope 
displayed limited functional group diversity. Second, noting that heterocycles such as 
piperidines, pyrollidines, and piperazines are prevalent in compounds of medicinal 
interest, we initiated a medicinal chemistry program to explore their utility in the context 
of cancer and infectious disease therapeutics. With a robust method of DAAA to generate 
chiral gem-disubstituted versions of medicinally relevant heterocycles, we initially sought 
to utilize our piperazinones15 in a collaboration with the Kurosu group at UTennessee to 
design novel C. dificile inhibitors. During this collaboration we worked with a N4-PMB-
protected piperazin-2-one, in which we failed to remove the recalcitrant PMB group 
using a variety of common cleavage conditions that were orthogonal to the sensitive allyl 
functionality. 















ii.  Allyl 
cyanoformate














R1 = i-butyl, Bn, CH2OBn
5 linear steps, 5-15% overall yield
A. Previous route to allylic alkylation substrates (Stoltz 2015)
B. Streamlined route to allylic alkylation substrates (This research)
R1
1.1 1.2 1.3
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The substrate-dependent drawbacks of our approach leave room for an improved 
method to synthesize chiral disubstituted piperazines. In an effort to expand upon our 
group’s longstanding interest in transition-metal catalyzed allylic alkylation, we sought to 
identify an alternative protecting group that could overcome the aforementioned 
limitations by enabling both facile substrate synthesis and protecting group cleavage. 
After extensive explorations directed toward this goal, we were pleased to discover that 
replacing the N4-benzyl protecting group with a simple Boc (tert-butoxycarbonyl) 
protecting group addressed the issue of difficult substrate synthesis. Presumably, the 
electron-withdrawing Boc group attenuates the nucleophilicity of N4, enabling divergent 
access to a wider array of substrates 1.3 via enolate functionalization of dicarbonyl 
compound 1.2, which could be synthesized in only two steps from Boc-piperazinone 1.1 
(Scheme 1.3B) 
With a streamlined approach toward a wide range of decarboxylative alkylation 
substrates, we began optimizing the reaction conditions: with model substrate 1.3m, 
conditions based on our previous report15 using 10 mol % (S)-(CF3)3-t-BuPHOX ligand 
and 4 mol % Pd2(pmdba)3 in 0.014 M toluene gave the product 3m in only 76% ee (Table 
1.2, entry 1). Other commonly used allylic alkylation ligands such as (S)-t-BuPHOX (L2) 
and (S,S)-ANDEN-Ph Trost (L3) were tested, both giving suboptimal enantioselectivities 
(entries 2–3). We then examined the effect of solvent on the enantioselectivity (entries 4–










Table 1.2 Optimization of the reaction conditionsa 
 
 
Entry Ligand Solvent Yield (%)b ee (%)c 
1 L2 Tol 75 76 
2 L2 Tol 70 1 
3 L3 Tol 83 52 
4 L1 THF — 13 
5 L1 MTBE — 80 
6 L1 2:1 Hex/Tol 93 93 
 
 
[a] Screens performed on a 0.04 mmol scale. [b] All reported yields are for isolated products. [c] The ee values were 
determined by chiral SFC analysis. Bz = benzoyl, Boc = tert-butoxycarbonyl, pmdba = bis(4-methoxybenzylidene)acetone 
 
Employing these satisfactory reaction conditions, we then explored the substrate 
scope of the decarboxylative alkylation of various N4-Boc protected piperazinones 
(Table 1.3). We first tested the α-monosubstituted piperazinone 1.3a, finding that typical 
conditions in a 0.033 M solution of toluene afforded the product 1.4a in high yield and 
enantioselectivity. Another monosubstituted piperazinone 1.4b with a N1-anisoyl 
protecting group, was also obtained in high yield and ee. Furthermore, replacement of the 
N4-Boc protecting group with Cbz (1.3c), and 2-chloro substitution of the allyl group 




















Pd2(pmdba)3 (4 mol %)
L (10 mol %)
Solvent (0.014 M)
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Next, we examined α,α-disubstituted substrates, finding that for the simple cases 
of methyl substitution (1.3e, 1.3f), performing the reaction at 0.033 M concentration in  
toluene gave high yields and ee, with no improvement with the use of 2:1 hexanes-
toluene at 0.014 M concentration. The exception was N4-benzoyl protected substrate 1.3g, 
which in our previous work gave 52% ee in toluene; under our optimized conditions in 
2:1 hexanes-toluene, the substrate gave an improved albeit modest ee of 70%. Larger 
substituents such as α-benzylated compound 1.3h or benzyloxymethyl ether 1.3i required 
the use of 2:1 hexanes-toluene to achieve high enantioselectivity. This unique mixed-
solvent requirement was observed in all substituents other than methyl. A wide range of 
functional groups was tolerated: notably, the nitrile, ketone, and methylcarbamate 
substrates, which could not be accessed in our previously described efforts, gave high ee 
and yields (1.3j-m).  
Table 1.3. Substrate scope exploration. 
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1.4a[c]: R1 = Bz,  
90% yield, 92% ee 
1.4b[c]: R1 = An,  





































[a] Conditions: piperazin-2-one 3 (1.0 equiv), Pd2(dba)3 (4 mol %), (S)-(CF3)3-tBuPHOX (10 mol %), in 2:1 hexanes/toluene 
(0.014 M) at 40 °C for 12-24 h. [b] Pd2(pmdba)3 (4 mol %) instead of Pd2(dba)3. [c] Toluene (0.033 M) instead of 2:1 
hexanes/toluene. All reported yields are for isolated products. The ee values were determined by chiral SFC analysis. An = 4-
methoxybenzoyl, dba = dibenzylideneacetone. 
 
With the N-Boc piperazin-2-one substrates providing excellent results, we 
wondered whether an isomeric substrate class, the N-Boc tetrahydropyrimidin-2-ones 
(1.5), would perform similarly as well (Scheme 1.4c). The resulting α,α-disubstituted 
tetrahydropyrimidin-2-one products (1.6) are especially interesting as they may be 
hydrolyzed to afford valuable β2,2-amino acids (1.7), which are used in peptidomimetic 
therapeutics and in the design of unnatural peptides and proteins with unique secondary 

























































Pd2(dba)3 (4 mol %)
(S)-(CF3)3-tBuPHOX (10 mol %)
2:1 hexanes-toluene
40 °C1.3a-n 1.4a-n
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approach toward β2,2-amino acids. In 2018 the Shibasaki group described the 
decarboxylative allylic alkylation of an N,O heterocycle to set the quaternary stereocenter, 
followed by N−O bond heterolysis to generate β2,2-amino acids (Scheme 1.4a).47 Later in 
2018, Cossy and co-workers described a similar approach involving intermolecular 
allylic alkylation (Scheme 1.4b).48 Notably, the substrate scope for these two examples is 
limited to mostly α-benzylic and α-aryl compounds. If decarboxylative alkylation could 
be achieved with the versatile tetrahydropyrimidin-2-one scaffold, a broader range of 
chiral β2,2-amino acids might be accessible (Scheme 1.4c). Additionally, 
tetrahydropyrimidinones may be reductively transformed into hexahydropyrimidines, 
which are found in bioactive molecules such as the antibiotic hexetidine and the 
macrocyclic natural product verbamethine.49,50  
 
 


















Up to 94% ee
R = Me, CH2Ar
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Beginning our investigations with methyl substrate 1.5a (Table 1.4), we were 
pleased to find that our optimized conditions in 2:1 hexanes-toluene furnished the desired 
decarboxylative alkylation product 1.6a in high yield and ee. The reaction proved 
amenable to a variety of α-substituents, including ethyl (1.6b), methyl ester (1.6c), 2-
chloroallyl (1.6d), and benzyl (1.6e). Furthermore, the reaction is scalable, with the 
benzyl substrate 1.5e giving good results in a 1 gram reaction. In contrast, the nitrile and 
benzyloxymethyl ether products 1.6f and 1.6g were isolated with reduced 
enantioselectivities. Pleasingly, the fluorine and propargyl substrates 1.5h and 1.5i 
performed well, and may serve as a precursor to a novel fluorinated β2,2-amino acid, or 





Table 1.4. Pd-catalyzed decarboxylative alkylation of tetrahydropyrimidin-2-ones. Scope of α-
substituents[a] 
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1.6a: R5 = Me,  
83% yield, 93% ee 
6b: R5 = Et,  























[a] Conditions: tetrahydropyrimidin-2-one 5 (1.0 equiv), Pd2(pmdba)3 (4 mol %), (S)-(CF3)3-tBuPHOX (10 mol %), in 2:1 
hexanes/toluene (0.014 M) at 40 °C for 12-24 h. All reported yields are for isolated products. [b] Reaction performed with 1 
gram of substrate 5e. The ee values were determined by chiral SFC analysis. 
 
Having demonstrated excellent results for the decarboxylative alkylation of 
piperazin-2-ones and tetrahydropyrimidin-2-ones, we began exploring their synthetic 
utility. In contrast to the relative difficulty of removing the N4-benzyl type protecting 
groups in our previous work, both Boc groups of 1.4m were easily removed by treatment 
with excess TFA to give aminopiperazinone 1.8 (Scheme 1.5a). With LiOH, the benzoyl 
group could be orthogonally removed to provide the free amide 1.9 (Scheme 1.5b). The 
amide 1.9 could then be reduced with LiAlH4 to the corresponding chiral 
aminopiperazine 1.10. To further illustrate the synthetic versatility realized by Boc-
deprotection of N4, we hydrogenated the allyl olefin of methyl piperazinone 1.4e before  
 
cleaving the Boc group to obtain 1.11. We then applied Gaunt’s51 method of C−H 
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bears resemblance to the core of various β-lactam antibiotics and β-lactamase inhibitors 
(Scheme 1.5c). Lastly, we transformed four tetrahydropyrimidinone substrates, 1.6c-e 
and 1.6h, into their corresponding acyclic forms (Scheme 1.5d & e). Using a two-step 
protocol involving TFA-mediated Boc cleavage followed by saponification with LiOH, 
we successfully obtained the crude β2,2-amino acid (Scheme 1.5d); to facilitate silica gel 
chromatographic isolation, we chose to mask the free amine and carboxylic acid with Boc 
and benzyl groups, respectively, resulting in protected β2,2-amino acid 1.13. We note that 
in this four step sequence, we only performed one chromatographic separation to isolate 
the protected β-amino acid. In contrast, novel unprotected β2,2-amino acids 1.14–16 
bearing pendant carboxylic acid, chloroallyl, and fluorine atom functional groups could 
be obtained directly by purification with reverse phase preparatory HPLC following the 






















Scheme 1.5. Product derivatization 
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[a] Boc cleavage to the free amine. [b]  Benzoyl cleavage and reduction to the piperazine. [c]  Boc cleavage, allyl 
hydrogenation, and C−H carbonylation of the free amine. [d,e] hydrolysis and subsequent protection of the β2,2-amino acid. 
[f] KOH, 1:1 MeOH/H2O, rt; then, HCl, MeOH, rt. BQ = benzoquinone. Piv = pivalate. 
 
1.3  CONCLUSIONS 
In summary, we have developed a decarboxylative asymmetric allylic alkylation 
reaction to synthesize unprecedented chiral α,α-disubstituted piperazin-2-ones and 
tetrahydropyrimidin-2-ones. This work represents a significant improvement upon 
existing technology, featuring ease of substrate synthesis, facile N4-Boc deprotection, 






















































2. LiOH, MeOH/H2O, 80 °C
3. Boc2O
4. BnBr, K2CO3, DMF

















2. LiOH, MeOH/H2O, 80 °C
1.6c: R = CH2CH2CO2Me
1.6d: R =






1.14: R = CH2CH2CO2H, 46% yield
1.15: R =                       , 69% yield
1.16[f]: R = F, 65% yield
Cl
Chapter 1 – Enantioselective synthesis of gem-disubstituted N-Boc diazaheterocycles 17	
valuable chiral gem-disubstituted piperazines that are anticipated to provide stereodefined 
access to new chemical space in drug discovery. Similarly, the tetrahydropyrimidinone 
scaffold could be hydrolyzed to provide access to corresponding protected and free β2,2-
amino acids. We anticipate this decarboxylative allylic alkylation protocol will find 
utility in the field of medicinal chemistry as well as in natural products synthesis.  
 
1.4  EXPERIMENTAL SECTION 
1.4.1  MATERIALS AND METHODS 
Unless otherwise stated, reactions were performed in flame-dried glassware under 
an argon or nitrogen atmosphere using dry, deoxygenated solvents. Solvents were dried 
by passage through an activated alumina column under argon. tert-Butyl 3-
oxopiperazine-1-carboxylate 1.1 was obtained from Combi-Blocks. Commercially 
obtained reagents were used as received. Chemicals were purchased from Sigma 
Aldrich/Strem/Alfa Aesar/Combi-Blocks and used as received.   
Reaction temperatures were controlled by an IKAmag temperature modulator. 
Glove box manipulations were performed under a nitrogen atmosphere. Thin-layer 
chromatography (TLC) was performed using E. Merck silica gel 60 F254 precoated 
plates (0.25 mm) and visualized by UV fluorescence quenching, iodine on silica, 
ninhydrin, or KMnO4 staining. SiliaFlash P60 Academic Silica gel (particle size 0.040–
0.063 mm) was used for flash chromatography.  
Analytical SFC was performed with a Mettler SFC supercritical CO2 analytical 
chromatography system utilizing a Chiralpak IC column (4.6 mm x 25 cm) obtained from 
Daicel Chemical Industries, Ltd. with visualization at 254 nm. Reverse Phase Preparatory 
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HPLC was performed with a Teledyne ISCO ACCQPrep HP125 preparative liquid 
chromatography system equipped with a RediSep Prep C18 5 µm column (20 x 250 mm).  
1H NMR spectra were recorded on a Varian Inova 600 MHz or 500 MHz spectrometer or 
a Bruker Avance HD 400 MHz spectrometer and are reported relative to residual CHCl3 
(δ 7.26 ppm) or CH3OH (δ 3.31 ppm). 13C NMR spectra were recorded on a Varian Inova 
500 MHz spectrometer or a Bruker Avance HD 400 MHz spectrometer and are reported 
relative to residual CDCl3 (δ 77.16 ppm) or CD3OD (δ 49.00 ppm). Data for 1H NMR are 
reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, sept = 
septuplet, m = multiplet, br s = broad singlet. Data for 13C NMR are reported in terms of 
chemical shifts (δ ppm). Some reported spectra include minor solvent impurities of water 
(δ 1.56 or 4.87 ppm), ethyl acetate (δ 4.12, 2.05, 1.26 ppm), methylene chloride (δ 5.30 
ppm), acetone (δ 2.17 ppm), grease (δ 1.26, 0.86 ppm), and/or silicon grease (δ 0.07 
ppm), which do not impact product assignments.  
IR spectra were obtained using a Perkin Elmer Paragon 1000 spectrometer using 
thin films deposited on NaCl plates and reported in frequency of absorption (cm-1). High 
resolution mass spectra (HRMS) were obtained from an Agilent 6200 Series TOF with an 
Agilent G1978A Multimode source in electrospray ionization (ESI+), atmospheric 
pressure chemical ionization (APCI+), or mixed ionization mode (MM: ESI-APCI+). 
Optical rotations were measured with a Jasco P-2000 polarimeter operating on the 
sodium D-line (589 nm), using a 100 mm pathlength cell and are reported as: [α]DT 
(concentration in g/100 mL, solvent). Stereochemistry is assigned by analogy to previous 
results.4,7,10,13,52,53 
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1.4.1.1 Preparation of Known Compounds 
Allyl cyanoformate was prepared according to the method of Weber.54 
Phosphinooxazoline (PHOX) ligands (S)-L1, (S)-L2, and achiral GlyPhox  were prepared 
by methods described in our previous work.4,55 Di-benzoylated allylic alkylation substrate 
1.3g was prepared according to the method of Korch.15 Tris(4,4’-
methoxydibenzylideneacetone)dipalladium(0) [Pd2(pmdba)3] was prepared according to 
the method of Ibers56 or Fairlamb.57 AgOPiv was prepared using Grubbs’ procedure.58 
tert-Butyl ((phenylsulfonyl)methyl)carbamate and benzyl 
((phenylsulfonyl)methyl)carbamate were prepared according to the method of Zwierzak 
or Dikshit.59,60 Benzyl 3-oxopiperazine-1-carboxylate was prepared according to the 
method of Batey.61 2-chloroallyl chloroformate was prepared according to the method of 
Stoltz.62 
 
1.4.2  EXPERIMENTAL PROCEDURES AND SPECTROSCOPIC DATA 
1.4.2.1 Procedures for the Synthesis of Piperazinone Allylic Alkylation 
Substrates 
 
tert-butyl 4-benzoyl-3-oxopiperazine-1-carboxylate. To a solution of tert-butyl 3-
oxopiperazine-1-carboxylate 1.1 (5.0 g, 24.9 mmol, 1 equiv) in THF (250 mL) at −78 °C 
was added dropwise nBuLi (11.4 mL, 2.4M solution in hexane, 27.5 mmol, 1.1 equiv) 
over 20 minutes. The resulting yellow solution was stirred for 10 min at −78 °C. Benzoyl 
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orange solution. The reaction was stirred for 2.5 h at −78 °C, quenched by addition of 
saturated aqueous NH4Cl (100 mL), and diluted with ethyl acetate (100 mL). The layers 
were separated and the aqueous layer was extracted with ethyl acetate (3 × 100 mL). The 
combined organic layers were dried over anhydrous Na2SO4, decanted, and concentrated 
under reduced pressure onto silica gel. The silica-loaded crude reaction mixture was 
purified by silica gel flash column chromatography (10% →15% →20% EtOAc/hexanes) 
to give protected ketopiperazine as a white solid (3.2 g, 42.1% yield). Product identity 
was confirmed by comparison to previously reported characterization data.63 
 
 
tert-butyl 4-(4-methoxybenzoyl)-3-oxopiperazine-1-carboxylate. To a solution of tert-
Butyl 3-oxopiperazine-1-carboxylate (5.0 g, 24.9 mmol, 1 equiv) in THF (250 mL) at −78 
°C was added dropwise nBuLi (11.4 mL, 2.4M solution in hexane, 27.5 mmol, 1.1 equiv) 
over 20 minutes. The resulting yellow solution was stirred for 10 min at −78 °C. Anisoyl 
chloride (4.1 mL, 30.0 mmol, 1.2 equiv) was then added dropwise at −78 °C, giving a 
bright orange solution. The reaction was stirred for 2 h at −78 °C, quenched by addition 
of saturated aqueous NH4Cl (100 mL), and diluted with ethyl acetate (100 mL). The 
layers were separated and the aqueous layer was extracted with ethyl acetate (3 × 100 
mL). The combined organic layers were dried over anhydrous Na2SO4, decanted, and 
concentrated under reduced pressure onto silica gel. The silica-loaded crude reaction 






Chapter 1 – Enantioselective synthesis of gem-disubstituted N-Boc diazaheterocycles 21	
anisoyl protected ketopiperazine as a white foam, which was directly used without further 
purification in subsequent acylation reactions with allyl cyanoformate.  
 
 
benzyl 4-benzoyl-3-oxopiperazine-1-carboxylate. To a solution of benzyl 3-
oxopiperazine-1-carboxylate61 (1.0 g, 4.3 mmol, 1.0 equiv) in THF (42 mL) at −78 °C 
was added dropwise nBuLi (1.96 mL, 2.4M solution in hexane, 4.7 mmol, 1.1 equiv) 
over 20 minutes. The solution was stirred for 10 min at −78 °C. Benzoyl chloride (0.595 
mL, 5.1 mmol, 1.2 equiv) was then added dropwise at −78 °C, giving a light yellow 
solution. The reaction was stirred for 1 h at −78 °C, quenched by addition of saturated 
aqueous NH4Cl (50 mL), and diluted with ethyl acetate (50 mL). The layers were 
separated and the aqueous layer was extracted with ethyl acetate (3 × 50 mL). The 
combined organic layers were dried over anhydrous Na2SO4, decanted, and concentrated 
under reduced pressure onto silica gel. The silica-loaded crude reaction mixture was 
purified by silica gel flash column chromatography (33% EtOAc/hexanes) to give Bz-
Cbz-protected ketopiperazine SI-3 as a white solid (1.0 g, 70.0% yield); 1H NMR (500 
MHz, CDCl3) δ 7.61 – 7.56 (m, 2H), 7.54 – 7.49 (m, 1H), 7.44 – 7.31 (m, 7H), 5.21 (s, 
2H), 4.30 (s, 2H), 3.95 (dd, J = 6.8, 4.4 Hz, 2H), 3.83 (dd, J = 6.9, 4.3 Hz, 2H); 13C 
NMR (126 MHz, CDCl3) δ (a mixture of two rotamers) 172.8, 168.0, 167.6, 154.5, 
136.0, 135.0, 132.3, 128.7, 128.5, 128.4, 128.3, 128.3, 68.0, 48.5, 43.3, 41.7, 41.4; IR 
(Neat Film, NaCl) 3386, 3063, 3033, 2954, 2894, 1706, 1600, 1584, 1498, 1449, 1422, 
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699, 639, 612 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C19H19N2O4 [M+H]+: 
339.1339, found 339.1338. 
 
 
2-allyl 1-(tert-butyl) 4-benzoyl-3-oxopiperazine-1,2-dicarboxylate (1.2). To a solution 
of Bz-protected oxopiperazine (1.5 g, 4.9 mmol, 1.0 equiv) in THF (40 mL) at −78 °C 
was added LiHMDS (907 mg, 5.42 mmol, 1.10 equiv.) in THF (10mL) dropwise. The 
resulting orange reaction mixture was stirred for 15 min at −78 °C. Then, allyl 
cyanoformate (590 µL, 5.2 mmol, 1.05 equiv) was added dropwise at −78 °C, giving a 
yellow solution. After stirring for 1.5 h at −78 °C, the reaction was quenched with 
saturated aqueous NH4Cl (20 mL) and diluted with ethyl acetate (50 mL). The aqueous 
phase was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were 
dried over anhydrous Na2SO4, decanted, and concentrated under reduced pressure onto 
silica. The silica-loaded crude mixture was purified by silica gel flash chromatography 
(10% → 20% EtOAc/hexanes) to give the allyl ester 1.2 as a white solid (1.3 g, 68% 
yield): 1H NMR (500 MHz, CDCl3) δ (a mixture of two rotamers) 7.59 (d, J = 7.7 Hz, 
2H), 7.52 (t, J = 7.6 Hz, 1H), 7.40 (t, J = 7.6 Hz, 2H), 5.92 (m, 1H), 5.44 – 5.07 (m, 3H), 
4.84 – 4.57 (m, 2H), 4.28 – 3.61 (m, 4H), 1.43 (br s, 9H); 13C NMR (126 MHz, CDCl3) 
δ (a mixture of two rotamers) 172.7, 166.9, 164.4, 154.1, 153.5, 134.6, 132.6, 131.0, 
128.6, 128.4, 119.9, 119.4, 82.2, 82.0, z67.1, 62.7, 61.7, 43.2, 42.6, 41.5, 40.2, 29.4, 28.3; 
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1127 1088 1059 1009 958 861 794 770 728 694 623 cm-1; HRMS (MM: ESI-APCI) m/z 
calc’d for C16H17N2O6 [(M-tBu)+H]+: 333.1081, found 333.1075. 
 
 
2-allyl 1-(tert-butyl) 4-(4-methoxybenzoyl)-3-oxopiperazine-1,2-dicarboxylate (1.3b). 
Following the procedure described for the preparation of 1.2, anisoyl protected 
oxopiperazine (1.0 g, 3.0 mmol, 1.0 equiv) was treated with LiHMDS (550 mg, 3.3 
mmol, 1.1 equiv) and acylated with allyl cyanoformate (336 µL, 3.1 mmol, 1.05 equiv) to 
give, after purification by silica gel flash chromatography (Dry load SiO2, 18% 
EtOAc/hexanes), allyl ester 1.3b as a white solid (566 mg, 45% yield): 1H NMR (400 
MHz, CDCl3) δ (a mixture of two rotamers) 7.61 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.8 Hz, 
2H), 5.91 (ddt, J = 16.4, 10.8, 5.8 Hz, 1H), 5.46–5.12 (m, 3H), 4.70 (s, 2H), 4.13–3.65 
(m, 4H),  3.81 (s, 3H), 1.46 (m, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two 
rotamers) 171.9, 171.8, 167.0, 164.4, 164.2, 163.4, 154.0, 153.4, 131.4, 131.0, 126.3, 
119.6, 119.2, 113.6, 82.0, 81.8, 66.9, 62.5, 61.6, 55.5, 43.3, 42.8, 41.5, 40.1, 28.2; IR 
(Neat Film, NaCl) 3384, 3060, 2978, 2843, 2568, 2049, 1732, 1605, 1580, 1513, 1456, 
1372, 1258, 1088, 1059, 959, 844, 769, 736, 706, 634 cm-1; HRMS (MM: ESI-APCI) 
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2-allyl 1-benzyl 4-benzoyl-3-oxopiperazine-1,2-dicarboxylate (1.3c). Following the 
procedure described for the preparation of 2, Cbz protected oxopiperazine (1.0 g, 3.0 
mmol, 1.0 equiv) was treated with LiHMDS (544 mg, 3.3 mmol, 1.1 equiv) and acylated 
with allyl cyanoformate (331 µL, 3.1 mmol, 1.05 equiv) to give, after purification by 
silica gel flash chromatography (dry load SiO2, 20 → 25% EtOAc/hexanes), allyl ester 
1.3a as a white solid (720 mg, 58% yield): 1H NMR (500 MHz, CDCl3) δ (a mixture of 
two rotamers) 7.65 – 7.56 (m, 2H), 7.56 – 7.46 (m, 1H), 7.46 – 7.28 (m, 7H), 5.87 (dtd, J 
= 47.5, 10.7, 5.4 Hz, 1H), 5.55 – 5.04 (m, 5H), 4.84 – 4.48 (m, 2H), 4.24 – 3.99 (m, 2H), 
3.99 – 3.66 (m, 2H); 13C NMR (126 MHz, CDCl3) δ (a mixture of two rotamers) 172.4, 
172.3, 166.5, 164.0, 163.8, 154.8, 154.2, 135.7, 135.6, 134.4, 132.5, 130.9, 130.8, 128.7, 
128.6, 128.5, 128.5, 128.4, 128.3, 128.2, 128.1, 119.6, 119.5, 68.3, 68.2, 67.2, 67.1, 62.1, 
61.9, 42.8, 42.3, 41.3, 40.8; IR (Neat Film, NaCl) 3386, 3064, 3033, 2955, 2897, 1746, 
1713, 1694, 1651, 1600, 1584, 1498, 1450,  1417, 1368, 1304, 1278, 1229, 1195, 1178, 
1160, 1124, 1088, 1061, 1014, 985, 951, 860, 794, 768, 729, 696, 675, 623 cm-1; HRMS 
(MM: ESI-APCI) m/z calc’d for C23H23N2O6 [M+H]+: 423.1551, found 423.1547. 
 
 
1-(tert-butyl) 2-(2-chloroallyl) 4-benzoyl-3-oxopiperazine-1,2-dicarboxylate (1.3d). 
Following the procedure described for the preparation of 1.2, benzoyl protected 
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mmol, 1.1 equiv) and acylated with 2-chloroallyl chloroformate62 (235 mg, 1.5 mmol, 
1.05 equiv) to give, after purification by silica gel flash chromatography (Dry load SiO2, 
15% EtOAc/hexanes), 2-chloroallyl ester 1.3d as an off-white solid (431 mg, 70% yield): 
1H NMR (500 MHz, CDCl3): δ (a mixture of two rotamers) 7.59–7.54 (m, 2H), 7.50–
7.44 (m, 1H), 7.43–7.37 (m, 2H), 6.67 (m, 1H), 5.42–5.33 (m, 2H), 4.54 (m, 2H), 3.95–
3.89 (m, 2H), 3.72 (t, J = 5.2 Hz, 2H), 1.51 (s, 9H); 13C NMR (101 MHz, CDCl3): δ (a 
mixture of two rotamers) 167.5, 167.3, 152.4, 152.2, 151.1, 151.0, 135.1, 134.9, 134.3, 
131.3, 131.2, 128.5, 128.4, 128.0, 127.9, 126.7, 115.9, 115.7, 107.9, 107.6, 82.3, 82.2, 
69.9, 69.8, 44.2, 43.1, 42.3, 41.7, 28.3; IR (Neat Film, NaCl) 3396, 3129, 3062, 2979, 
2936, 2253, 1770, 1691, 1372, 1242, 1050, 987, 950, 922, 859, 839, 764, 731, 707, 647 





dicarboxylate (1.3e). Sodium hydride (60% in mineral oil, 25 mg, 0.62 mmol, 1.2 equiv) 
was added to a solution of allyl ester 2 (200 mg, 0.52 mmol, 1.0 equiv) in THF (5 mL) at 
0 °C. After stirring for 30 min at 0 °C, MeI (160 µL, 2.57 mmol, 5.0 equiv) was added. 
The reaction mixture was allowed to warm to room temperature and stirred for 16 h. The 
reaction was quenched with aqueous NH4Cl (10 mL) and extracted with EtOAc (3 x 5 
mL). The combined organic phases were dried over anhydrous Na2SO4, decanted, and 
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purified by silica gel flash chromatography (20% EtOAc/hexanes) to give methylated 
allyl ester 3e as a colorless oil (180 mg, 85% yield): 1H NMR (400 MHz, CDCl3): δ 7.59 
– 7.46 (m, 3H), 7.46 – 7.32 (m, 2H), 5.92 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H), 5.41 – 5.19 
(m, 2H), 4.66 (d, J = 5.8 Hz, 2H), 4.24 – 4.09 (m, 1H), 4.05 – 3.90 (m, 2H), 3.81 – 3.64 
(m, 1H), 1.84 (s, 3H), 1.46 (s, 9H); 13C NMR (101 MHz, CDCl3): δ (a mixture of two 
rotamers) 172.5, 169.2, 168.0, 153.2, 134.8, 132.4, 131.5, 128.4, 128.0, 119.1, 82.7, 68.7, 
66.9, 43.7, 40.9, 28.3, 21.5; IR (Neat Film, NaCl) 3384, 3064, 2980, 2939, 2876, 1962, 
1766, 1694, 1600, 1584, 1451, 1394, 1368, 1306, 1270, 1232, 1206, 1164, 1096, 1060, 
1032, 1016, 993, 968, 936, 854, 795, 770, 727, 696, 675, 633, 618 cm-1; HRMS (MM: 




dicarboxylate (1.3f). Following the procedure described for the preparation of 1.3e, 
anisoyl protected oxopiperazine 1.3b (120 mg, 0.29 mmol, 1.0 equiv) was treated with 
NaH (60% in mineral oil, 13 mg, 0.32 mmol, 1.1 equiv) and methylated with MeI (90 µL, 
1.43 mmol, 5.0 equiv) to give, after purification by silica gel flash chromatography (dry 
load SiO2, 15% → 20% → 25% → 30% EtOAc/hexanes), methylated allyl ester 1.3f as a 
colorless oil (110 mg, 89% yield): 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.8 Hz, 
2H), 6.85 (d, J = 8.9 Hz, 2H), 5.92 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H), 5.40 – 5.17 (m, 2H), 
4.66 (d, J = 5.8 Hz, 2H), 4.15 – 4.02 (m, 1H), 4.02 – 3.87 (m, 2H), 3.83 (s, 3H), 3.80 – 
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168.1, 163.4, 153.2, 131.5, 131.0, 126.6, 119.0, 113.7, 82.6, 68.5, 66.8, 55.5, 43.8, 41.0, 
28.3, 21.6; IR (Neat Film, NaCl) 3081, 2978, 2938, 2842, 1766, 1702, 1604, 1579, 
1512, 1460, 1394, 1368, 1308, 1287, 1259, 1235, 1208, 1169, 1114, 1095, 1060, 1021, 
1004, 969,  933, 845, 789, 770, 733, 706, 648, 634 cm-1; HRMS (MM: ESI-APCI) m/z 




dicarboxylate (1.3h). Following the procedure described for the preparation of 1.3e, 
anisoyl-protected allyl ester 1.3b (200 mg, 0.48 mmol, 1.0 equiv) was treated with 
potassium hydride (23 mg, 0.57 mmol, 1.2 equiv) and alkylated with benzyl bromide 
(170 µL, 1.43 mmol, 3.0 equiv) to give, after purification by silica gel flash 
chromatography (Dry load SiO2, 20% → 25% EtOAc/hexanes), the benzyl ester 1.3h as a 
colorless oil (100 mg, 41% yield) (Note: attempts using sodium hydride as a base failed 
to give conversion of starting material. Instead, potassium hydride resulted in conversion 
to the desired product.):  1H NMR (400 MHz, CDCl3) δ (a mixture of two rotamers) 7.52 
(m, 2H), 7.42 – 7.23 (m, 3H), 7.11 (m, 2H), 6.92 – 6.75 (m, 2H), 5.97 (ddt, J = 17.2, 
10.4, 5.8 Hz, 1H), 5.50 – 5.17 (m, 2H), 4.87 – 4.57 (m, 2H), 3.86 (s, 3H), 3.79 – 3.56 (m, 
4H), 2.95 (ddd, J = 13.3, 7.4, 3.0 Hz, 1H), 2.86 (br s, 1H), 1.55 (s, 9H); 13C NMR (101 
MHz, CDCl3) δ (a mixture of two rotamers) 172.1, 168.0, 167.4, 166.9, 163.4, 153.6, 
153.4, 136.0, 135.3, 131.8, 131.3, 130.7, 128.8, 128.7, 128.4, 128.2, 127.8, 127.7, 127.5, 
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40.0, 38.8, 28.5; IR (Neat Film, NaCl) 2978, 1764, 1698, 1604, 1512, 1496, 1455, 1394, 
1366, 1307, 1282, 1256, 1196, 1155, 1078, 1020, 1000, 921, 844, 768 733, 704 cm-1; 




dicarboxylate (1.3i). Following the procedure described for the preparation of 1.3e, allyl 
ester 1.2 (150 mg, 0.39 mmol, 1.00 equiv) was treated with sodium hydride (17 mg, 0.42 
mmol, 1.1 equiv) and alkylated with benzyl chloromethyl ether (107 µL, 0.77 mmol, 2.0 
equiv) to give, after purification by silica gel flash chromatography (Dry load SiO2, 10% 
→ 15% EtOAc/hexanes), benzyloxy methyl ether 1.3i as a colorless oil (50 mg, 55% 
yield BRSM): 1H NMR (500 MHz, CDCl3) δ (a mixture of two rotamers) 7.64 – 7.55 
(m, 2H), 7.51 – 7.44 (m, 1H), 7.41 – 7.27 (m, 7H), 5.88 (ddt, J = 17.3, 10.4, 5.8 Hz, 1H), 
5.40 – 5.17 (m, 2H), 4.74 – 4.47 (m, 4H), 4.38 (m, 1H), 4.17 (m, 1H), 4.08 – 3.84 (m, 
4H), 1.42 (m, 9H); 13C NMR (126 MHz, CDCl3) δ (a mixture of two rotamers) 173.0, 
167.4, 167.2, 166.5, 153.6, 153.1, 141.0, 137.9, 137.5, 134.8, 132.4, 131.6, 131.1, 128.7, 
128.7, 128.6, 128.4, 128.3, 128.0, 127.7, 127.6, 127.1, 119.5, 118.9, 82.7, 81.9, 73.9, 
73.3, 72.6, 71.2, 71.1, 66.8, 65.4, 43.6, 43.4, 42.5, 41.7, 28.4, 28.3; IR (Neat Film, 
NaCl) 3528, 3064, 3031, 2978, 2934, 1762, 1694, 1600, 1496, 1453, 1394, 1366, 1314, 
1270, 1231, 1205, 1161, 1094, 1055, 1014, 972, 941, 854, 795, 770, 730, 696, 674, 624 
cm-1; HRMS (MM: ESI-APCI) m/z calculated for C24H25N2O7 [(M-tBu)+H]+: 











dicarboxylate (1.3j). DBU (7.1 µL, 0.048 mmol, 0.10 equiv) was added to a solution of 
allyl ester 1.3b (200 mg, 0.478 mmol, 1.0 equiv) and acrylonitrile (94 µL, 1.43 mmol, 3.0 
equiv) in DMF (2.4 mL) at room temperature. After stirring for 2 h at 70 °C and 24 h at 
55 °C, additional DBU (14 µL, 0.1 mmol, 0.2 equiv) was added and the orange solution 
was maintained at 70 °C for 4 h. Then, additional DBU (21 µL, 0.143 mmol, 0.30 equiv) 
was added and the mixture was stirred at 70 °C for 3 h. After allowing the reaction 
mixture to cool to room temperature, the reaction was quenched with saturated aqueous 
NH4Cl (2 mL) and diluted with EtOAc (6 mL). The aqueous phase was extracted with 
EtOAc (3 x 5 mL). The combined organic layers were dried over anhydrous Na2SO4, 
decanted, and concentrated under reduced pressure onto silica gel. The silica-loaded 
residue was purified by flash chromatography (20% EtOAc/hexanes) to give the α-
cyanoethylated allyl ester 1.3j as a pale yellow oil (77.6 mg, 34% yield): 1H NMR (400 
MHz, CDCl3) δ 7.54 (s, 2H), 6.85 (d, J = 8.9 Hz, 2H), 5.92 (ddt, J = 17.2, 10.4 Hz, 5.9 
Hz, 1H), 5.36 (dd, J = 17.2, 1.4 Hz, 1H), 5.29 (d, J = 10.5 Hz, 1H), 4.69 (d, J = 5.8 Hz, 
2H), 4.25 (s, 1H), 4.06 (ddd, J = 13.1, 5.7, 3.1 Hz, 1H), 3.96 (ddd, J = 13.1, 8.6, 3.4 Hz, 
1H), 3.83 (s, 3H), 3.64 – 3.49 (m, 1H), 2.77 (s, 2H), 2.49 (m, 1H), 2.44 – 2.31 (m, 1H), 
1.47 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 171.7, 167.24, 166.3, 163.5, 153.4, 131.1, 
126.2, 119.6, 119.1, 113.8, 82.9, 70.5, 67.3, 55.5, 43.9, 42.3, 29.8, 28.2, 12.8; IR (Neat 
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1160, 1018, 933, 846, 769, 737, 704 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for 
C24H30N3O7 [M+H]+: 472.2078, found 472.2078.  
 
2-allyl 1-(tert-butyl) 4-(4-methoxybenzoyl)-3-oxo-2-(3-oxobutyl)piperazine-1,2-
dicarboxylate (1.3k). To a solution of allyl ester 1.3b (200 mg, 0.5 mmol, 1.0 equiv) and 
methyl vinyl ketone (80 µL, 0.96 mmol, 2.0 equiv) in acetone (2 mL) at room 
temperature was added DBU (7.1 µL, 0.05 mmol, 0.1 equiv). After stirring for 24 h at 55 
°C, additional DBU (7.1 µL, 0.05 mmol, 0.1 equiv) was added and the orange solution 
was maintained at 55 °C for an additional 24 h. The reaction mixture was allowed to cool 
to ambient temperature and concentrated under reduced pressure onto silica gel. The 
silica-loaded crude reaction mixture was purified by silica gel flash column 
chromatography (33% EtOAc/hexanes) to afford the ketone 1.3k as a pale yellow oil (90 
mg, 39% yield): 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.9 
Hz, 2H), 5.92 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H), 5.35 (dd, J = 17.2, 1.5 Hz, 1H), 5.26 (d, J 
= 10.4 Hz, 1H), 4.71 – 4.60 (m, 2H), 4.11 – 3.93 (m, 3H), 3.82 (s, 3H), 3.71 – 3.59 (m, 
1H), 2.72 (q, J = 9.3, 8.1 Hz, 1H), 2.60 (dt, J = 9.6, 6.2 Hz, 3H), 2.10 (s, 3H), 1.45 (s, 
9H); 13C NMR (101 MHz, CDCl3) δ 207.8, 172.0, 167.9, 167.4, 163.4, 153.5, 131.5, 
131.1, 126.6, 119.2, 113.7, 82.4, 70.6, 66.9, 55.5, 43.5, 42.1, 38.8, 29.8, 28.7, 28.3; IR 
(Neat Film, NaCl): 2977, 2934, 1761, 1704, 1604, 1512, 1456, 1394, 1367, 1312, 1257, 
1199, 1168, 1090, 1018, 845, 768 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for 














3-oxopiperazine-1,2-dicarboxylate (1.3l). Following the procedure described for the 
preparation of 1.3m, anisoyl-protected allyl ester 1.3b (400 mg, 0.96 mmol, 1.0 equiv) 
was treated with Cs2CO3 (779 mg, 02.39 mmol, 2.5 equiv) and alkylated with benzyl 
((phenylsulfonyl)methyl)carbamate59,60 (350 mg, 1.15 mmol, 2.5 equiv) to give, after 
purification by silica gel flash chromatography (Dry load SiO2, 10% → 15% → 20% 
EtOAc/hexanes), the aminomethyl allyl ester 1.3l as a white foam (300 mg, 54% yield): 
1H NMR (400 MHz, CDCl3) δ (a mixture of two rotamers) 7.69 – 7.50 (m, 2H), 7.41 – 
7.25 (m, 5H), 6.95 – 6.72 (m, 2H), 5.92 (ddt, J = 17.3, 10.4, 5.9 Hz, 1H), 5.49 – 4.96 (m, 
5H), 4.85 – 4.53 (m, 2H), 4.27 – 3.87 (m, 5H), 3.83 (d, J = 14.6 Hz, 3H), 3.60 (d, J = 
22.7 Hz, 1H), 1.47 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 
171.7, 167.3, 166.5, 163.4, 156.8, 153.7, 152.7, 136.4, 134.21, 132.5, 131.5, 131.2, 129.4, 
129.3, 128.9, 128.6, 128.3, 126.5, 119.8, 119.3, 113.7, 83.1, 82.1, 71.4, 70.6, 68.3, 67.8, 
67.0, 55.5, 45.0, 44.2, 43.7, 42.9, 41.9, 28.3; IR (Neat Film, NaCl) 3366, 2977, 1704, 
1604, 1513, 1456, 1394, 1367, 1313, 1257, 1232, 1169, 1091, 1018, 1002, 845, 767, 698 
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2-allyl 1-(tert-butyl) 4-benzoyl-2-(((tert-butoxycarbonyl)amino)methyl)-3-  
oxopiperazine-1,2-dicarboxylate (1.3m). To a suspension of allyl ester 1.2 (200 mg, 0.5 
mmol, 1.0 equiv) and tert-butyl ((phenylsulfonyl)methyl)carbamate59,60 (168 mg, 0.6 
mmol, 1.2 equiv), in dichloromethane (2.5 mL) at room temperature was added Cs2CO3 
(419 mg, 1.3 mmol, 2.5 equiv). After stirring for 3 h, saturated aqueous NH4Cl (1 mL) 
was added and the biphasic mixture was vigorously stirred for 20 min. The aqueous 
phase was extracted with dichloromethane (3 x 3 mL). The combined organic phases 
were dried over anhydrous Na2SO4, decanted, and concentrated under reduced pressure 
onto silica gel. The silica-loaded crude reaction mixture was purified by silica gel flash 
column chromatography (15% EtOAc/hexanes) to give methylcarbamate allyl ester 1.3m 
as a white foam (202 mg, 76% yield): 1H NMR (400 MHz, CDCl3) δ (a mixture of two 
rotamers) 7.55 (d, J = 7.5 Hz, 2H), 7.49 (t, J = 7.5 Hz, 1H), 7.36 (t, J = 7.7 Hz, 2H), 5.91 
(ddt, J = 16.5, 10.4, 5.8 Hz, 1H), 5.34 – 5.27 (m, 2H), 4.96 (m, 1H), 4.66 (br s, 2H), 4.19 
– 3.85 (m, 5H), 3.79 – 3.64 (m, 1H), 1.48 (s, 9H), 1.40 (s, 9H); 13C NMR (101 MHz, 
CDCl3) δ (a mixture of two rotamers) 172.4, 167.3, 166.8, 156.1, 153.6, 152.9, 134.9, 
132.4, 131.7, 131.1, 128.3, 128.3, 119.6, 119.0, 83.1, 82.1, 79.9, 71.4, 70.6, 67.0, 44.3, 
43.8, 43.2, 42.2, 41.6, 28.4, 28.3; IR (Neat Film, NaCl) 3386, 2978, 1760, 1698, 1601, 
1505, 1451, 1394, 1367, 1314, 1232, 1203, 1164, 1092, 1067, 1012, 915, 854, 766, 730, 
696 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C26H36N3O8 [M+H]+: 518.2497, 
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tert-Butyl 4-oxotetrahydropyrimidine-1(2H)-carboxylate. A solution of 3-
aminopropanamide hydrochloride (5 g, 40.1 mmol, 1.0 equiv), potassium hydroxide (3.38 
g, 60.2 mmol, 1.5 equiv), and formaldehyde (37% in water, 5.97 mL, 80.3 mmol, 2.0 
equiv) in ethanol (13 mL) was stirred at reflux for 4 h. The suspension was then 
maintained at 55 °C while triethylamine (5.5 mL, 40.1 mmol, 1 equiv) and di-tert-butyl 
dicarbonate (9.2 g, 42.1 mmol, 1.05 equiv) were added successively. The reaction was 
stirred for 2 h at 55 °C and then allowed to cool to ambient temperature. The precipitate 
was filtered off, the filtrate was concentrated under reduced pressure, and was then 
purified by silica gel flash chromatography (1 → 3% MeOH/CH2Cl2) to afford Boc-
protected tetrahydropyrimidinone as a white solid (4.09 g, 51% yield over two steps): 1H 
NMR (500 MHz, CDCl3) δ 8.14 – 7.60 (m, 1H), 4.77 – 4.61 (m, 2H), 3.58 (t, J = 6.5 Hz, 
2H), 2.41 (t, J = 6.5 Hz, 2H), 1.41 (s, 9H); 13C NMR (126 MHz, CDCl3) δ (a mixture of 
two rotamers) 171.5, 153.8, 153.4, 81.1, 54.8, 54.0, 40.4, 39.4, 31.4, 28.3; IR (Neat 
Film, NaCl) 3193, 2970, 1710, 1643, 1488, 1404, 1366, 1326, 1276, 1245, 1210, 1159, 
1136, 1020, 949, 776 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C9H17N2O3 
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tert-Butyl 3-benzoyl-4-oxotetrahydropyrimidine-1(2H)-carboxylate. To a solution of 
tetrahydropyrimidinone (2.07 g, 10.4 mmol, 1.0 equiv) in THF (100 mL) at −78 °C was 
added n-butyllithium (2.2 M in hexanes, 4.94 mL, 10.9 mmol, 1.05 equiv) dropwise over 
10 min. After stirring the solution at −78 °C for 20 min, benzoyl chloride (1.43 mL, 12.4 
mmol, 1.2 equiv) was added dropwise at −78 °C. The reaction solution was stirred at −78 
°C for 40 min, allowed to warm up to room temperature, and was then quenched with 
saturated aqueous NH4Cl (50 mL). The mixture was diluted with EtOAc (100 mL) and 
the aqueous phase was extracted with EtOAc (3 x 80 mL). The combined organic phases 
were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure 
onto silica gel. The silica-loaded residue was purified by silica gel flash chromatography 
(30% EtOAc/hexanes) to give Bz-protected tetrahydropyrimidinone as a white solid (2.72 
g, 86% yield): 1H NMR (400 MHz, Chloroform-d) δ 7.55 (dt, J = 8.3, 1.4 Hz, 2H), 7.50 
(t, J = 7.4 Hz, 1H), 7.39 (t, J = 7.6 Hz, 2H), 5.28 (s, 2H), 3.74 (t, J = 6.6 Hz, 2H), 2.68 (t, 
J = 6.6 Hz, 2H), 1.49 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 172.3, 170.7, 153.8, 135.0, 
132.2, 128.4, 128.2, 81.7, 57.0, 40.4, 33.4, 28.3; IR (Neat Film, NaCl) 2978, 1698, 
1480, 1450, 1408, 1367, 1304, 1266, 1239, 1141, 1015, 936, 863, 797, 700, 618 cm-1; 
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5-Allyl 1-(tert-butyl) 3-benzoyl-4-oxotetrahydropyrimidine-1,5(2H)-dicarboxylate. 
To a solution of diisopropylamine (224 µL, 1.59 mmol, 1.2 equiv) in THF (3 mL) at −78 
°C was added n-butyllithium (2.2 M in hexanes, 664 µL, 1.46 mmol, 1.1 equiv). The 
solution was maintained at −78 °C for 15 min and then cannulated over 10 min into a 
solution of Bz-protected tetrahydropyrimidine (404 mg, 1.33 mmol, 1.0 equiv) in THF 
(10 mL) at −78 °C. After stirring the solution at −78 °C for 25 min, allyl cyanoformate 
(156 µL, 1.46 mmol, 1.1 equiv) was added dropwise at −78 °C. The reaction mixture was 
maintained at −78 °C for 50 min and was then quenched with saturated aqueous NH4Cl 
(10 mL). The reaction mixture was diluted with EtOAc (10mL) and allowed to warm to 
room temperature. The aqueous phase was extracted with EtOAc (3 x 15 mL) and the 
combined organic phases were dried over anhydrous Na2SO4, decanted, and concentrated 
under reduced pressure onto silica gel. The silica-loaded residue was purified by silica gel 
flash chromatography (18 → 20 → 30% EtOAc/hexanes) to give re-isolated starting 
material (154 mg, 38% yield) and allyl ester as a white crystalline solid (310 mg, 60% 
yield, 97% yield based on recovered starting material):  1H NMR (400 MHz, CDCl3) δ 
7.70 (d, J = 7.2 Hz, 2H), 7.51 (t, J = 7.4 Hz, 1H), 7.40 (t, J = 7.6 Hz, 2H), 5.95 (ddt, J = 
17.2, 10.4, 5.9 Hz, 1H), 5.37 (dq, J = 17.2, 1.5 Hz, 1H), 5.36 (m, 1H), 5.30 (dd, J = 10.4, 
1.3 Hz, 1H), 5.17 (d, J = 12.6 Hz, 1H), 4.69 (d, J = 6.0 Hz, 2H), 4.27 (ddd, J = 13.7, 5.4, 
1.2 Hz, 1H), 3.85 (dd, J = 13.7, 6.2 Hz, 1H), 3.63 (t, J = 5.7 Hz, 1H), 1.49 (s, 9H); 13C 
NMR (101 MHz, CDCl3) δ 172.9, 167.8, 167.0, 153.4, 134.6, 132.5, 131.3, 128.7, 128.3, 
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1714, 1601, 1480, 1450, 1416, 1369, 1287, 1148, 1072, 1017, 934 , 859, 796, 768, 736, 
703, 626 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C20H25N2O6 [M+H]+: 
389.1707, found 389.1708. 
 
1-(tert-butyl) 3-benzoyl-5-methyl-4-oxotetrahydropyrimidine-1,5(2H)-dicarboxylate 
(1.5a). To a solution of allyl ester (100 mg, 0.26 mmol, 1.0 equiv) in acetonitrile (2.6 
mL) at 0 °C was added cesium carbonate (168 mg, 0.52 mmol, 2.0 equiv). After stirring 
the suspension for 30 min at 0 °C, methyl iodide (48 µL, 0.77 mmol, 3.0 equiv) was 
added. The reaction mixture was stirred for 3 h at 0 °C and diluted with saturated aqueous 
NH4Cl (2 mL) and EtOAc (2 mL). The aqueous phase was extracted with EtOAc (4 x 3 
mL) and the combined organic phases were dried over anhydrous Na2SO4, decanted, and 
concentrated under reduced pressure onto silica gel. The residue was purified by silica gel 
flash chromatography (15% EtOAc/hexanes) to give methylated allyl ester 1.5a as a 
colorless oil (100 mg, 95% yield): 1H NMR (500 MHz, CDCl3) δ (a mixture of two 
rotamers) 7.71 (d, J = 15.3 Hz, 2H), 7.51 (t, J = 7.4 Hz, 1H), 7.39 (t, J = 6.8 Hz, 2H), 
5.96 (ddt, J = 16.6, 10.4, 6.0 Hz, 1H), 5.48 – 5.17 (m, 4H), 4.71 (d, J = 6.1 Hz, 2H), 4.43 
(m, 1H), 3.38 (m, 1H), 1.49 (s, 9H), 1.47 (s, 3H); 13C NMR (101 MHz, CDCl3) δ (a 
mixture of two rotamers) 173.2, 170.9, 170.7, 153.2, 135.0, 132.3, 131.3, 128.4, 128.2, 
119.7, 82.1, 67.1, 58.9, 58.1, 52.8, 50.6, 50.3, 28.3, 19.3; IR (Neat Film, NaCl) 3406, 
3065, 2980, 2939, 1714, 1602, 1450, 1423, 1369, 1288, 1251, 1162, 1134, 1104, 1028, 
984, 938, 902, 857, 804, 765, 732, 697, 657, 635 cm-1; HRMS (MM: ESI-APCI): m/z 
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5-allyl 1-(tert-butyl) 3-benzoyl-5-ethyl-4-oxotetrahydropyrimidine-1,5(2H)-
dicarboxylate (1.5b). Following the procedure described for the preparation of 1.5a, 
allyl ester (200 mg, 0.52 mmol, 1.0 equiv) was treated with cesium carbonate (336 mg, 
1.03 mmol, 2.0 equiv) and alkylated with ethyl iodide (124 µL, 1.54 mmol, 3.0 equiv) to 
give, after purification by silica gel flash chromatography (dry load SiO2, 15% 
EtOAc/hexanes), ethylated allyl ester 1.5b as a colorless oil (182 mg, 85% yield): 1H 
NMR (400 MHz, CDCl3) δ (a mixture of two rotamers) 7.70 (d, J = 8.0 Hz, 2H), 7.50 (t, 
J = 7.4 Hz, 1H), 7.38 (t, J = 7.7 Hz, 2H), 5.95 (ddt, J = 16.6, 10.4, 6.0 Hz, 1H), 5.38 (dd, 
J = 17.2, 1.5 Hz, 1H), 5.31 (d, J = 10.3 Hz, 2H), 5.20 (d, J = 12.5 Hz, 1H), 4.70 (t, J = 5.5 
Hz, 2H), 4.47 – 4.26 (m, 1H), 3.49 (d, J = 13.5 Hz, 1H), 1.96 (q, J = 7.5 Hz, 2H), 1.49 (s, 
9H), 0.96 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two 
rotamers) 172.9, 170.4, 170.1, 169.8, 153.2, 135.0, 132.3, 131.2, 128.4, 128.2, 119.8, 
81.9, 66.9, 57.9, 57.4, 56.7, 47.8, 47.4, 28.3, 26.4, 9.1; IR (Neat Film, NaCl) 2976, 
1703, 1450, 1422, 1367, 1288, 1247, 1156, 1134, 1015, 942, 894, 802, 766, 718, 696 cm-
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5-allyl 1-(tert-butyl) 3-benzoyl-5-(3-methoxy-3-oxopropyl)-4-
oxotetrahydropyrimidine-1,5(2H)-dicarboxylate (1.5c). To a suspension of allyl ester 
(100 mg, 0.26 mmol, 1.0 equiv) and potassium carbonate (178 mg, 1.29 mmol, 5.0 equiv) 
in acetone (1.0 mL) at room temperature was added methyl acrylate (47 µL, 0.52 mmol, 
2.0 equiv). The reaction mixture was stirred for 3.5 h at 55 °C, allowed to cool to room 
temperature, and filtered through a cotton plug. The filter cake was washed with acetone 
(3 x 1 mL) and the combined organic phases were concentrated by under reduced 
pressure onto silica gel. The silica-loaded residue was purified by silica gel flash 
chromatography (19% EtOAc/hexanes) to give pyrimidinone 1.5c as a colorless oil (101 
mg, 83% yield): 1H NMR (400 MHz, CDCl3) δ (a mixture of two rotamers) 7.70 (br s, 
2H), 7.50 (t, J = 7.4 Hz, 1H), 7.38 (t, J = 7.7 Hz, 2H), 5.95 (ddt, J = 16.6, 10.3, 6.0 Hz, 
1H), 5.38 (dd, J = 17.1, 1.6 Hz, 1H), 5.32 (d, J = 10.4 Hz, 1H), 5.25 (m, 2H), 4.70 (d, J = 
6.0 Hz, 2H), 4.41 (m, 1H), 3.62 (s, 3H), 3.47 (m, 1H), 2.58 (ddd, J = 16.0, 9.5, 6.4 Hz, 
1H), 2.46 – 2.33 (m, 1H), 2.21 (ddd, J = 10.0, 6.3, 3.2 Hz, 2H), 1.48 (s, 9H); 13C NMR 
(101 MHz, CDCl3) δ (a mixture of two rotamers) 173.0, 172.9, 169.7, 153.1, 134.9, 
132.4, 131.1, 128.4, 128.3, 120.1, 82.2, 67.2, 58.3, 57.6, 55.6, 51.9, 48.7, 48.2, 29.7, 
28.3; IR (Neat Film, NaCl) 2978, 1704, 1423, 1368, 1248, 1153, 987, 803, 722, 696 cm-
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5-allyl 1-(tert-butyl) 3-benzoyl-5-(2-chloroallyl)-4-oxotetrahydropyrimidine-1,5(2H)-
dicarboxylate (1.5d). To a suspension of allyl ester (200 mg, 0.51 mmol, 1.0 equiv) and 
tetrabutylammonium iodide (17 mg, 0.05 mmol, 0.1 equiv), in THF (5.1 mL) at 0 °C was 
added NaH (60% in mineral oil, 25 mg, 0.62 mmol, 1.2 equiv). After stirring for 30 min 
at 0 °C, 2,3-dichloro-1-propene (95 µL, 1.02 mmol, 2 equiv) was added and the reaction 
mixture heated at 40 °C for 16 h. The reaction was quenched with aqueous NH4Cl (10 
mL) and extracted with EtOAc (3 x 5 mL). The combined organic phases were dried over 
anhydrous Na2SO4, decanted, and concentrated under reduced pressure onto silica gel. 
The silica-loaded residue was purified by silica gel flash chromatography (10% → 15% 
EtOAc/hexanes) to give 2-chloro-allyl allyl ester 1.5d as a colorless oil (140 mg, 59% 
yield): 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.6 Hz, 2H), 7.51 (s, 1H), 7.39 (t, J = 
7.5 Hz, 2H), 6.07 – 5.90 (m, 1H), 5.71 – 5.48 (m, 1H), 5.33 (m, 4H), 5.03 (d, J = 12.5 Hz, 
1H), 4.85 – 4.43 (m, 3H), 3.58 (mz, 1H), 3.32 (d, J = 15.1 Hz, 1H), 3.03 (d, J = 15f.1 Hz, 
1H), 1.48 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 173.3, 
169.9, 168.7, 153.4, 136.3, 134.9, 132.4, 131.2, 128.7, 128.2, 120.1, 118.8, 82.1, 67.7, 
58.5, 57.8, 55.1, 47.7, 47.2, 41.0, 28.3; IR (Neat Film, NaCl) 2978, 1703, 1632, 1478, 
1450, 1423, 1368, 1289, 1246, 1137, 902, 803, 721, 695, 633 cm-1; HRMS (MM: ESI-










Chapter 1 – Enantioselective synthesis of gem-disubstituted N-Boc diazaheterocycles 40	
 
5-Allyl 1-(tert-butyl) 3-benzoyl-5-benzyl-4-oxotetrahydropyrimidine-1,5(2H)-
dicarboxylate (1.5e). To a solution of allyl ester (100 mg, 0.26 mmol, 1.0 equiv) in THF 
(2.6 mL) at room temperature was added sodium hydride (11 mg, 0.28 mmol, 1.1 equiv). 
After stirring for 15 min, benzyl bromide (37 µL, 0.31 mmol, 1.2 equiv) was added. The 
reaction mixture was maintained at room temperature for 22 h and at 55 °C for 24 h. The 
reaction was quenched with aqueous NH4Cl (2 mL) and diluted with EtOAc (2mL). The 
aqueous phase was extracted with EtOAc (3 x 3mL) and the combined organic phases 
were dried over anhydrous Na2SO4, decanted, and concentrated under reduced pressure 
onto silica gel. The silica-loaded residue was purified by silica gel flash chromatography 
(15% EtOAc/hexanes) to give benzylated allyl ester 1.5e as a colorless oil (94 mg, 76% 
yield): 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 7.6 Hz, 2H), 7.52 (t, J = 7.5 Hz, 1H), 
7.39 (t, J = 7.5 Hz, 2H), 7.29 – 7.19 (m, 3H), 7.14 (dd, J = 7.4, 2.2 Hz, 2H), 5.95 (ddt, J = 
16.6, 10.4, 6.0 Hz, 1H), 5.44 – 5.19 (m, 3H), 4.73 (m, 3H), 4.56 – 4.37 (m, 1H), 3.50 (d, J 
= 14.0 Hz, 1H), 3.33 (d, J = 13.9 Hz, 1H), 3.14 (d, J = 14.0 Hz, 1H), 1.45 (s, 9H); 13C 
NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 173.1, 170.4, 169.3, 153.2, 
135.0, 134.9, 132.4, 131.3, 130.9, 128.7, 128.7, 128.2, 127.5, 119.9, 81.9, 67.3, 58.0, 
57.5, 57.3, 47.8, 47.2, 38.1, 28.3; IR (Neat Film, NaCl) 3063, 2978, 2935, 1704, 1602, 
1479, 1451, 1418, 1368, 1287, 1251, 1152, 1093, 1002, 927, 902, 857, 804, 764, 727, 














1,5(2H)-dicarboxylate (1.5f). To a solution of allyl ester (100 mg, 0.26 mmol, 1.0 equiv) 
and acrylonitrile (34 µL, 0.52 mmol, 2.0 equiv) in acetonitrile (1.3 mL) at room 
temperature was added DBU (1.9 µL, 0.013 mmol, 0.05 equiv). After 22 h at room 
temperature, the reaction mixture was heated to 70 °C for 32 h, allowed to cool to room 
temperature, and treated with additional DBU (1.9 µL, 0.013 mmol, 0.05 equiv). After 2 
h at 70 °C, the reaction mixture was allowed to cool to room temperature, directly 
concentrated onto silica gel, and purified by silica gel flash chromatography (22% 
EtOAc/hexanes) to give cyanoethylated pyrimidinone 1.5f as a colorless oil (71.5 mg, 
63% yield): 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 7.7 Hz, 2H), 7.53 (t, J = 7.4 Hz, 
1H), 7.41 (t, J = 7.6 Hz, 2H), 5.97 (ddt, J = 16.7, 10.3, 6.1 Hz, 1H), 5.41 (dd, J = 17.4, 
1.5 Hz, 1H), 5.36 (d, J = 10.5 Hz, 1H), 5.28 (m, 2H), 4.74 (m, 2H), 4.41 (d, J = 13.8 Hz, 
1H), 3.49 (d, J = 13.8 Hz, 1H), 2.72 (dt, J = 16.2, 7.9 Hz, 1H), 2.50 (dt, J = 16.6, 7.8 Hz, 
1H), 2.20 (t, J = 7.9 Hz, 2H), 1.49 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of 
two rotamers) 173.0, 169.4, 169.0, 153.1, 134.6, 132.7, 130.8, 128.4, 128.4, 120.6, 118.9, 
82.6, 67.6, 67.6, 58.8, 57.9, 55.1, 49.0, 48.4, 29.2, 28.4, 13.6; IR (Neat Film, NaCl) 
2979, 2250, 1698, 1450, 1423, 1369, 1286, 1250, 1155, 1030, 939, 857, 803, 718, 696, 
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5-allyl 1-(tert-butyl) 3-benzoyl-5-((benzyloxy)methyl)-4-oxotetrahydropyrimidine-
1,5(2H)-dicarboxylate (1.5g). Following the procedure described for the preparation of 
1.5a, allyl ester (200 mg, 0.52 mmol, 1.0 equiv) was treated with sodium hydride (29 mg, 
0.72 mmol, 1.4 equiv) and alkylated with benzyl chloromethyl ether (127 µL, 0.93 mmol, 
1.8 equiv) to give, after two rounds of purification by silica gel flash chromatography 
(dry load SiO2, 16 → 25% EtOAc/hexanes), BOM-alkylated allyl ester 1.5g as a colorless 
oil (57 mg, 22% yield): 1H NMR (400 MHz, CDCl3) δ 7.73 (t, J = 8.3 Hz, 2H), 7.50 (t, J 
= 7.9 Hz, 1H), 7.41 – 7.24 (m, 7H), 5.94 (ddt, J = 16.5, 10.3, 6.0 Hz, 1H), 5.63 (d, J = 
12.2 Hz, 1H), 5.43 – 5.25 (m, 2H), 4.95 (d, J = 12.4 Hz, 1H), 4.74 (dd, J = 13.0, 5.9 Hz, 
1H), 4.70 – 4.36 (m, 4H), 4.07 (d, J = 9.2 Hz, 1H), 3.96 – 3.80 (m, 1H), 3.74 (d, J = 9.3 
Hz, 1H), 1.48 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 173.2, 
169.0, 168.7, 168.3, 153.6, 153.3, 137.5, 134.9, 132.2, 131.3, 131.0, 128.6, 128.1, 128.0, 
127.7, 119.9, 119.7, 81.9, 73.9, 70.0, 67.1, 58.7, 57.9, 57.0, 47.0, 46.7, 28.3; IR (Neat 
Film, NaCl) 2978, 2360, 1704, 1453, 1418, 1368, 1290, 1248, 1153, 1128, 1072, 1003, 
904, 857, 803, 735, 697, 633 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C28H33N2O7 
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5-allyl 1-(tert-butyl) 3-benzoyl-5-fluoro-4-oxotetrahydropyrimidine-1,5(2H)-
dicarboxylate (1.5h). To a solution of allyl ester (100 mg, 0.257 mmol, 1.0 equiv) in 
THF (2.6 mL) at room temperature was added sodium hydride (11 mg, 0.28 mmol, 1.1 
equiv). After stirring for 15 min, Selectfluor (109 mg, 0.31 mmol, 1.2 equiv) was added 
and the reaction mixture was stirred for 1.5 h at room temperature. The reaction was 
quenched with aqueous NH4Cl (2 mL) and diluted with EtOAc (2 mL). The aqueous 
phase was extracted with EtOAc (3 x 3 mL) and the combined organic phases were dried 
over anhydrous Na2SO4, filtered and concentrated by reduced pressure onto silica gel. 
The residue was purified by silica gel flash chromatography (4:1 hexanes/EtOAc) to give 
fluorinated allyl ester 1.5h as a colorless oil (92 mg, 0.226 mmol, 88%); 1H NMR (400 
MHz, CDCl3) δ (a mixture of two rotamers) 7.67 (s, 2H), 7.52 (t, J = 7.5 Hz, 1H), 7.39 
(t, J = 7.6 Hz, 2H), 5.95 (ddt, J = 16.6, 10.3, 6.0 Hz, 1H), 5.63 – 5.07 (m, 4H), 4.88 – 
4.77 (m, 1H), 4.75 (s, 1H), 4.43 (m, 1H), 3.99 (m, 1H), 1.49 (s, 9H); 13C NMR (101 
MHz, CDCl3) δ (a mixture of two rotamers) 172.4, 165.3, 164.4, 153.1, 133.8, 132.9, 
130.5, 128.6, 128.5, 120.4, 89.3 (d, JCF = 192.9 Hz, appears as four peaks due to the 
presence of two rotamers and coupling with fluorine), 82.8, 67.8, 59.0, 58.4, 49.2, (d, JCF 
= 28.3 Hz), 48.4 (d, JCF = 27.3 Hz), 28.2; IR (Neat Film, NaCl) 2979, 2360, 1770, 1715, 
1601, 1478, 1450, 1418, 1369, 1287, 1252, 1157, 1134, 1072, 1018, 907, 857, 829, 803, 
764, 730, 695, 658, 633 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C20H27FN3O6 
[M+NH4]+: 424.1878, found 424.1877. 
 
 
Chapter 1 – Enantioselective synthesis of gem-disubstituted N-Boc diazaheterocycles 44	
 
5-allyl 1-(tert-butyl) 3-benzoyl-4-oxo-5-(prop-2-yn-1-yl)tetrahydropyrimidine-
1,5(2H)-dicarboxylate 1.5i. To a solution of allyl ester (200 mg, 0.51 mmol, 1.0 equiv) 
in THF (5 mL) at 0 °C was quickly added sodium hydride (23 mg, 0.57 mmol, 1.1 equiv). 
After stirring at 0 °C for 30 minutes, propargyl bromide (111 µL, 1.03 mmol, 2 equiv) 
was added and the reaction mixture was heated to 50 °C. After three hours, more 
propargyl bromide (111 µL, 1.03 mmol, 2 equiv) was added and the reaction was allowed 
to continue for 16 h at 50 °C. The reaction was quenched with aqueous NH4Cl (10 mL) 
and extracted with EtOAc (3 x 5 mL). The combined organic phases were dried over 
anhydrous Na2SO4, decanted, and concentrated under reduced pressure. The crude 
residue was purified by silica gel flash chromatography (50% CH2Cl2/hexanes → 70% 
CH2Cl2/hexanes →  20% EtOAc/hexanes) to afford the propargylated allyl ester 1.5i as a 
colorless oil (160 mg, 73% yield): 1H NMR (400 MHz, CDCl3) δ 7.74 (s, 2H), 7.50 (d, J 
= 7.4 Hz, 1H), 7.38 (t, J = 7.5 Hz, 2H), 5.96 (dd, J = 17.0, 10.6 Hz, 1H), 5.64 (dd, J = 
12.4, 2.1 Hz, 1H), 5.39 (d, J = 17.2 Hz, 1H), 5.33 (d, J = 10.4 Hz, 1H), 5.16 – 4.88 (m, 
1H), 4.82 – 4.32 (m, 3H), 4.01 – 3.63 (m, 1H), 3.03 (d, J = 18.2 Hz, 1H), 2.71 (dd, J = 
17.0, 2.7 Hz, 1H), 2.09 (t, J = 2.6 Hz, 1H), 1.49 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 
(a mixture of two rotamers) 173.3, 169.6, 168.6, 153.5, 134.9, 132.4, 131.2, 130.9, 128.6, 
128.2, 120.0, 82.2, 78.8, 72.6, 67.5, 58.9, 58.2, 55.2, 48.2, 28.3, 23.0; IR (Neat Film, 
NaCl) 3280, 2978, 1704, 1600, 1479, 1450, 1422, 1368, 1287, 1245, 1155, 1140, 1073, 
1016, 929, 904, 856, 803, 765, 733 695, 656 cm-1; HRMS (MM: ESI-APCI): m/z calc’d 
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1.4.2.3 General Procedure for Allylic Alkylation Optimization Screen 
Optimization of Reaction Parameters 
 
[a] Screens performed on a 0.04 mmol scale. All reported yields are for isolated products. The ee 
values were determined by chiral SFC analysis. Bz = benzoyl, Boc = tert-butoxycarbonyl, pmdba = bis(4-
methoxybenzylidene)acetone 
 
In a nitrogen-filled glovebox, an oven-dried 1 dram vial was charged with 
Pd2(pmdba)3 (1.7 mg, 0.0015 mmol, 4 mol %), ligand (10 mol %), solvent (1 mL), and a 
magnetic stir bar. The vial was stirred at ambient glovebox temperature (27 °C) for 30 
min and then substrate 1.3m (20 mg, 0.04 mmol, 1.0 equiv) was added as a solution in 
solvent (1.8 mL, total concentration 0.014 M). The vial was sealed with a teflon cap and 
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thin layer chromatography, the reaction mixture was removed from the glovebox and 
concentrated under reduced pressure. The residue was purified by silica gel flash 
chromatography to afford the oxopiperazine 1.4m.  
 
1.4.2.4 General Procedure for Pd-Catalyzed Decarboxylative Allylic 
Alkylation Reactions 
Please note The absolute configuration for all other products has been inferred by 
analogy.4,7,10,13,52,53 For respective SFC conditions, please refer to the section 
Determination of Enantiomeric Excess. 
In a nitrogen-filled glovebox, an oven-dried 1 dram vial or 20 mL scintillation 
vial was charged with Pd2(pmdba)3 or Pd2(dba)3 (4 mol %), (S)-(CF3)3-tBu-PHOX (10 
mol %), hexane/toluene (2:1), and a magnetic stir bar. The vial was stirred at ambient 
glovebox temperature (27 °C) for 30 min and then the substrate (1.0 equiv) was added as 
a solution in hexane/toluene (2:1, total concentration 0.014 M or 0.033 M). The vial was 
sealed with a teflon cap and heated to 40 °C. When complete consumption of the starting 
material was observed by thin layer chromatography, the reaction mixture was removed 
from the glovebox and concentrated under reduced pressure. The residue was purified by 
silica gel flash chromatography to afford the desired oxopiperazine.  
 
 
1.4.2.5 Experimental Procedures and Spectroscopic data for the Pd-
Catalyzed Decarboxylative Asymmetric Allylic Alkylation of Piperazinone 
Substrates 
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tert-butyl (S)-2-allyl-4-benzoyl-3-oxopiperazine-1-carboxylate (1.4a). Following the 
general procedure, allyl ester 3a (25 mg, 0.064 mmol, 1.0 equiv) in toluene (1.45 mL) 
was added to a solution of Pd2(dba)3 (2.3 mg, 0.0026 mmol, 4 mol %) and (S)-(CF3)3-
tBu-PHOX (3.8 mg, 0.0064 mmol, 10 mol %) in toluene (0.5 mL). Purification by flash 
chromatography (20% EtOAc/hexanes) gave monosubstituted oxopiperazine 1.4a as a 
yellow oil (21 mg, 90% yield, 92% ee).  1H NMR (400 MHz, CDCl3) δ (a mixture of 
two rotamers) 7.64 – 7.46 (m, 3H), 7.41 (m, 2H), 5.83 (ddt, J = 17.2, 10.0, 7.3 Hz, 1H), 
5.22 – 5.07 (m, 2H), 4.70 (m, 1H), 4.45 – 3.99 (m, 1H), 3.99 – 3.70 (m, 2H), 3.42 (m, 
1H), 2.90 – 2.52 (m, 2H), 1.50 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two 
rotamers) 173.6, 170.6, 153.8, 135.3, 133.2, 132.2, 128.3, 128.3, 119.0, 81.3, 58.4, 44.5, 
38.1, 37.2, 28.5. IR (Neat Film, NaCl) 2977, 2930, 1692, 1600, 1450, 1413, 1392, 1366, 
1300, 1231, 1159, 1130, 1008, 973, 920, 856, 795, 762, 729, 696, 656 cm-1; HRMS 
(MM: ESI-APCI): m/z calc’d for C19H25N2O4 [M+H]+: 345.1809, found 345.1810; 
[α]D23.0 +49.5 (c 1.00, CHCl3); SFC conditions: 15% IPA, 2.5 mL/min, Chiralpak AD–H 




tert-butyl (S)-2-allyl-4-(4-methoxybenzoyl)-3-oxopiperazine-1-carboxylate (1.4b). 
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1.0 equiv) in toluene (0.6 mL) was added to a solution of Pd2(dba)3 (1.7 mg, 0.0014 
mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (2.8 mg, 0.0036 mmol, 10 mol %) in toluene 
(0.5 mL). Purification by flash chromatography (20% EtOAc/hexanes) gave 
monosubstituted oxopiperazine 1.4b as a light yellow oil (12 mg, 92% yield, 96% ee): 1H 
NMR (400 MHz, CDCl3) δ (a mixture of two rotamers) 7.60 (d, J = 8.9 Hz, 2H), 6.89 (d, 
J = 8.9 Hz, 2H), 5.85 (ddt, J = 17.1, 10.0, 7.3 Hz, 1H), 5.24 – 5.04 (m, 2H), 4.69 (m, 1H), 
4.19 (m, 1H), 3.85 (m, 5H), 3.42 (m, 1H), 2.89 – 2.56 (m, 2H), 1.49 (s, 9H); 13C NMR 
(101 MHz, CDCl3) δ 173.0, 170.6, 163.3, 153.9, 133.4, 131.2, 127.1, 118.9, 113.7, 81.3, 
58.4, 55.6, 44.6, 38.3, 37.4, 28.5; IR (Neat Film, NaCl) 2976, 1694, 1605, 1512, 1462, 
1416, 1366, 1315, 1257, 1234, 1170, 1130, 1003, 973, 842, 770 cm-1; HRMS (MM: 
ESI-APCI): m/z calc’d for C20H27N2O5 [M+H]+: 375.1914, found 375.1931; [α]D23.0 
+41.7 (c 1.00, CHCl3); SFC conditions: 15% IPA, 2.5 mL/min, Chiralpak AD–H 





benzyl (S)-2-allyl-4-benzoyl-3-oxopiperazine-1-carboxylate (1.4c). Following the 
general procedure, Cbz-protected allyl ester 1.3c (20 mg, 0.047 mmol, 1.0 equiv) in 
toluene (0.9 mL) was added to a solution of Pd2(dba)3 (2.2 mg, 0.0019 mmol, 4 mol %) 
and (S)-(CF3)3-tBu-PHOX (3.5 mg, 0.0047 mmol, 10 mol %) in toluene (0.5 mL). 
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oxopiperazine 1.4c as a colorless oil (15 mg, 83% yield, 99% ee): 1H NMR (500 MHz, 
CDCl3) δ (a mixture of two rotamers) 7.62 – 7.46 (m, 3H), 7.44 – 7.29 (m, 7H), 5.79 (m, 
1H), 5.16 (m, 4H), 4.83 (m, 1H), 4.26 (m, 1H), 3.97 (m, 1H), 3.87 (m, 1H), 3.49 (m, 1H), 
2.89 – 2.53 (m, 2H); 13C NMR (126 MHz, CDCl3) δ (a mixture of two rotamers) 173.5, 
170.2, 154.7, 136.0, 135.2, 132.9, 132.3, 128.8, 128.6, 128.6, 128.4, 128.3, 119.3, 68.0, 
58.4, 44.3, 39.6, 38.9, 37.2, 36.9; IR (Neat Film, NaCl) 3065, 2951, 1702, 1600, 1449, 
1427, 1395, 1362, 1302, 1228, 1163, 1127, 1015, 975, 922, 796, 761,730, 697, 656 cm-1; 
HRMS (MM: ESI-APCI): m/z calc’d for C22H23N2O4 [M+H]+: 379.1652, found 
379.1659; [α]D23.0 +66.0 (c 1.0, CHCl3); SFC conditions: 30% IPA, 2.5 mL/min, 
Chiralpak IC column, λ = 210 nm, tR (min): major = 4.873, minor = 6.748. 
 
 
tert-butyl (S)-4-benzoyl-2-(2-chloroallyl)-3-oxopiperazine-1-carboxylate (1.4d). 
Following the general procedure, 2-chloroallyl ester 1.3d (20 mg, 0.047 mmol, 1.0 
equiv.) in hexanes/toluene (2:1, 1.9 mL) was added to a solution of Pd2(pmdba)3 (2.1 mg, 
0.0019 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (2.8 mg, 0.0047 mmol, 10 mol %) in 
hexanes/toluene (2:1, 1.5 mL). Purification by silica gel flash chromatography (15% 
EtOAc/hexanes) gave oxopiperazine 1.4d as a light yellow oil (15 mg, 85% yield, 98% 
ee). 1H NMR (400 MHz, CDCl3) δ (A mixture of two rotamers) 7.56 (d, J = 7.8 Hz, 2H), 
7.51 (t, J = 7.4 Hz, 1H), 7.41 (t, J = 7.5 Hz, 2H), 5.30 (s, 1H), 5.24 (s, 1H), 5.06 – 4.88 
(m, 1H), 4.40 – 4.06 (m, 1H), 3.94 (m, 1H), 3.84 (m, 1H), 3.55 – 3.29 (m, 1H), 2.95 (dd, 
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137.5, 135.3, 132.3, 128.4, 128.3, 116.8, 81.9, 57.0, 44.6, 41.8, 37.7, 28.4. IR (Neat 
Film, NaCl) 2977, 2359, 1694, 1635, 1456, 1418, 1394, 1367, 1284, 1232, 1200, 1158, 
1007, 971, 892, 856, 796, 730, 696 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for 
C19H24ClN2O4 [M+H]+: 379.1419, found 379.1416; [α]D23.1 +33.8 (c 1.00, CHCl3); SFC 
conditions: 15% IPA, 2.5 mL/min, Chiralpak AD–H column, λ = 254 nm, tR (min): 
major = 4.482, minor = 3.224. 
 
 
tert-butyl (S)-2-allyl-4-benzoyl-2-methyl-3-oxopiperazine-1-carboxylate (1.4e). 
Following the general procedure, methylated allyl ester 1.3e (23 mg, 0.057 mmol, 1.0 
equiv) in toluene (1.2 mL) was added to a solution of Pd2(pmdba)3 (2.7 mg, 0.0023 
mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (3.7 mg, 0.0057 mmol, 10 mol %) in toluene 
(0.5 mL). Purification by flash chromatography (15% EtOAc/hexanes) gave di-
substituted oxopiperazine 1.4e as a light yellow oil (17 mg, 85% yield, 96% ee). 1H 
NMR (500 MHz, CDCl3) δ 7.57 – 7.46 (m, 3H), 7.40 (t, J = 7.6 Hz, 2H), 5.81 – 5.67 (m, 
1H), 5.17 – 5.13 (m, 1H), 5.12 (d, J = 1.1 Hz, 1H), 4.16 – 4.02 (m, 1H), 4.03 – 3.91 (m, 
1H), 3.79 (ddd, J = 12.9, 9.0, 3.0 Hz, 1H), 3.53 (ddd, J = 14.1, 9.0, 2.8 Hz, 1H), 3.11 (m, 
1H), 2.84 – 2.70 (m, 1H), 1.77 (s, 3H), 1.53 (s, 9H); 13C NMR (126 MHz, CDCl3) δ 
174.3, 172.8, 135.8, 133.1, 131.8, 128.3, 127.6, 119.5, 81.2, 67.3, 44.2, 42.7, 41.0, 28.6, 
25.5; IR (Neat Film, NaCl) 3076, 2977, 2934, 1692, 1641, 16001,102, 1450, 1392, 
1366, 1301, 1230, 1166, 1106, 1047, 1016, 955, 922, 852, 790, 757, 727, 695 cm-1; 
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359.1966; [α]D22.8 +6.5 (c 2.0, CHCl3); SFC conditions: 7% IPA, 2.5 mL/min, Chiralpak 




(1.4f). Following the general procedure, anisoyl-protected allyl ester 1.3f  (25 mg, 0.058 
mmol, 1.0 equiv) in toluene (1.3 mL) was added to a solution of Pd2(pmdba)3 (2.5 mg, 
0.0023 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (3.4 mg, 0.0058 mmol, 10 mol %) in 
toluene (0.5 mL). Purification by flash chromatography (20% EtOAc/hexanes) gave di-
substituted oxopiperazine 1.4f as a light pink oil (19 mg, 86% yield, 96% ee). 1H NMR 
(400 MHz, CDCl3) δ 7.70 – 7.53 (m, 2H), 6.99 – 6.82 (m, 2H), 5.86 – 5.67 (m, 1H), 5.23 
– 5.04 (m, 2H), 4.01 (dddd, J = 33.5, 13.9, 5.8, 2.8 Hz, 2H), 3.85 (s, 3H), 3.74 (ddd, J = 
12.7, 9.0, 2.8 Hz, 1H), 3.52 (ddd, J = 13.9, 9.0, 2.7 Hz, 1H), 3.20 (s, 1H), 2.80 (ddt, J = 
14.0, 7.1, 1.2 Hz, 1H), 1.77 (s, 3H), 1.52 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 174.1, 
172.4, 163.0, 153.9, 133.2, 130.6, 127.5, 119.4, 113.6, 81.2, 67.1, 55.5, 44.2, 42.8, 41.1, 
28.6, 25.6; IR (Neat Film, NaCl) 3076, 2977, 2934, 1692, 1641, 16001,102, 1450, 1392, 
1366, 1301, 1230, 1166, 1106, 1047, 1016, 955, 922, 852, 790, 757, 727, 695 cm-1; 
HRMS (MM: ESI-APCI): m/z calc’d for C21H29N2O5 [M+H]+: 389.2071, found 
389.2083; [α]D22.0 +75.6 (c 2.9, CHCl3); SFC conditions: 10% IPA, 2.5 mL/min, 
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tert-butyl (S)-2-allyl-4-(4-methoxybenzoyl)-2-methyl-3-oxopiperazine-1-carboxylate 
(1.4g). Following the general procedure, di-Bz-protected allyl ester 1.3g (10 mg, 0.025 
mmol, 1.0 equiv) in toluene (1.3 mL) was added to a solution of Pd2(dba)3 (0.9 mg, 
0.00098 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (1.5 mg, 0.0025 mmol, 10 mol %) in 
toluene (0.5 mL). Purification by flash chromatography (20% EtOAc/hexanes) gave di-
substituted oxopiperazine 1.4f as a colorless oil (8 mg, 89% yield, 70% ee). Product 
identity matched previously reported characterization data.4 SFC conditions: 10% 




(1.4h). Following the general procedure, benzylated allyl ester 1.3h (10 mg, 0.02 mmol, 
1.0 equiv) in hexanes/toluene (2:1, 0.9 mL) was added to a solution of Pd2(pmdba)3 (0.86 
mg, 0.00078 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (1.2 mg, 0.002 mmol, 10 mol 
%) in hexanes/toluene (2:1, 0.5 mL). Purification by flash chromatography (5% → 10% 
→ 15% EtOAc/hexanes) gave di-substituted oxopiperazine 1.4h as a colorless oil (7 mg, 
77% yield, 96% ee): 1H NMR (400 MHz, CDCl3) δ (A mixture of two rotamers) 7.57 (t, 
J = 8.5 Hz, 2H), 7.29 (d, J = 5.7 Hz, 3H), 7.22 – 7.07 (m, 2H), 6.91 (d, J = 8.3 Hz, 2H), 
5.82 (ddt, J = 17.0, 9.6, 7.1 Hz, 1H), 5.29 – 5.13 (m, 2H), 3.88 (m, 4H), 3.74 – 3.45 (m, 
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NMR (101 MHz, CDCl3) δ (A mixture of two rotamers) 172.7, 172.3, 172.0, 163.2, 
154.7, 153.4, 137.1, 136.4, 133.1, 132.6, 131.3, 130.4, 128.7, 128.5, 127.5, 127.2, 119.9, 
119.7, 113.5, 82.2, 80.6, 71.7, 55.6, 43.6, 43.3, 42.9, 42.6, 41.8, 29.8, 28.9, 28.6; IR 
(Neat Film, NaCl) 2975, 1691, 1604, 1512, 1454, 1365,1309, 1282, 1258, 1167, 1104, 
1077, 1021, 993, 925, 839, 768, 740, 704cm-1; HRMS (MM: ESI-APCI): m/z calc’d for 
C27H33N2O5 [M+H]+: 465.2384, found 465.2390; [α]D23.4 +31.0 (c 0.47, CHCl3); SFC 
conditions: 15% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 254 nm, tR (min): major 




carboxylate (1.4i). (Following the general procedure, benzyloxy methyl ether allyl ester 
1.3i (25 mg, 0.049 mmol, 1.0 equiv) in hexanes/toluene (2:1, 3.0 mL) was added to a 
solution of Pd2(pmdba)3 (2.2 mg, 0.0020 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (2.9 
mg, 0.0049 mmol, 10 mol %) in hexanes/toluene (2:1, 0.5 mL). Purification by flash 
chromatography (15% EtOAc/hexanes) gave di-substituted oxopiperazine 1.4i as a 
colorless oil (20 mg, 87% yield, 92% ee): 1H NMR (500 MHz, CDCl3) δ (A mixture of 
two rotamers) 7.61 (dd, J = 8.2, 1.4 Hz, 2H), 7.51 – 7.43 (m, 1H), 7.38 – 7.26 (m, 7H), 
5.72 (ddt, J = 17.6, 10.3, 7.4 Hz, 1H), 5.21 – 5.09 (m, 2H), 4.57 (t, J = 13.3 Hz, 3H), 4.32 
– 3.63 (m, 5H), 3.25 – 2.93 (m, 1H), 2.60 (br s, 1H), 1.50 (s, 9H); 13C NMR (126 MHz, 
CDCl3) δ 173.3, 172.5, 153.4, 135.6, 132.1, 131.9, 128.6, 128.3, 128.2, 127.9, 127.5, 
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2931, 1692, 1601, 1474, 1452, 1392, 1365, 1317, 1286, 1251, 1232, 1164, 1102, 1062, 
1016, 969, 924, 857, 730, 696, 671 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for 
C27H33N2O5 [M+H]+: 465.2384, found 465.2388; [α]D23.8 –13.9 (c 0.33, CHCl3); SFC 
conditions: 7% IPA, 2.5 mL/min, Chiralpak OJ-H column, λ = 254 nm, tR (min): major = 
3.737, minor = 4.398. 
 
tert-butyl (S)-2-allyl-2-(2-cyanoethyl)-4-(4-methoxybenzoyl)-3-oxopiperazine-1-
carboxylate (1.4j). Following the general procedure, α-cyanoethylated allyl ester 1.3j 
(25 mg, 0.053 mmol, 1.0 equiv) in hexanes/toluene (2:1, 2.8 mL) was added to a solution 
of Pd2(dba)3 (1.9 mg, 0.0021 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (3.1 mg, 0.0053 
mmol, 10 mol %) in hexanes/toluene (2:1, 1.0 mL). Purification by silica gel flash 
chromatography (dry load SiO2, 3:1 hexanes/EtOAc) gave oxopiperazine 1.4j as a 
colorless oil (20 mg, 88% yield, 97% ee): 1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 8.8 
Hz, 2H), 6.92 (d, J = 8.9 Hz, 2H), 5.79 (ddt, J = 16.6, 10.4, 7.5 Hz, 1H), 5.24 (d, J = 1.7 
Hz, 1H), 5.20 (dd, J = 9.9, 1.9 Hz, 1H), 3.98 – 3.87 (m, 2H), 3.86 (s, 3H), 3.84 – 3.71 (m, 
2H), 3.27 (m, 1H), 2.82 (m, 1H), 2.69 (dd, J = 13.8, 7.4 Hz, 1H), 2.47 (dt, J = 14.1, 7.4 
Hz, 1H), 2.32 (t, J = 7.2 Hz, 2H), 1.53 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 172.4, 
171.5, 163.4, 153.6, 132.0, 131.2, 127.0, 120.6, 119.1, 113.7, 82.0, 69.0, 55.6, 43.8, 43.2, 
42.0, 32.3, 28.5, 13.1; IR (Neat Film, NaCl) 2976, 2933, 2359, 2247, 1694, 1605, 1579, 
1512, 1456, 1366, 1281, 1258 1168, 1113, 1020, 974, 928, 843, 768, 614 cm-1; HRMS 
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[α]D23.2 –4.3 (c 1.0, CHCl3); SFC conditions: 15% IPA, 2.5 mL/min, Chiralpak OD-H 




carboxylate (1.4k). Following the general procedure, ketone 1.3k (25 mg, 0.051 mmol, 
1.0 equiv) in hexanes/toluene (2:1, 2.2 mL) was added to a solution of Pd2(dba)3 (1.9 mg, 
.002 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (3.0 mg, 0.0051 mmol, 10 mol %) in 
hexanes/toluene (2:1, 1.5 mL). Purification by silica gel flash chromatography (dry load 
SiO2, 30% EtOAc/hexanes) gave ketone 1.4k as a pale yellow oil (17 mg, 73% yield, 
97% ee); 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 8.9 Hz, 2H), 6.89 (d, J = 8.9 Hz, 
2H), 5.79 (ddt, J = 14.6, 9.4, 7.5 Hz, 1H), 5.18 (dd, J = 13.8, 1.9 Hz, 2H), 3.92 – 3.81 (m, 
6H), 3.80 – 3.66 (m, 1H), 3.22 (s, 1H), 2.74 (dd, J = 13.8, 7.3 Hz, 1H), 2.72, (m, 1H), 
2.50 – 2.27 (m, 3H), 2.13 (s, 3H), 1.51 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 207.5, 
172.6, 172.4, 163.2, 132.8, 131.0, 127.3, 120.0, 113.6, 81.6, 69.5, 55.6, 43.9, 43.2, 39.1, 
32.3, 30.0, 28.6, 24.8; IR (Neat Film, NaCl) 2975, 1694, 1605, 1512, 1456, 1392, 1366, 
1282, 1258, 1168, 1113, 1062, 1019, 974, 923, 841, 768 cm-1; HRMS (MM: ESI-
APCI): m/z calc’d for C24H33N2O6 [M+H]+: 445.2333, found 445.2335; [α]D23.2 +25.1 (c 
0.97, CHCl3); SFC conditions: 7% IPA, 2.5 mL/min, Chiralpak OD-H column, λ = 235 
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tert-butyl (R)-2-allyl-2-((((benzyloxy)carbonyl)amino)methyl)-4-(4-methoxybenzoyl)-
3-oxopiperazine-1-carboxylate (1.4l). Following the general procedure, aminomethyl 
allyl ester 3l (100 mg, 0.17 mmol, 1.0 equiv) in hexanes/toluene (2:1, 10 mL) was added 
to a solution of Pd2(dba)3 (6.3 mg, 0.0069 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (10 
mg, 0.017 mmol, 10 mol %) in hexanes/toluene (2:1, 2 mL). Purification by silica gel 
flash chromatography (15% → 20% → 30% EtOAc/hexanes) gave di-substituted 
oxopiperazine 1.4l as a yellow oil (60 mg, 65% yield, 92% ee); 1H NMR (400 MHz, 
CDCl3) δ (a mixture of two rotamers) 7.64 (t, J = 8.9 Hz, 2H), 7.44 – 7.23 (m, 5H), 6.89 
(d, J = 8.5 Hz, 2H), 5.79 (dq, J = 16.8, 7.8 Hz, 1H), 5.32 – 4.93 (m, 5H), 4.31 – 3.97 (m, 
1H), 3.95 – 3.64 (m, 7H), 3.64 – 3.45 (m, 1H), 3.45 – 2.87 (m, 1H), 2.64 (dd, J = 14.0, 
7.3 Hz, 1H), 1.48 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 172.6, 172.3, 163.1, 156.4, 
153.7, 136.6, 132.2, 131.1, 128.6, 128.4, 128.3, 127.3, 120.1, 113.6, 70.2, 67.0, 55.6, 
46.9, 43.8, 43.2, 39.6, 28.6;  IR (Neat Film, NaCl) 3357, 2975, 2361, 1694, 1605, 1512, 
1456, 1366, 1317, 1283, 1255, 1169, 1094, 1061, 1020, 923, 841, 768, 699 cm-1; HRMS 
(MM: ESI-APCI): m/z calc’d for C29H36N3O7 [M+H]+: 538.2548, found 538.2543; 
[α]D22.8 +3.74 (c 2.0, CHCl3); SFC conditions: 15% IPA, 2.5 mL/min, Chiralpak OD-H 
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tert-Butyl (R)-2-allyl-4-benzoyl-2-(((tert-butoxycarbonyl)amino)methyl)-3- 
oxopiperazine-1-carboxylate (1.4m). Following the general procedure, allyl ester 1.3m 
(100 mg, 0.19 mmol, 1.0 equiv) in hexanes/toluene (2:1, 8.0 mL) was added to a solution 
of Pd2(pmdba)3 (8.5 mg, 0.0077 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (11.4 mg, 
0.019 mmol, 10 mol %) in hexanes/toluene (2:1, 4.0 mL). Purification by flash 
chromatography (15% EtOAc/hexanes) gave di-substituted oxopiperazine 1.4m as a pale 
yellow foam (85 mg, 93% yield, 93% ee): 1H NMR (400 MHz, CDCl3) δ (a mixture of 
two rotamers) 7.61 (d, J = 7.6 Hz, 2H), 7.51 (tt, J = 7.5, 2.1 Hz, 1H), 7.41 (t, J = 7.5 Hz, 
2H), 5.91 – 5.66 (m, 1H), 5.19 (d, J = 15.6 Hz, 2H), 4.73 (s, 1H), 4.09 – 3.72 (m, 5H), 
3.67 (dd, J = 14.0, 7.0 Hz, 1H), 3.43 – 2.97 (m, 1H), 2.72 – 2.51 (m, 1H), 1.54 (s, 9H), 
1.43 (s, 9H); 13C NMR (101 MHz, CDCl3) 172.9, 172.8, 155.7, 153.6, 135.8, 132.3, 
131.9, 128.2, 128.0, 120.1, 81.2, 79.7, 70.5, 46.5, 43.7, 43.2, 39.4, 28.6, 28.5; IR (Neat 
Film, NaCl): = 3374, 2977, 1694, 1504, 1454, 1392, 1366, 1317, 1286, 1231, 1165, 
1094, 1060, 1014, 921, 855, 765, 729, 696 cm-1; HRMS (MM: ESI-APCI): m/z calc’d 
for C25H36N3O6 [M+H]+: 474.2599, found: 474.2602; [α]D23.2 +2.7 (c 1.00, CH3Cl); SFC 
conditions: 10% IPA, 2.5 mL/min, Chiralpak OD-H column, λ = 254 nm, tR (min): major 
= 4.429, minor = 3.910. 
 
 
1.4.2.6 Experimental Procedures and Spectroscopic Data for the Pd-
Catalyzed Decarboxylative Asymmetric Allylic Alkylation of 
Tetrahydropyrimidinone Substrates 
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tert-butyl (R)-5-allyl-3-benzoyl-5-methyl-4-oxotetrahydropyrimidine-1(2H)-
carboxylate (1.6a). Following the general procedure, methylated pyrimidinone 1.5a (15 
mg, 0.037 mmol, 1.0 equiv) in hexanes/toluene (2:1, 1.0 mL) was added to a solution of 
Pd2(pmdba)3 (1.6 mg, 0.0015 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (2.2 mg, 0.0037 
mmol, 10 mol %) in hexanes/toluene (2:1, 1.7 mL). Purification by silica gel flash 
chromatography (13% EtOAc/hexanes) gave α-methyl pyrimidinone 1.6a as a colorless 
oil (11 mg, 83% yield, 93% ee): 1H NMR (500 MHz, CDCl3) δ 7.57 – 7.46 (m, 3H), 
7.40 (t, J = 7.6 Hz, 2H), 5.78 (dq, J = 16.9, 8.0 Hz, 1H), 5.31 (d, J = 8.4 Hz, 1H), 5.25 – 
5.09 (m, 3H), 3.69 (d, J = 13.8 Hz, 1H), 3.55 (m, 1H), 2.52 (m, 1H), 2.31 (dd, J = 13.9, 
8.0 Hz, 1H), 1.51 (s, 9H), 1.26 (s, 3H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two 
rotamers) 176.8, 176.5, 173.9, 153.7, 135.6, 132.5, 132.1, 128.3, 127.9, 120.0, 81.8, 59.4, 
59.0, 50.6, 49.7, 45.2, 41.0, 28.4, 22.4; IR (Neat Film, NaCl) 2976, 2932, 1698, 1426, 
1367, 1286, 1246, 1136, 1027, 924, 858, 802, 750, 719, 695, 635 cm-1; HRMS (MM: 
ESI-APCI): m/z calc’d for C20H27N2O4 [M+H]+: 359.1965, found 359.1963; [α]D23.2 –
25.7 (c 1.0, CHCl3); SFC conditions: 7% IPA, 2.5 mL/min, Chiralpak OJ-H column, λ = 
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tert-butyl (R)-5-allyl-3-benzoyl-5-ethyl-4-oxotetrahydropyrimidine-1(2H)-
carboxylate (1.6b). Following the general procedure, ethylated allyl ester 1.5b (15 mg, 
0.036 mmol, 1.0 equiv) in hexanes/toluene (2:1, 1.0 mL) was added to a solution of 
Pd2(pmdba)3 (1.6 mg, 0.0014 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (2.1 mg, 0.0036 
mmol, 10 mol %) in hexanes/toluene (2:1, 1.6 mL). Purification by silica gel flash 
chromatography (13% EtOAc/hexanes) gave α-ethyl tetrahydropyrimidinone 1.6b as a 
colorless oil (13 mg,  98% yield, 94% ee); 1H NMR (400 MHz, CDCl3) δ 7.57 – 7.45 
(m, 3H), 7.39 (t, J = 7.5 Hz, 2H), 5.87 – 5.62 (m, 1H), 5.48 – 5.24 (m, 1H), 5.20 – 5.03 
(m, 3H), 3.75 (dd, J = 14.0, 1.4 Hz, 1H), 3.65 – 3.52 (m, 1H), 2.50 (dd, J = 14.2, 6.7 Hz, 
1H), 2.27 (d, J = 16.1 Hz, 1H), 1.79 (dq, J = 14.9, 7.5 Hz, 1H), 1.68 (dq, J = 14.6, 7.4 Hz, 
1H), 1.51 (s, 9H), 0.95 (t, J = 7.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ (a mixture of 
two rotamers) 175.8, 174.1, 153.7, 135.8, 132.9, 132.0, 128.3, 128.0, 119.7, 81.7, 59.2, 
58.8, 48.6, 48.0, 47.6, 39.1, 38.6, 28.7, 28.4, 8.4; IR (Neat Film, NaCl) 2976, 2927, 
1698, 1426, 1367, 1286, 1263, 1246, 1136, 1017, 923, 859, 801, 738, 695, 635 cm-1; 
HRMS (MM: ESI-APCI): m/z calc’d for C21H29N2O4 [M+H]+: 373.2122, found: 
373.2122; [α]D22.2 –21.0 (c 1.0, CHCl3); SFC conditions: 7% IPA, 2.5 mL/min, 
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methyl ester pyrimidinone 1.5c (15 mg, 0.032 mmol, 1.0 equiv) in hexanes/toluene (2:1, 
1.0 mL) was added to a solution of Pd2(pmdba)3 (1.2 mg, 0.0013 mmol, 4 mol %) and 
(S)-(CF3)3-tBu-PHOX (1.9 mg, 0.0032 mmol, 10 mol %) in hexanes/toluene (2:1, 1.3 
mL). Purification by silica gel flash chromatography (15% EtOAc/hexanes) gave methyl 
ester 1.6c as a colorless oil (9.1 mg, 67% yield, 95% ee): 1H NMR (400 MHz, CDCl3) δ 
7.50 (dd, J = 13.1, 7.2 Hz, 3H), 7.38 (t, J = 7.5 Hz, 2H), 5.73 (dq, J = 16.6, 7.4 Hz, 1H), 
5.47 – 5.22 (m, 1H), 5.22 – 5.04 (m, 3H), 3.66 (m, 5H), 2.49 (dt, J = 12.9, 6.4 Hz, 1H), 
2.37 (m, 2H), 2.31 – 2.19 (m, 1H), 2.14 – 1.91 (m, 2H), 1.51 (s, 9H); 13C NMR (101 
MHz, CDCl3) δ (a mixture of two rotamers)  175.2, 174.9, 173.9, 173.3, 153.5, 135.6, 
132.1, 132.0, 128.4, 127.9, 120.3, 82.0, 59.2, 58.8, 51.1, 48.7, 47.7, 39.1, 38.8, 30.3, 28.9, 
28.3; IR (Neat Film, NaCl) 2978, 1738, 1698, 1428, 1368, 1286, 1247, 1147, 925, 856, 
802, 764, 696 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C23H31N2O6 [M+H]+: 
431.2177, found 431.2173; [α]D23.1 +5.5 (c 0.9, CHCl3); SFC conditions: 10% IPA, 2.5 






carboxylate (1.6d). Following the general procedure, 2-chloropropenyl allyl ester 5d (20 
mg, 0.049 mmol, 1.0 equiv) in hexanes/toluene (2:1, 3.0 mL) was added to a solution of 
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mmol, 10 mol %) in hexanes/toluene (2:1, 0.5 mL). Purification by flash chromatography 
(EtOAc/hexanes 15%) gave di-substituted oxopiperazine 1.6d as a yellow oil (17 mg, 
94% yield, 94% ee); 1H NMR (400 MHz, CDCl3) δ (a mixture of two rotamers) 7.65 – 
7.45 (m, 3H), 7.40 (t, J = 7.6 Hz, 2H), 5.95 – 5.76 (m, 1H), 5.76 – 5.47 (m, 1H), 5.31 (d, 
J = 1.3 Hz, 1H), 5.30 – 5.16 (m, 2H), 4.92 (s, 1H), 4.05 (s, 1H), 3.61 (d, J = 14.0 Hz, 
1H), 3.06 (d, J = 14.8 Hz, 1H), 2.69 – 2.55 (m, 1H), 2.45 (d, J = 14.5 Hz, 2H), 1.52 (s, 
9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 174.4, 173.9, 153.6, 
137.5, 135.6, 132.1, 132.0, 128.3, 128.1, 120.8, 118.1, 82.0, 59.1, 48.2, 47.6, 46.6, 42.8, 
42.3, 41.7, 28.4; IR (Neat Film, NaCl) 2977, 1698, 1630, 1478, 1426, 1368, 1286, 1246, 
1140, 902, 802, 765, 724, 695, 636 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for 
C22H28ClN2O4 [M+H]+: 419.1732, found 419.1732; [α]D22.6 +22.2 (c 1.0, CHCl3); SFC 
conditions: 10% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): major 





carboxylate (1.6e). Following the general procedure, benzylated allyl ester 1.5e (15 mg, 
0.031 mmol, 1.0 equiv) in hexanes/toluene (2:1, 1.0 mL) was added to a solution of 
Pd2(pmdba)3 (1.4 mg, 0.0013 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (1.9 mg, 0.0031 
mmol, 10 mol %) in hexanes/toluene (2:1, 1.2 mL). Purification by silica gel flash 
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colorless oil (11.5 mg, 84% yield, 95% ee); 1H NMR (500 MHz, CDCl3) δ 7.58 – 7.49 
(m, 3H), 7.42 (t, J = 7.7 Hz, 2H), 7.31 – 7.24 (m, 3H), 7.20 (d, J = 7.2 Hz, 2H), 5.86 
(dddd, J = 16.8, 10.2, 7.9, 6.6 Hz, 1H), 5.48 – 5.25 (m, 1H), 5.22 (d, J = 10.0 Hz, 1H), 
5.21 – 5.14 (m, 1H), 4.87 (d, J = 11.9 Hz, 1H), 3.89 – 3.72 (m, 1H), 3.55 (d, J = 13.7 Hz, 
1H), 3.37 – 3.21 (m, 1H), 2.80 – 2.68 (m, 1H), 2.65 (dd, J = 14.0, 6.6 Hz, 1H), 2.32 – 
2.19 (m, 1H), 1.52 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 
175.4, 173.9, 153.6, 136.1, 135.6, 132.6, 132.1, 131.0, 128.5, 128.3, 128.1, 127.1, 120.2, 
81.9, 58.8, 49.5, 47.2, 46.5, 41.1, 40.6, 28.4; IR (Neat Film, NaCl) 2978, 2930, 2360, 
1698, 1424, 1368, 1288, 1245, 1142, 1029, 924, 856, 802, 718, 696, 636 cm-1; HRMS 
(MM: ESI-APCI): m/z calc’d for C26H31N2O4 [M+H]+: 435.2278, found: 435.2274; 
[α]D22.1 –5.6 (c 1.0, CHCl3); SFC conditions: 20% IPA, 2.5 mL/min, Chiralpak IC 






carboxylate (1.6f). Following the general procedure, cyanoethylated 
tetrahydropyrimidinone 1.5f (15 mg, 0.034 mmol, 1.0 equiv) in hexanes/toluene (2:1, 1.0 
mL) was added to a solution of Pd2(pmdba)3 (1.2 mg, 0.0014 mmol, 4 mol %) and (S)-
(CF3)3-tBu-PHOX (2.0 mg, 0.0034 mmol, 10 mol %) in hexanes/toluene (2:1, 1.4 mL). 
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cyanoethylated tetrahydropyrimidinone 1.6f as a colorless oil (9.0 mg, 67% yield, 74% 
ee): 1H NMR (500 MHz, CDCl3) δ 7.56 – 7.49 (m, 3H), 7.43 (t, J = 7.6 Hz, 2H), 5.75 
(dddd, J = 16.8, 10.2, 7.9, 6.6 Hz, 1H), 5.35 – 5.13 (m, 4H), 3.86 – 3.55 (m, 2H), 2.57 – 
2.51 (m, 1H), 2.44 (dd, J = 10.0, 5.9 Hz, 2H), 2.32 (dd, J = 14.1, 8.0 Hz, 1H), 2.09 (dt, J 
= 14.6, 8.5 Hz, 1H), 1.96 (ddd, J = 14.3, 9.8, 6.2 Hz, 1H), 1.53 (s, 9H); 13C NMR (101 
MHz, CDCl3) δ 174.6, 173.7, 153.4, 135.4, 132.4, 131.2, 128.5, 127.8, 121.2, 119.2, 
82.5, 59.4, 48.3, 47.7, 39.1, 31.0, 28.4, 12.6; IR (Neat Film, NaCl) 2977, 2931, 2248, 
1694, 1601, 1478, 1427,1368, 1285, 1263, 1246, 1141, 1027, 926,901, 857, 802, 763, 
721, 696, 636, cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C22H28N3O4 [M+H]+: 
398.2074, found 398.2071; [α]D23.2 +10.0 (c 1.0, CHCl3); SFC conditions: 30% IPA, 2.5 






1(2H)-carboxylate (1.6g). Following the general procedure, allyl ester 1.5g (15 mg, 
0.029 mmol, 1.0 equiv) in hexanes/toluene (2:1, 1.6 mL) was added to a solution of 
Pd2(pmdba)3 (1.3 mg, 0.0012 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (1.7 mg, 0.0029 
mmol, 10 mol %) in hexanes/toluene (2:1, 0.5 mL). Purification by flash chromatography 
(10 → 15% EtOAc/hexanes) gave di-substituted oxopiperazine 1.6g as a yellow oil (13 
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(m, 1H), 7.42 – 7.22 (m, 7H), 5.77 (ddt, J = 15.0, 10.3, 7.4 Hz, 1H), 5.54 – 5.49 (m, 1H), 
5.28 – 5.10 (m, 2H), 5.06 (d, J = 12.1 Hz, 1H), 4.63 – 4.40 (m, 2H), 3.94 (m, 1H), 3.82 
(d, J = 13.9 Hz, 1H), 3.75 (d, J = 8.9 Hz, 1H), 3.40 (d, J = 9.0 Hz, 1H), 2.42 (m, 2H), 
1.50 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 174.7, 173.5, 153.6, 137.8, 135.5, 132.0, 
128.6, 128.3, 128.2, 127.9, 127.7, 112.0, 81.8, 73.8, 58.8, 50.0, 46.9, 46.3, 38.6, 28.4; IR 
(Neat Film, NaCl) 2977, 2926, 2283, 1698, 1641, 1478, 1451, 1426, 1367, 1287, 1246, 
1151, 1028, 906, 857, 801, 740, 697, 635 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for 
C27H32N2O5 [M+H]+: 465.2384, found 465.2378; [α]D23.4 +11.9 (c 0.67, CHCl3); SFC 
conditions: 20% IPA, 2.5 mL/min, Chiralpak IC column, λ = 210 nm, tR (min): major = 







carboxylate (1.6h). Following the general procedure, fluorinated tetrahydropyrimidinone 
1.5h (300 mg, 0.74 mmol, 1.0 equiv) in hexanes/toluene (2:1, 39 mL) was added to a 
solution of Pd2(pmdba)3 (24 mg, 0.022 mmol, 3 mol %) and (S)-(CF3)3-tBu-PHOX (35 
mg, 0.059 mmol, 10 mol %) in hexanes/toluene (2:1, 15 mL). Purification by silica gel 
flash chromatography (15% EtOAc/hexanes) gave fluorinated tetrahydropyrimidinone 
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7.59 (dd, J = 8.3, 1.3 Hz, 2H), 7.54 (t, J = 7.4 Hz, 1H), 7.42 (t, J = 7.8 Hz, 2H), 5.82 (ddt, 
J = 14.9, 9.6, 7.2 Hz, 1H), 5.66 – 5.34 (m, 1H), 5.29 (s, 1H), 5.25 (d, J = 5.3 Hz, 1H), 
5.24 – 5.13 (m, 1H), 4.13 – 3.72 (m, 2H), 2.81 (td, J = 14.3, 6.9 Hz, 1H), 2.67 (ddd, J = 
22.4, 14.5, 7.6 Hz, 1H), 1.51 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (a mixture of two 
rotamers) 172.5, 168.23 (d, JCF = 23.6 Hz), 153.4, 134.3, 132.7, 129.7, 129.6, 128.5, 
128.5, 128.3, 128.0, 121.4, 92.2 (d, JCF = 197.0 Hz, appears as four peaks due to the 
presence of two rotamers and coupling with fluorine), 82.4, 57.7, 49.4 (appears as four 
poorly resolved peaks due to the presence of two rotamers and coupling with fluorine), 
38.2 (d, JCF = 22.8 Hz), 28.3; IR (Neat Film, NaCl) 2978, 1710, 1416, 1368, 1286, 1245, 
1158, 1137, 906, 858, 801, 749, 723, 694, 662 cm-1; HRMS (MM: ESI-APCI): m/z 
calc’d for C19H24N2O4 [M+H]+: 363.1715, found: 363.1713; [α]D21.8 –28.6 (c 0.96, 
CHCl3); SFC conditions: 10% IPA, 2.5 mL/min, Chiralpak IC column, λ = 254 nm, tR 





1(2H)-carboxylate (1.6i). Following the general procedure, propargylated allyl ester 1.5i 
(20 mg, 0.047 mmol, 1.0 equiv) in hexanes/toluene (2:1, 2.8 mL) was added to a solution 
of Pd2(pmdba)3 (2.1 mg, 0.0019 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (2.8 mg, 
0.0047 mmol, 10 mol %) in hexanes/toluene (2:1, 0.5 mL). Purification by flash 
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tetrahydropyrimidinone 1.6i as a yellow oil (15 mg, 83% yield, 90% ee): 1H NMR (400 
MHz, CDCl3) δ 7.58 (s, 1H), 7.50 (t, J = 7.4 Hz, 2H), 7.39 (t, J = 7.5 Hz, 2H), 5.89 – 
5.68 (m, 1H), 5.42 (s, 1H), 5.31 – 4.98 (m, 3H), 4.15 – 3.57 (m, 2H), 2.61 (dd, J = 16.9, 
2.7 Hz, 2H), 2.42 (dd, J = 16.9, 2.7 Hz, 2H), 2.11 (t, J = 2.6 Hz, 1H), 1.54 (s, 9H); 13C 
NMR (101 MHz, CDCl3) δ (a mixture of two rotamers) 174.3, 173.7, 153.6, 135.4, 
132.2, 131.8, 128.3, 128.2, 120.6, 82.0, 79.6, 72.4, 59.3, 58.9, 48.2, 47.8, 40.1, 39.6, 28.4, 
25.1; IR (Neat Film, NaCl) 3271, 2978, 2930, 1698, 1478, 1450, 1425, 1368, 1284, 
1247, 1139, 1028, 927, 854, 802, 764, 720, 695, 635 cm-1; HRMS (MM: ESI-APCI): 
m/z calc’d for C22H27N2O4 [M+H]+: 383.1965, found 383.1973; [α]D23.0 +22.1 (c 0.47, 
CHCl3); SFC conditions: 10% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 210 nm, 




1.4.2.7 Experimental Procedure for the Gram Scale Decarboxylative 




carboxylate (1.6e). In a nitrogen-filled glovebox, a 250 mL schlenk flask was charged 
with Pd2(pmdba)3 (69 mg, 0.063 mmol, 4 mol %), (S)-(CF3)3-tBu-PHOX (99 mg, 0.17 
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stirred at ambient glovebox temperature (27 °C) for 30 min and then 1.5e (1g, 2.1 mmol, 
1.0 equiv) was added as a solution in hexane/toluene (2:1, 100 mL, total concentration 
0.014M). The flask was sealed with a Kontes valve, removed from the glovebox, and 
heated to 40 °C for 16 h. The solution was concentrated under reduced pressure and 
purified by silica gel flash chromatography (15% EtOAc/hexanes) to give benzyl 
tetrahydropyrimidinone 1.6e as a yellow oil (780 mg, 87% yield, 95% ee); spectroscopic 
data vide supra.  
 
 
1.4.2.8 Experimental Procedures for the Transformations of 




tert-butyl (R)-((2-allyl-4-benzoyl-3-oxopiperazin-2-yl)methyl)carbamate (1.8). 
Trifluoroacetic acid (114 µL, 1.5 mmol, 20 equiv) was added dropwise to a solution of 
methylcarbamate oxopiperazine 1.4m (35 mg, 0.07 mmol, 1.0 equiv) in CH2Cl2 (0.74 
mL) at 0 °C. The reaction mixture was allowed to warm up to room temperature, stirred 
for 3 h and concentrated under reduced pressure. The residue was repeatedly taken up in 
CH2Cl2 (1.0 mL) and concentrated, four times. The crude residue was then purified by 
silica gel flash chromatography (10% MeOH/CH2Cl2) to yield deprotected oxopiperazine 




Chapter 1 – Enantioselective synthesis of gem-disubstituted N-Boc diazaheterocycles 68	
8.0 Hz, 3H), 7.37 (t, J = 7.4 Hz, 2H), 5.66 (dd, J = 16.0, 8.8 Hz, 1H), 5.30 (d, J = 9.8 Hz, 
1H), 5.25 (d, J = 16.8 Hz, 1H), 3.99 – 3.79 (m, 1H), 3.73 – 3.55 (m, 1H), 3.44 – 3.16 (m, 
2H), 3.05 (d, J = 13.2 Hz, 1H), 2.89 (d, J = 11.6 Hz, 1H), 2.76 (dd, J = 14.0, 7.0 Hz, 1H), 
2.45 (dd, J = 14.2, 7.1 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 173.7, 172.4, 135.5, 
132.2, 129.7, 128.4, 128.0, 122.5, 62.0, 47.0, 43.5, 39.7, 38.1; IR (Neat Film, NaCl) 
2976, 1682, 1470, 1282, 1203, 1135, 926, 836, 799, 722, 696 cm-1; HRMS (MM: ESI-
APCI): m/z calc’d for C15H20N3O4 [M+H]+: 274.1550, found 274.1555; [α]D22.3 +15.1 




carboxylate (1.9). LiOH monohydrate (2.5 mg, 0.06 mmol, 1.4 equiv) was added in one 
portion to a solution of methylcarbamate oxopiperazine 1.4m (20 mg, 0.04 mmol, 1.0 
equiv) in methanol/water (1:1, 1.8 mL) at room temperature. The reaction mixture was 
stirred for 1 h, diluted with EtOAc (2 mL) and washed with saturated aqueous NaHCO3 
(2 mL). The aqueous phase was extracted with EtOAc (3x3 mL) and the combined 
organic phases were washed with brine (3 mL), dried over anhydrous Na2SO4, decanted, 
and concentrated under reduced pressure onto silica gel. The silica-loaded residue was 
purified by silica gel flash chromatography (hexanes/EtOAc 1:1) to yield lactam 1.9 as a 
white foam (14 mg, 92% yield): 1H NMR (400 MHz, CDCl3) δ 6.96 (s, 1H), 5.72 (ddt, J 
= 17.2, 10.2, 7.4 Hz, 1H), 5.16 – 5.04 (m, 2H), 4.88 (t, J = 6.9 Hz, 1H), 4.26 – 3.91 (m, 
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(s, 1H), 1.52 (s, 9H), 1.41 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 172.7, 155.7, 153.9, 
132.7, 119.2, 81.2, 79.3, 69.1, 46.0, 43.1, 40.9, 38.9, 28.6, 28.5; IR (Neat Film, NaCl) 
3337, 2977, 2360, 1698, 1520, 1367, 1243, 1168, 1085, 1058, 919, 866, 768, 733 cm-1; 
HRMS (MM: ESI-APCI): m/z calc’d for C18H32N3O5 [M+H]+: 370.2336, found 




carboxylate (1.10). To a solution of lactam 1.9 (50 mg, 0.14 mmol, 1 equiv) in THF (1.4 
mL) at 0 °C was quickly added LAH (8 mg, 0.2 mmol, 1.5 equiv) in one portion. The 
mixture was stirred at room temperature and three portions of LAH (8 mg, 0.2 mmol, 1.5 
equiv) were added over four hours until all starting material was consumed as determined 
by TLC analysis. The reaction mixture was then cooled to 0 °C and diluted with Et2O. 
H2O (40 µL), 15% aqueous NaOH (40 µL), and H2O (120 µL) were added successively 
at 0 °C. The mixture was stirred for 5 minutes at room temperature and then MgSO4 was 
added. The mixture was stirred for another 5 minutes at room temperature and then 
filtered over a pad of celite, rinsing with EtOAc. The solvent was concentrated under 
reduced pressure and the crude residue was purified by silica gel flash chromatography 
(MeOH/CH2Cl2, 1 → 2 →  4%) to afford piperazine 1.10 as a colorless oil (30 mg, 63% 
yield); 1H NMR (400 MHz, CDCl3) δ 5.84 – 5.66 (m, 1H), 5.28 – 5.01 (m, 3H), 3.75 
(dd, J = 14.1, 5.6 Hz, 1H), 3.62 (dt, J = 13.6, 4.2 Hz, 1H), 3.35 (dd, J = 14.1, 7.3 Hz, 1H), 
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– 2.63 (m, 2H), 2.57 – 2.26 (m, 2H), 1.46 (s, 9H), 1.44 (s, 9H); 13C NMR (101 MHz, 
CDCl3) δ 156.8, 156.0, 133.1, 119.1, 80.6, 79.6, 59.9, 50.8, 46.2, 45.1, 42.3, 38.1, 28.6, 
28.5; IR (Neat Film, NaCl) 3789, 3662, 3451, 3341, 3074, 2976, 2930, 2284, 1693, 
1641, 1502, 1453, 1391, 1365, 1298, 1249, 1169, 1085, 996, 914, 859, 771 cm-1; HRMS 
(MM: ESI-APCI): m/z calc’d for C18H34N3O4 [M+H]+: 356.2544, found 356.2549; 




(S)-1-benzoyl-3-methyl-3-propylpiperazin-2-one 1.11. Piperazinone 1.4e (80 mg, 0.22 
mmol, 1 equiv) was dissolved in MeOH (2.2 mL). The reaction flask was purged with 
Argon before adding Pd/C (10%, 24 mg, 0.022 mmol, 0.1 equiv). The flask was 
evacuated and filled with H2 three times, and then sparged with H2 for 5 minutes. The 
reaction was stirred at room temperature for 6 hours before being filtered through a pad 
of silica gel while rinsing with EtOAc. The crude hydrogenated product was then 
dissolved in CH2Cl2 (2.2 mL) and TFA (171 µL, 2.23 mmol, 10 equiv) was added. The 
reaction was stirred for 16 hours and then quenched with saturated aqueous NaHCO3 (5 
mL). The solution was extracted with EtOAc (3x5 mL), dried over Na2SO4, decanted, 
and concentrated under reduced pressure. The crude piperazinone was purified by silica 
gel flash chromatography (2.5 → 5% MeOH/CH2Cl2) to afford the desired product 1.11 
(55 mg, 94% yield over two steps): 1H NMR (400 MHz, CDCl3) δ 7.58 – 7.50 (m, 2H), 
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J = 12.5, 6.7, 5.4 Hz, 1H), 3.32 – 3.18 (m, 2H), 1.92 (ddd, J = 13.6, 12.1, 4.7 Hz, 1H), 
1.62 (ddd, J = 13.6, 12.2, 4.5 Hz, 1H), 1.42 (s, 3H), 1.54 – 1.23 (m, 2H), 0.96 (t, J = 7.3 
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 176.7, 174.7, 136.4, 131.6, 128.3, 127.5, 61.2, 
48.2, 41.2, 38.7, 25.0, 16.9, 14.5; IR (Neat Film, NaCl) 3331, 2960, 2872, 1681, 1600, 
1448, 1378, 1284, 1202, 1176, 1152, 1112, 966, 794, 726, 694, 669 cm-1; HRMS (MM: 
ESI-APCI): m/z calc’d for C15H21N2O2 [M+H]+: 261.1598, found 261.1596; [α]D22.6 –
59.6 (c 1.35, CHCl3). 
 
(R)-4-benzoyl-6-propyl-1,4-diazabicyclo[4.2.0]octane-5,8-dione (1.12). To a 10 mL 
round-bottom flask was added Pd(OPiv)2 (3 mg, 0.0096 mmol, 0.1 equiv), AgOPiv58 (60 
mg, 0.29 mmol, 3 equiv), Xantphos (6 mg, 0.0096 mmol, 0.1 equiv), and 1,4-
benzoquinone (21 mg, 0.19 mmol, 2 equiv). A solution of piperazine 1.11 (25 mg, 0.096 
mmol, 1 equiv) in toluene (1 mL) was then added and the flask was evacuated and filled 
with carbon monoxide three times. The flask was then stirred at 80 °C for 16 hours. The 
reaction mixture was allowed to cool to room temperature, diluted with EtOAc, and 
filtered through celite while rinsing with additional EtOAc. The solvent was concentrated 
under reduced pressure onto silica gel and then purified by silica gel flash 
chromatography (2:1 hexanes/EtOAc) to provide the β-lactam 1.12 and as a light yellow 
oil (15 mg, 55% yield): 1H NMR (400 MHz, CDCl3) δ (5:1 ratio of desired product and 
an inseparable isomer resulting from insertion into another β-C−H) 7.56 – 7.51 (m, 3H), 
7.46 – 7.40 (m, 2H), 4.51 (ddd, J = 14.0, 6.1, 2.9 Hz, 1H), 3.94 (ddt, J = 12.3, 10.8, 5.7 
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2H), 1.98 (ddd, J = 14.2, 11.2, 5.5 Hz, 1H), 1.87 (ddd, J = 14.2, 11.0, 5.7 Hz, 1H), 1.59 – 
1.40 (m, 2H), 1.00 (t, J = 7.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 174.2, 173.2, 
169.1, 135.1, 132.6, 128.6, 128.3, 59.7, 46.7, 41.5, 39.7, 37.8, 17.7, 14.3; IR (Neat Film, 
NaCl) 3374, 2961, 1760, 1688, 1600, 1505, 1449, 1350, 1318, 1279, 1228, 1183, 1151, 
1110, 963, 936, 796, 726, 694, 662 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for 




(S)-2-benzyl-2-(((tert-butoxycarbonyl)amino)methyl)pent-4-enoic acid (1.13). To a 
solution of benzyl tetrahydropyrimidinone 1.6e (200 mg, 0.46 mmol, 1 equiv) in 
methylene chloride (4.6 mL) was added TFA (352 µL, 4.6 mmol, 10 equiv) dropwise at 
room temperature. The solution was stirred for 24 hours at room temperature and then 
quenched with aqueous NaHCO3 (10 mL). The layers were separated and the aqueous 
layer was extracted with CH2Cl2 (4 x 5 mL). The combined organic layers were dried 
over Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was 
dissolved in MeOH/H2O (1:1, 5 mL) and LiOH monohydrate (290 mg, 6.9 mmol, 15 
equiv) was added. The reaction mixture was heated to 80 °C for 60 hours and then 
allowed to cool to room temperature. Then, NEt3 (77 µL, 0.55 mmol, 1.2 equiv) and 
Boc2O (110 mg, 0.51 mmol, 1.1 equiv) were added successively at room temperature. 
The reaction was stirred for 1 hour at room temperature and then acidified with 1 M HCl 
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were dried over Na2SO4. The crude Boc-protected β-amino acid was taken up in DMF 
(2.3 mL). K2CO3 (95 mg, 0.69 mmol, 1.5 equiv) and BnBr (66 µL, 0.55 mmol, 1.2 equiv) 
were added at room temperature. The reaction was stirred at room temperature for 1 hour 
and then quenched with saturated aqueous NH4Cl. The solution was extracted with 
EtOAc (3 x 5 mL) and the combined organic layers were concentrated under reduced 
pressure and placed under high vacuum until trace DMF had evaporated. The residue was 
taken up in CH2Cl2, concentrated under reduced pressure onto silica gel and purified by 
silica gel flash chromatography (5 → 10% EtOAc/hexanes) to afford protected β2,2-amino 
acid 1.13 as a white solid (80 mg, 40% yield): 1H NMR (400 MHz, CDCl3) δ 7.42 – 7.27 
(m, 5H), 7.20 (dd, J = 4.9, 1.9 Hz, 3H), 7.10 – 6.93 (m, 2H), 5.92 – 5.75 (m, 1H), 5.18 – 
5.04 (m, 4H), 4.96 – 4.81 (m, 1H), 3.34 (qd, J = 14.0, 6.5 Hz, 2H), 2.98 (d, J = 13.8 Hz, 
1H), 2.86 (d, J = 13.8 Hz, 1H), 2.49 (ddt, J = 14.2, 6.7, 1.4 Hz, 1H), 2.31 (ddt, J = 14.2, 
7.9, 1.1 Hz, 1H), 1.43 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 175.1, 156.1, 136.6, 
135.6, 133.4, 130.2, 128.8, 128.6, 128.5, 128.4, 126.9, 119.2, 79.4, 66.8, 51.6, 44.1, 41.0, 
38.8, 28.5; IR (Neat Film, NaCl) 3452, 3065, 3031, 2977, 2930, 1721, 1640, 1604, 
1503, 1454, 1391, 1365, 1245, 1169, 1094, 1030z, 994, 917, 859, 776, 741, 700 cm-1; 
HRMS (MM: ESI-APCI): m/z calc’d for C25H32NO4 [M+H]+: 410.2326, found 
410.2324; [α]D23.4 +3.47 (c 1.0, CHCl3). 
 
 
(R)-2-allyl-2-(aminomethyl)pentanedioic acid (1.14). To a solution of methyl ester 
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was added TFA (250 µL, 3.25 mmol, 10 equiv) dropwise at room temperature. The 
solution was stirred for 24 h at room temperature and then concentrated under reduced 
pressure. Remaining TFA was removed with by azeotroping with CH2Cl2 three times. 
The crude residue was dissolved in MeOH/H2O (1:1, 3.1 mL, 0.1 M) and LiOH 
monohydrate (205 mg, 4.89 mmol, 15 equiv) was added. The reaction mixture was 
heated to 80 °C for 16 h and then allowed to cool to room temperature. The reaction 
mixture was then acidified with 4 M HCl in dioxanes (~1 mL) until pH 1. Then, the 
solvent was concentrated under reduced pressure, resulting in precipitation of a white 
solid. A minimal amount of DMSO (~1 mL) was added to resolvate this precipitate. This 
solution was subjected to purification by reverse phase preparatory HPLC (0 → 40% 
MeCN/H2O gradient over 11 minutes, 20x250 mm C18 column, 25 mL/min flow rate) to 
yield β-amino acid 1.14 (30 mg, 46% yield) as a colorless oil. Note: HPLC fractions were 
spotted onto a silica TLC plate and eluted in (n-BuOH/H2O/EtOAc/AcOH, 1:1:1:1), then 
stained with ninhydrin to identify product-containing fractions. LC-MS was used to 
verify the fractions containing product. Note: HPLC H2O solvent contained 0.25% TFA. 
1H NMR (400 MHz, Methanol-d4) δ 5.88 – 5.68 (m, 1H), 5.32 – 5.13 (m, 2H), 3.18 – 
2.99 (m, 2H), 2.51 (ddt, J = 14.4, 7.1, 1.3 Hz, 1H), 2.47 – 2.33 (m, 3H), 1.99 (td, J = 7.6, 
1.3 Hz, 2H); 13C NMR (101 MHz, MeOD) δ 176.7, 176.6, 133.1, 120.6, 48.3, 43.5, 39.1, 
29.38, 29.35; IR (Neat Film, NaCl) 2924, 1678, 1198, 1138 cm-1; HRMS (MM: ESI-
APCI): m/z calc’d for C9H16NO4 [M+H]+: 202.1074, found 202.1075; [α]D22.7 –3.51 (c 
1.0, MeOH). 
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(S)-2-allyl-2-(aminomethyl)-4-chloropent-4-enoic acid (1.15). To a solution of 
chloroallyl tetrahydropyrimidinone 1.6d (30 mg, 0.072 mmol, 1 equiv) in CH2Cl2 (700 
µL, 0.1 M) was added TFA (55 µL, 0.72 mmol, 10 equiv) dropwise at room temperature. 
The solution was stirred for 5 h at room temperature and then concentrated under reduced 
pressure. Remaining TFA was removed with by azeotroping with CH2Cl2 three times. 
The crude residue was dissolved in MeOH/H2O (1:1, 700 µL, 0.1 M) and LiOH 
monohydrate (45 mg, 1.07 mmol, 15 equiv) was added. The reaction mixture was heated 
to 80 °C for 16 h and then allowed to cool to room temperature. The reaction mixture was 
then acidified with 4 M HCl in dioxane (~1 mL) until pH 1. Then, the solvent was 
concentrated under reduced pressure, resulting in precipitation of a white solid. A 
minimal amount of DMSO (~1 mL) was added to resolvate this precipitate. This solution 
was subjected to purification by reverse phase preparatory HPLC (10 → 40% 
MeCN/H2O gradient over 11 minutes, 20x250 mm C18 column, 25 mL/min flow rate) to 
yield chloroallyl β-amino acid 1.15 (10 mg, 69% yield) as a colorless oil. Note: HPLC 
fractions were spotted onto a silica TLC plate and eluted in (n-BuOH/H2O/EtOAc/AcOH, 
1:1:1:1), then stained with ninhydrin to identify product-containing fractions. LC-MS was 
used to verify the fractions containing product. Note: HPLC H2O solvent contained 
0.25% TFA. 1H NMR (600 MHz, Methanol-d4) δ 5.84 (td, J = 17.2, 7.3 Hz, 1H), 5.40 
(s, 2H), 5.28 – 5.18 (m, 2H), 3.29 (d, J = 13.5 Hz, 1H), 3.12 (d, J = 13.5 Hz, 1H), 2.94 (d, 
J = 15.1 Hz, 1H), 2.77 (d, J = 14.8 Hz, 1H), 2.57 (dd, J = 14.5, 7.0 Hz, 1H), 2.47 (dd, J = 
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48.4, 44.2, 43.5, 39.6. Note: A 1H-13C HMBC experiment revealed the chemical shift of 
the chiral quaternary carbon to be at 48.4 ppm, obscured by the CD3OD resonance. IR 
(Neat Film, NaCl) 2926, 1673, 1432, 1200, 1140, 900, 836, 800, 722 cm-1; HRMS 
(MM: ESI-APCI): m/z calc’d for C9H15ClNO2 [M+H]+: 204.0786, found 204.0787; 
[α]D22.5 –4.64 (c 0.67, MeOH). 
 
 
(S)-2-(aminomethyl)-2-fluoropent-4-enoic acid (1.16). To a solution of fluoro 
tetrahydropyrimidinone 1.6h (20 mg, 0.055 mmol, 1 equiv) in 1:1 MeOH/H2O (550 µL, 
0.1 M) at room temperature was added KOH (31 mg, 0.55 mmol, 10 equiv). The cloudy 
solution became clear over seconds and was stirred for 5 min at room temperature until 
TLC analysis showed complete consumption of starting material. AcOH (~100 µL) was 
added to acidify the solution, which was then extracted with CH2Cl2 three times. The 
combined organic layers were dried with Na2SO4 and then concentrated under reduced 
pressure. HCl was generated in situ by adding AcCl (205 µL, 2.87 mmol, 52 equiv) 
dropwise to a separate 1 dram vial containing MeOH (550 µL) at 0 °C. This HCl solution 
was stirred for 5 min at 0 °C and was then transferred by pipette into a 1 dram vial 
containing the crude saponified residue. The reaction was stirred at rt for 2 h and was 
then concentrated under reduced pressure. The crude residue was dissolved in 1:1 
H2O/MeCN (2.5 mL) and was then subjected to purification by reverse phase preparatory 
HPLC (0 → 40% MeCN/H2O gradient over 11 minutes, 20x250 mm C18 column, 25 





Chapter 1 – Enantioselective synthesis of gem-disubstituted N-Boc diazaheterocycles 77	
oil. Note: HPLC fractions were spotted onto a silica TLC plate and eluted in (n-
BuOH/H2O/EtOAc/AcOH, 1:1:1:1), then stained with ninhydrin to identify product-
containing fractions. LC-MS was used to verify the fractions containing product. Note: 
HPLC H2O solvent contained 0.25% TFA.  1H NMR (600 MHz, Methanol-d4) δ 5.80 
(ddt, J = 17.3, 10.1, 7.2 Hz, 1H), 5.30 – 5.17 (m, 2H), 3.51 (dd, J = 26.1, 13.9 Hz, 1H), 
3.38 – 3.32 (dd, J = 26.1, 13.9 Hz, 1H), 2.81 – 2.63 (m, 2H); 13C NMR (101 MHz, 
MeOD) δ 171.1 (d, JCF = 26.2 Hz), 130.7, 121.3, 95.0 (d, JCF = 190.2 Hz), 44.74 (d, JCF = 
22.1 Hz), 40.44 (d, JCF = 22.1 Hz); IR (Neat Film, NaCl) 2924, 1674, 1422, 1202, 1141, 
931, 798, 722 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C6H11NO2 [M+H]+: 
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1.4.2.9 Determination of Enantiomeric Excess 
	
Please note racemic products were synthesized according to the general procedure, using 
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Figure A1.2 Infrared spectrum (Thin Film, NaCl) of compound 1.2. 
 
 Figure A1.3 13C NMR (126 MHz, CDCl3) of compound 1.2. 
 




































Figure A1.5 Infrared spectrum (Thin Film, NaCl) of compound 1.3b. 
 
 Figure A1.6 13C NMR (101 MHz, CDCl3) of compound 1.3b. 
 





































Figure A1.8 Infrared spectrum (Thin Film, NaCl) of compound 1.3c. 
 
 Figure A1.9 13C NMR (126 MHz, CDCl3) of compound 1.3c. 
 







































Figure A1.11 Infrared spectrum (Thin Film, NaCl) of compound 1.3d. 
 
 Figure A1.12 13C NMR (101 MHz, CDCl3) of compound 1.3d. 
 





































Figure A1.14 Infrared spectrum (Thin Film, NaCl) of compound 1.3e. 
 
Figure A1.15  13C NMR (101 MHz, CDCl3) of compound 1.3e. 
 





































Figure A1.17 Infrared spectrum (Thin Film, NaCl) of compound 1.3f. 
 
 Figure A1.18  13C NMR (101 MHz, CDCl3) of compound 1.3f. 
 





































Figure A1.20  Infrared spectrum (Thin Film, NaCl) of compound 1.3h. 
 
 Figure A1.21 13C NMR (101 MHz, CDCl3) of compound 1.3h. 
 





































Figure A1.23 Infrared spectrum (Thin Film, NaCl) of compound 1.3i. 
 
 Figure A1.24 13C NMR (126 MHz, CDCl3) of compound 1.3i. 
 







































Figure A1.26 Infrared spectrum (Thin Film, NaCl) of compound 1.3j. 
 
Figure A1.27  13C NMR (101 MHz, CDCl3) of compound 1.3j. 
 





































Figure A1.29 Infrared spectrum (Thin Film, NaCl) of compound 1.3k. 
 
Figure A1.30  13C NMR (101 MHz, CDCl3) of compound 1.3k. 
 





































Figure A1.32  Infrared spectrum (Thin Film, NaCl) of compound 1.3l. 
 
 Figure A1.33 13C NMR (101 MHz, CDCl3) of compound 1.3l. 
 





































Figure A1.35 Infrared spectrum (Thin Film, NaCl) of compound 1.3m. 
 
Figure A1.36  13C NMR (101 MHz, CDCl3) of compound 1.3m. 
 





































Figure A1.37 Infrared spectrum (Thin Film, NaCl) of compound 1.4a. 
 
Figure A1.39  13C NMR (101 MHz, CDCl3) of compound 1.4a. 
 





































Figure A1.41 Infrared spectrum (Thin Film, NaCl) of compound 1.4b. 
 
 Figure A1.42  13C NMR (101 MHz, CDCl3) of compound 1.4b. 
 





































Figure A1.44 Infrared spectrum (Thin Film, NaCl) of compound 1.4c. 
 
 Figure A1.45 13C NMR (101 MHz, CDCl3) of compound 1.4c. 
 







































Figure A1.47 Infrared spectrum (Thin Film, NaCl) of compound 1.4d. 
 
Figure A1.48  13C NMR (126 MHz, CDCl3) of compound 1.4d. 
 





































Figure A1.50 Infrared spectrum (Thin Film, NaCl) of compound 1.4e. 
 
Figure A1.51 13C NMR (126 MHz, CDCl3) of compound 1.4e. 
 





































Figure A1.53 Infrared spectrum (Thin Film, NaCl) of compound 1.4f. 
 
Figure A1.54  13C NMR (101 MHz, CDCl3) of compound 1.4f. 
 





































Figure A1.56 Infrared spectrum (Thin Film, NaCl) of compound 1.4h. 
 
Figure A1.57  13C NMR (101 MHz, CDCl3) of compound 1.4h. 
 





































Figure A1.59 Infrared spectrum (Thin Film, NaCl) of compound 1.4i. 
 
 Figure A1.60 13C NMR (126 MHz, CDCl3) of compound 1.4i. 
 








































Figure A1.62 Infrared spectrum (Thin Film, NaCl) of compound 1.4j. 
 
Figure A1.63  13C NMR (101 MHz, CDCl3) of compound 1.4j. 
 





































Figure A1.65 Infrared spectrum (Thin Film, NaCl) of compound 1.4k. 
 
 Figure A1.66 13C NMR (101 MHz, CDCl3) of compound 1.4k. 
 





































Figure A1.68 Infrared spectrum (Thin Film, NaCl) of compound 1.4l. 
 
Figure A1.69  13C NMR (101 MHz, CDCl3) of compound 1.4l. 
 





































Figure A1.71 Infrared spectrum (Thin Film, NaCl) of compound 1.4m. 
 
 Figure A1.72 13C NMR (101 MHz, CDCl3) of compound 1.4m. 
 






































Figure A1.71 Infrared spectrum (Thin Film, NaCl) of compound 1.5a. 
 
Figure A1.72 13C NMR (101 MHz, CDCl3) of compound 1.5a. 
 





































Figure A1.74  Infrared spectrum (Thin Film, NaCl) of compound 1.5b. 
 
Figure A1.75   13C NMR (101 MHz, CDCl3) of compound 1.5b. 
 





































Figure A1.77   Infrared spectrum (Thin Film, NaCl) of compound 1.5c. 
 
 Figure A1.78 13C NMR (101 MHz, CDCl3) of compound 1.5c. 
 





































Figure A1.80 Infrared spectrum (Thin Film, NaCl) of compound 1.5d. 
 
Figure A1.81  13C NMR (101 MHz, CDCl3) of compound 1.5d. 
 





































Figure A1.83 Infrared spectrum (Thin Film, NaCl) of compound 1.5e. 
 
Figure A1.84  13C NMR (101 MHz, CDCl3) of compound 1.5e. 
 





































Figure A1.86 Infrared spectrum (Thin Film, NaCl) of compound 1.5f. 
 
Figure A1.87 13C NMR (101 MHz, CDCl3) of compound 1.5f. 
 





































Figure A1.89 Infrared spectrum (Thin Film, NaCl) of compound 1.6. 
 
Figure A1.90  13C NMR (101 MHz, CDCl3) of compound 1.5g. 
 





































Figure A1.92 Infrared spectrum (Thin Film, NaCl) of compound 1.5h. 
 
Figure A1.93  13C NMR (101 MHz, CDCl3) of compound 1.5h. 
 





































Figure A1.95 Infrared spectrum (Thin Film, NaCl) of compound 1.5i. 
 
Figure A1.96  13C NMR (101 MHz, CDCl3) of compound 1.5i. 
 





































Figure A1.98 Infrared spectrum (Thin Film, NaCl) of compound 1.6a. 
 
Figure A1.99  13C NMR (101 MHz, CDCl3) of compound 1.6a. 
 





































Figure A1.101 Infrared spectrum (Thin Film, NaCl) of compound 1.6b. 
 
Figure A1.102  13C NMR (101 MHz, CDCl3) of compound 1.6b. 
 





































Figure A1.104 Infrared spectrum (Thin Film, NaCl) of compound 1.6c. 
 
Figure A1.105  13C NMR (101 MHz, CDCl3) of compound 1.6c. 
 





































Figure A1.107 Infrared spectrum (Thin Film, NaCl) of compound 1.6d. 
 
Figure A1.108 13C NMR (101 MHz, CDCl3) of compound 1.6d. 
 





































Figure A1.110 Infrared spectrum (Thin Film, NaCl) of compound 1.6e. 
 
Figure A1.111 13C NMR (101 MHz, CDCl3) of compound 1.6e. 
 





































Figure A1.113 Infrared spectrum (Thin Film, NaCl) of compound 1.6f. 
 
 Figure A1.114 13C NMR (101 MHz, CDCl3) of compound 1.6f. 
 





































Figure A1.116 Infrared spectrum (Thin Film, NaCl) of compound 1.6f. 
 
Figure A1.117 13C NMR (101 MHz, CDCl3) of compound 1.6f. 
 






































Figure A1.119 Infrared spectrum (Thin Film, NaCl) of compound 1.6g. 
 
Figure A1.120 13C NMR (101 MHz, CDCl3) of compound 1.6g. 
 





































Figure A1.122 Infrared spectrum (Thin Film, NaCl) of compound 1.6h. 
 
Figure A1.123 13C NMR (101 MHz, CDCl3) of compound 1.6h. 
 





































Figure A1.125 Infrared spectrum (Thin Film, NaCl) of compound 1.6i. 
 
Figure A1.126 13C NMR (101 MHz, CDCl3) of compound 1.6i. 
 





































Figure A1.128 Infrared spectrum (Thin Film, NaCl) of compound 1.8. 
 
Figure A1.129  13C NMR (101 MHz, CDCl3) of compound 1.8. 
 





































Figure A1.131 Infrared spectrum (Thin Film, NaCl) of compound 1.9. 
 
 Figure A1.132 13C NMR (101 MHz, CDCl3) of compound 1.9. 
 





































Figure A1.134 Infrared spectrum (Thin Film, NaCl) of compound 1.10. 
 
Figure A1.135 13C NMR (101 MHz, CDCl3) of compound 1.10. 
 





































Figure A1.137 Infrared spectrum (Thin Film, NaCl) of compound 1.11. 
 
Figure A1.138 13C NMR (101 MHz, CDCl3) of compound 1.11. 
 





































Figure A1.140 Infrared spectrum (Thin Film, NaCl) of compound 1.12. 
 
Figure A1.141 13C NMR (101 MHz, CDCl3) of compound 1.12. 
 






































Figure A1.143 Infrared spectrum (Thin Film, NaCl) of compound 1.13. 
 
Figure A1.144 13C NMR (101 MHz, CDCl3) of compound 1.13. 
 





































Figure A1.146 Infrared spectrum (Thin Film, NaCl) of compound 1.14. 
 
Figure A1.147 13C NMR (101 MHz, CD3OD) of compound 1.14. 
 





































Figure A1.149 Infrared spectrum (Thin Film, NaCl) of compound 1.15. 
 
Figure A1.150 13C NMR (101 MHz, CD3OD) of compound 1.15. 
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Figure A1.151 1H-13C HMBC (CD3OD) of compound 1.15 





































Figure A1.153 Infrared spectrum (Thin Film, NaCl) of compound 1.16. 
 
 Figure A1.154 13C NMR (101 MHz, CD3OD) of compound 1.16. 
 








































Figure A1.156 Infrared spectrum (Thin Film, NaCl) of compound SI-3. 
 
 Figure A1.157 13C NMR (126 MHz, CDCl3) of compound SI-3. 
 





































Figure A1.159 Infrared spectrum (Thin Film, NaCl) of compound SI-4. 
 
Figure A1.160 13C NMR (126 MHz, CDCl3) of compound SI-4. 
 





































Figure A1.162 Infrared spectrum (Thin Film, NaCl) of compound SI-5. 
 
Figure A1.163  13C NMR (101 MHz, CDCl3) of compound SI-5. 
 





































Figure A1.165 Infrared spectrum (Thin Film, NaCl) of compound SI-6. 
 
Figure A1.166 13C NMR (101 MHz, CDCl3) of compound SI-6. 
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Decarboxylative Asymmetric Allylic Alkylation of  
gem-Disubstituted Diazepanes†  
 
A2.1   INTRODUCTION AND BACKGROUND 
Diazepanes and benzodiazepines are medicinally important seven-membered 
diazaheterocycles found in a variety of pharmaceuticals, including the eponymous 
benzodiazepine class of GABA agonists widely used as anxiolytics, sedatives, and pain 
relievers. These heterocycles exhibit a range of biological activities, having been tested in 
cancer therapeutics (BMS-214662) and marketed in FDA-approved drugs for the 
treatment of various conditions including allergies (Emedastine), hypertension 
(Bunazosin), and more recently, insomnia (Suvorexant) (Figure A2.1). Merck’s 
Suvorexant, which is the first orexin receptor antagonist of its class, is especially 










Figure A2.1 Diazepines and diazepanes are medicinally important heterocycles 
 
While these diazepane-containing pharmaceuticals may occasionally contain 
chiral monosubstitutions, chiral gem-disubstitutions are absent. In fact, to our knowledge, 
there are no known stereoselective methods to generate chiral gem-disubstituted 
diazepanes. Such a method would be important, as there is increasing recognition of the 
correlation between three-dimensional complexity and drug-like properties. This 
increasing recognition is in part responsible for the resurgent interest in natural-product 
screening libraries.1 Thus, including more structurally complex gem-disubstituted 
diazepanes in the synthetic toolkit of medicinal chemistry would enable deeper structure-
activity-relationship (SAR) studies of novel molecular space, potentially resulting in new 
































































Figure A2.2 gem-Disubstituted diazepanes can augment biological properties of small molecules 
 
Here we report our preliminary investigations into the stereoselective synthesis of 
chiral gem-disubstituted oxo-diazepanes via the decarboxylative asymmetric allylic 
alkylation (DAAA) reaction. The resultant gem-disubstituted oxo-diazepanes can be 
reductively transformed into valuable chiral diazapanes. Our laboratory has extensively 
explored the utility of DAAA in generating all-carbon quaternary and tetrasubstituted 
centers; it has proven to be a robust method that tolerates an incredible range of 
substrates, from carbocyclic ketones to lactams to acyclic compounds. Oxodiazepane 
DAAA substrates can be synthesized beginning from Boc-piperidinone A2.1  (Scheme 
A2.1); Beckmann rearrangement2 of commercially available piperidinone A2.1 
(<$0.50/gram) results in Boc-diazepanone A2.2, which can then be benzoylated and 
acylated to afford dicarbonyl compound A2.3.  A2.3 then serves as a divergent point of 
entry into a variety of DAAA substrates.  
 











• No known synthetic methods
• Greater sp3 complexity is associated 
  with enhanced biological properties2
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 We chose the benzyl substrate A2.4a for initial optimizations (Table A2.1). 
Starting with conditions using (S)-(CF3)3-t-Bu-PHOX and 2:1 hexanes/toluene at 0.014 
M concentration, which were based on our previous report,3 we were pleased to obtain 
the desired oxo-diazepane in 85% ee. Polar aprotic ethereal solvents (entries 1 and 2) 
proved inferior to less polar solvents such as methylcyclohexane. Ultimately, we found 
that conducting the reaction in methylcyclohexane provided the highest enantioselectivity 
at 89% ee (Entry 6).  
 
Table A2.1 Optimization studies on the DAAA of benzyl substrate A2.4a 
 
Entry Solvent ee (%) 
1 THF 20 
3 Dioxane 38 
3 MTBE 70 
4 Toluene 69 
5 2:1 Hexanes/Toluene 85 
6 MeCyclohexane 89 
[a] Screens performed on a 0.04 mmol scale. [b] The ee values were determined by chiral SFC analysis. Bz = benzoyl, Boc = 
tert-butoxycarbonyl, pmdba = bis(4-methoxybenzylidene)acetone 
 
 With optimal conditions in hand, we began exploring the oxodiazepane DAAA substrate 
scope (Table A2.2). In substrates A2.4i-k, we examined the electronic effect of the N1 
protecting group, observing that anisoyl-protection yielded the product A2.5j with greater 
Pd2(pmdba)3 (4 mol %)
(S)-(CF3)3-t-BuPHOX (10 mol%)
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ee than the para-CF3 and benzoyl versions A2.5i and A2.5k. The reaction is tolerant of a 
variety of functional groups such as chloroallyl (A2.5b), methyl ester (A2.5c), fluoro 
(A2.5e, A2.5g), carbamate (A2.5f), and alkyne (A2.5h), providing the desired products in 
ee’s up to 95% and yields up to >99%. Notably, the nitrile product A2.5d was obtained in 
a reduced 79% ee, suggesting that the seven-membered ring enables the nitrile 
functionality to adopt a conformation that interferes with the transition state of the 
reaction; this result contrasts with previous results using piperidinones and 
morpholinones in which high enantioselectivity was observed with the corresponding 
nitrile substrates.4,5 






OR Pd2(dba)3 (4 mol %)
(S)-(CF3)3-t-BuPHOX (10 mol%)
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[a] Conditions: oxodiazepane A2.4a-l (1.0 equiv), Pd2(dba)3 (4 mol %), (S)-(CF3)3-tBuPHOX (10 mol %), in 
methylcyclohexane (0.014 M) at 40 °C for 12-24 h. [b] Pd2(pmdba)3 (4 mol %) instead of Pd2(dba)3. All reported yields are for 
isolated products. The ee values were determined by chiral SFC analysis. An = 4-methoxybenzoyl, dba = 
dibenzylideneacetone. 
Unfortunately, attempts to synthesize other medicinally important seven-membered 
diazaheterocycle DAAA substrates using isomeric and benzo-fused intermediates such as 
A2.6 and A2.7 were unsuccessful. With A2.6, attempts at acylation to form the 
dicarbonyl intermediate resulted in degradation of the starting material. With A2.7, its 
corresponding enolate was unreactive and starting material was reisolated. 
 
Scheme A2.2 Attempted synthesis of other medicinally relevant DAAA substrates 
 
We are currently exploring various product derivatizations and transformations, the 
results of which we hope will be published shortly. 
 
A2.2  CONCLUSIONS 
 In summary, we report the enantioselective synthesis of unprecedented gem-
disubstituted oxodiazepanes using the venerable Pd-catalyzed decarboxylative 
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yielding products in ee’s ranging from 79-95%. These novel chiral diazepanes are 
anticipated to find utility in the design of novel diazepane-containing pharmaceuticals; 
their added three-dimensional complexity should enable access to new chemical space in 
the quest for new medicines. 
A2.3  EXPERIMENTAL SECTION 
A2.3.1  MATERIALS AND METHODS 
Unless otherwise stated, reactions were performed in flame-dried glassware under 
an argon or nitrogen atmosphere using dry, deoxygenated solvents. Solvents were dried 
by passage through an activated alumina column under argon. tert-Butyl 4-oxopiperidine-
1-carboxylate A2.1 was obtained from Combi-Blocks. Commercially obtained reagents 
were used as received. Chemicals were purchased from Sigma Aldrich/Strem/Alfa 
Aesar/Combi-Blocks and used as received.   
Reaction temperatures were controlled by an IKAmag temperature modulator. 
Glove box manipulations were performed under a nitrogen atmosphere. Thin-layer 
chromatography (TLC) was performed using E. Merck silica gel 60 F254 precoated 
plates (0.25 mm) and visualized by UV fluorescence quenching, iodine on silica, 
ninhydrin, or KMnO4 staining. SiliaFlash P60 Academic Silica gel (particle size 0.040–
0.063 mm) was used for flash chromatography.  
Analytical SFC was performed with a Mettler SFC supercritical CO2 analytical 
chromatography system utilizing a Chiralpak IC column (4.6 mm x 25 cm) obtained from 
Daicel Chemical Industries, Ltd. with visualization at 254 nm. Reverse Phase Preparatory 
HPLC was performed with a Teledyne ISCO ACCQPrep HP125 preparative liquid 
chromatography system equipped with a RediSep Prep C18 5 µm column (20 x 250 mm).  
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1H NMR spectra were recorded on a Varian Inova 600 MHz or 500 MHz spectrometer or 
a Bruker Avance HD 400 MHz spectrometer and are reported relative to residual CHCl3 
(δ 7.26 ppm) or CH3OH (δ 3.31 ppm). 13C NMR spectra were recorded on a Varian Inova 
500 MHz spectrometer or a Bruker Avance HD 400 MHz spectrometer and are reported 
relative to residual CDCl3 (δ 77.16 ppm) or CD3OD (δ 49.00 ppm). Data for 1H NMR are 
reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, sept = 
septuplet, m = multiplet, br s = broad singlet. Data for 13C NMR are reported in terms of 
chemical shifts (δ ppm). Some reported spectra include minor solvent impurities of water 
(δ 1.56 or 4.87 ppm), ethyl acetate (δ 4.12, 2.05, 1.26 ppm), methylene chloride (δ 5.30 
ppm), acetone (δ 2.17 ppm), grease (δ 1.26, 0.86 ppm), and/or silicon grease (δ 0.07 ppm), 
which do not impact product assignments.  
IR spectra were obtained using a Perkin Elmer Paragon 1000 spectrometer using 
thin films deposited on NaCl plates and reported in frequency of absorption (cm-1). High 
resolution mass spectra (HRMS) were obtained from an Agilent 6200 Series TOF with an 
Agilent G1978A Multimode source in electrospray ionization (ESI+), atmospheric 
pressure chemical ionization (APCI+), or mixed ionization mode (MM: ESI-APCI+). 
Optical rotations were measured with a Jasco P-2000 polarimeter operating on the 
sodium D-line (589 nm), using a 100 mm pathlength cell and are reported as: [α]DT 
(concentration in g/100 mL, solvent). Stereochemistry is assigned by analogy to previous 
results. 4,6–10 
 
A2.3.2  EXPERIMENTAL PROCEDURES AND SPECTROSCOPIC DATA 
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A2.3.3 Procedures for the Synthesis of Oxodiazepane Allylic Alkylation 
Substrates 
 
tert-butyl 5-oxo-1,4-diazepane-1-carboxylate. Prepared according to a literature 
procedure, via Beckmann rearrangement.2  
 
 
tert-butyl 4-benzoyl-5-oxo-1,4-diazepane-1-carboxylate. To a solution of tert-butyl 5-
oxo-1,4-diazepane-1-carboxylate (5 g, 1 equiv) in THF (230 mL, 0.1 M) at -78 °C was 
slowly added nBuLi (12.8 mL, 2.18 M, 1.2 equiv). The cloudy solution was allowed to 
warm up at ambient temperature until the solution became clear, at which point it was 
again cooled to -78 °C. Then, BzCl (3.52 mL, 1.3 equiv) was added and the reaction 
turned light orange over several minutes. The reaction was stirred for 1 h at -78 °C and 
was then quenched with sat. NH4Cl (aq), extracted with EtOAc (3x). The combined 
organic layers were dried over Na2SO4, concentrated onto SiO2. The silica-adsorbed 
crude product was purified by silica gel flash chromatography (20% acetone/hexanes) to 
afford the desired product in quantitative yield (7.43g); 1H NMR (400 MHz, CDCl3) δ 
7.57 – 7.49 (m, 2H), 7.49 – 7.41 (m, 1H), 7.41 – 7.32 (m, 2H), 4.03 – 3.96 (m, 2H), 3.71 
(q, J = 6.1, 5.1 Hz, 4H), 2.82 – 2.75 (m, 2H), 1.47 (s, 9H); 13C NMR (101 MHz, CDCl3) 
δ 175.6, 173.7, 154.5, 135.9, 131.7, 128.2, 127.9, 80.7, (47.7 and 47.10 appear as two 
peaks due to hindered rotation), 45.4, (41.6 and 41.0 appear as two peaks due to hindered 








Appendix 2 – Decarboxylative Asymmetric Allylic Alkylation of gem-Disubstituted Diazepanes   
 
  
1422, 1392, 1366,1327, 1285, 1247, 1229, 1157, 1115, 1032, 1018, 976, 954, 915,862, 
793,769, 729, 696, 647 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C17H26N3O4 
[M+NH4]+: 336.1918, found 336.1912.  
 
 
6-allyl 1-(tert-butyl) 4-benzoyl-6-methyl-5-oxo-1,4-diazepane-1,6-dicarboxylate. To a 
solution of 6-allyl 1-(tert-butyl) 4-benzoyl-5-oxo-1,4-diazepane-1,6-dicarboxylate 
(240 mg, 1 equiv) in THF (6 mL, 0.1 M) at 0 °C was added NaH (60% in mineral oil, 26 
mg, 1.1 equiv). The solution was stirred at 0 °C for 40 min and then MeI (186 uL, 5 equiv) 
was added. The reaction was heated to 45 °C for 16 h, then quenched with sat. NH4Cl 
(aq), and then extracted with EtOAc (3x). The combined organic layers were dried over 
Na2SO4 and concentrated onto SiO2. The silica-adsorbed crude product was purified by 
silica gel flash chromatography (20% EtOAc/hexanes) to afford the desired product in as 
a light yellow oil (200 mg, 81% yield). 1H NMR (400 MHz, CDCl3) δ 7.70 – 7.63 (m, 
2H), 7.52 – 7.43 (m, 1H), 7.38 (t, J = 7.6 Hz, 2H), 5.96 (ddt, J = 16.6, 10.4, 6.0 Hz, 1H), 
5.40 (dq, J = 17.3, 1.5 Hz, 1H), 5.34 (d, J = 10.4 Hz, 1H), 4.73 (t, J = 6.2 Hz, 2H), 4.33 (s, 
1H), 4.10 (d, J = 14.8 Hz, 1H), 3.64 (dt, J = 14.0, 3.4 Hz, 4H), 1.57 (s, 3H), 1.45 (s, 9H); 
13C NMR (101 MHz, CDCl3) δ (174.5 and 174.1 appear as two peaks due to hindered 
rotation), 173.0, 171.7, (155.1 and 154.9 appear as two peaks due to hindered rotation), 
135.7, 131.9, 131.1, 128.3, 128.2, 120.1, 81.1, 66.8, 57.6, (49.7 and 49.0 appear as two 
peaks due to hindered rotation), (47.0 and 46.0 appear as two peaks due to hindered 
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1281, 1249, 1139, 1104, 1047, 983, 938, 768, 727, 694 cm-1; HRMS (MM: ESI-APCI): 
m/z calc’d for C22H28N2O6 [M+H]+: 417.2020, found 417.2010. 
 
 
6-allyl 1-(tert-butyl) 4-(4-methoxybenzoyl)-5-oxo-1,4-diazepane-1,6-dicarboxylate.  
To a solution of tert-butyl 4-(4-methoxybenzoyl)-5-oxo-1,4-diazepane-1-carboxylate 
(1 g, 1.0 equiv) in THF (20 mL, 0.1 M total concentration) at −78 °C was added 
LiHMDS (528 mg, 1.1 equiv) in THF (9 mL) dropwise. The resulting light yellow 
reaction mixture was stirred for 15 min at −78 °C. Then, allyl cyanoformate (368 µL, 1.2 
equiv) was added dropwise at −78 °C, giving a clear solution. After stirring for 1.5 h at 
−78 °C, the reaction was quenched with 1 M HCl (10 mL) and diluted with ethyl acetate 
(20 mL). The aqueous phase was extracted with ethyl acetate (3 x 30 mL). The combined 
organic layers were dried over anhydrous Na2SO4 and solid NaHCO3, decanted, and 
concentrated under reduced pressure onto silica. The silica-adsorbed crude mixture was 
purified by silica gel flash chromatography (10% → 20% EtOAc/hexanes) to give allyl 
1-(tert-butyl) 4-(4-methoxybenzoyl)-5-oxo-1,4-diazepane-1,6-dicarboxylate as a clear 
oil (600  mg, 48% yield). 1H NMR (400 MHz, CDCl3) δ 7.72 – 7.60 (m, 2H), 6.91 – 
6.79 (m, 2H), 5.92 (ddt, J = 17.3, 10.4, 5.9 Hz, 1H), 5.42 – 5.20 (m, 2H), 4.77 – 4.56 (m, 
2H), 4.40 – 3.92 (m, 4H), 3.82 (s, 5H), 3.58 – 3.24 (m, 1H), 1.46 (s, 9H); 13C NMR (101 
MHz, CDCl3) δ 173.1, 171.3, 167.6, 163.1, 154.6, 131.3, 131.2, 127.0, 119.4, 113.6, 
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45.12, (43.3 and 42.8 appear as two peaks due to hindered rotation), 28.3. IR (Neat Film, 
NaCl) 2977, 1746, 1693, 1603, 1578, 1511, 1454, 1419, 1392, 1366, 1324, 1255, 1168, 
1025, 995, 965, 842, 766 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C22H28N2O7 
[M+H]+: 433.1969, found 433.1966. 
 
6-allyl 1-(tert-butyl) 4-benzoyl-6-(((tert-butoxycarbonyl)amino)methyl)-5-oxo-1,4-
diazepane-1,6-dicarboxylate. A solution of A2.3 (200 mg, 1 equiv) and tert-butyl 
((phenylsulfonyl)methyl)carbamate11,12 (162 mg, 1.2 equiv) in CH2Cl2 (2.5 mL, 0.2 M) 
was stirred for 5 min at rt. Then at room temperature was added Cs2CO3 (405 mg, 2.5 
equiv). The reaction was stirred at rt for 30 min, then sat. aqueous NH4Cl (1 mL) was 
added and the biphasic mixture was vigorously stirred for 20 min. The aqueous phase 
was extracted with CH2Cl2 (3 x 3 mL). The combined organic phases were dried over 
anhydrous Na2SO4, decanted, and concentrated under reduced pressure onto silica gel. 
The silica-loaded crude reaction mixture was purified by automated silica gel flash 
chromatography (Teledyne ISCO) (10 → 40% acetone/hexanes) to give methylcarbamate 
allyl ester A2.4f as a white foam (200 mg, 76% yield): 1H NMR (400 MHz, CDCl3) δ 
7.83 – 7.71 (m, 2H), 7.59 – 7.46 (m, 1H), 7.40 (dd, J = 8.4, 7.0 Hz, 2H), 6.00 (ddt, J = 
16.6, 10.3, 6.1 Hz, 1H), 5.51 – 5.25 (m, 2H), 5.17 (s, 1H), 4.81 – 4.62 (m, 2H), 4.36 (dd, 
J = 51.1, 15.8 Hz, 1H), 4.14 – 3.20 (m, 7H), 1.43 (d, J = 8.5 Hz, 18H); 13C NMR (101 
MHz, CDCl3) δ (174.1 and 173.8 appear as two peaks due to hindered rotation), 172.7, 
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appear as two peaks due to hindered rotation), 135.4, 132.2, 131.3, 128.5, 128.3, 120.2, 
81.4, 79.5, 67.4, 62.6, 47.0, 46.8, 45.9, 43.2, 28.4, 28.4. IR (Neat Film, NaCl) 3457, 
2977, 2934, 2253, 1704, 1600, 1503, 1450, 1417, 1392, 1367, 1325, 1283, 1248, 1158, 
1042, 980, 913,77 860, 767, 729, 693, 663 cm-1; HRMS (MM: ESI-APCI): m/z calc’d 
for C27H37N3O8 [M+H]+: 532.2653, found 532.2664.  
 
 
6-allyl 1-(tert-butyl) 4-benzoyl-6-benzyl-5-oxo-1,4-diazepane-1,6-dicarboxylate 
(A2.4a). Sodium hydride (60% in mineral oil, 22 mg, 1.1 equiv) was added to a solution 
of allyl ester A2.3 (200 mg, 1.0 equiv) in THF (5 mL, 0.1 M) at 0 °C. After stirring for 30 
min at 0 °C, BnBr (71 µL, 1.2 equiv) was added. The reaction mixture was heated to 
50 °C and stirred for 16 h; at the 4 h mark, 2 equiv BnBr was added; at the 12 h mark, 2 
equiv more BnBr was added. The reaction was quenched with aqueous NH4Cl (10 mL) 
and extracted with EtOAc (3 x 5 mL). The combined organic phases were dried over 
anhydrous Na2SO4, decanted, and concentrated under reduced pressure onto silica gel. 
The silica-loaded residue was purified by silica gel flash chromatography (20% 
EtOAc/hexanes) to give benzylated allyl ester A2.4a as a white foam (130 mg, 53% 
yield). 1H NMR (400 MHz, Chloroform-d) δ 7.68 (d, J = 7.6 Hz, 2H), 7.55 – 7.46 (m, 
1H), 7.37 (t, J = 7.7 Hz, 2H), 7.31 – 7.25 (m, 3H), 7.24 – 7.12 (m, 2H), 5.86 (tq, J = 22.8, 
6.5 Hz, 1H), 5.38 (s, 1H), 5.36 – 5.27 (m, 1H), 4.63 (q, J = 6.3, 5.8 Hz, 2H), 4.12 (d, J = 
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1.45 (s, 9H); 13C NMR (101 MHz, CDCl3) δ (174.3 and 174.0 appear as two peaks due 
to hindered rotation), (172.1 and 171.9 appear as two peaks due to hindered rotation), 
(170.8 and 170.2 appear as two peaks due to hindered rotation), (155.5 and 154.9 appear 
as two peaks due to hindered rotation), (135.6 & 135.5 appear as two peaks due to 
hindered rotation), 135.4, 132.0, (131.1 & 130.9 appear as two peaks due to hindered 
rotation), (130.7 & 130.5 appear as two peaks due to hindered rotation), 128.4, 128.4, 
128.2, (127.4 & 127.3 appear as two peaks due to hindered rotation), (120.5 & 120.1 
appear as two peaks due to hindered rotation), (81.2 & 80.9 appear as two peaks due to 
hindered rotation), (66.9 & 66.8 appear as two peaks due to hindered rotation), (62.5 & 
62.1 appear as two peaks due to hindered rotation), (47.3 & 46.7 appear as two peaks due 
to hindered rotation), (46.2 & 45.7 appear as two peaks due to hindered rotation), (42.4 & 
42.1 appear as two peaks due to hindered rotation), 42.0, 28.4. IR (Neat Film, NaCl) 
3062, 3030, 2976, 2933, 1694, 1601, 1583, 1494, 1450, 1415, 1392, 1366, 1325, 1280, 
1247, 1154, 1131, 1092, 1041, 1022, 980, 939, 867, 795, 767, 727, 703, 661 cm-1; 





dicarboxylate (A2.4j). To a solution of anisoyl allyl ester (200 mg, 1 equiv) and Cs2CO3 
(301 mg, 2 equiv) in MeCN (4.6 mL, 0.1 M) was added MeI (143 uL, 5 equiv). The 
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and extracted with EtOAc (3 x 5 mL). The combined organic phases were dried over 
anhydrous Na2SO4, decanted, and concentrated under reduced pressure. The crude 
product was purified by automated silica gel flash chromatography (Teledyne ISCO) (0 
→ 90% EtOAc/hexanes) to give methylated allyl ester A2.4j as a clear oil (70 mg, 34% 
yield). 1H NMR (400 MHz, Chloroform-d) δ 7.75 – 7.65 (m, 2H), 6.90 – 6.82 (m, 2H), 
5.96 (ddt, J = 17.3, 10.4, 6.0 Hz, 1H), 5.40 (dq, J = 17.2, 1.4 Hz, 1H), 5.36 – 5.29 (m, 
1H), 4.71 (dddd, J = 14.2, 7.3, 4.4, 2.1 Hz, 2H), 4.27 – 4.15 (m, 1H), 4.14 – 4.04 (m, 1H), 
3.83 (s, 3H), 3.76 (d, J = 13.6 Hz, 1H), 3.62 (dt, J = 13.9, 3.2 Hz, 2H), 3.56 – 3.46 (m, 
1H), 1.60 – 1.55 (m, 3H), 1.44 (d, J = 17.8 Hz, 9H); 13C NMR (101 MHz, CDCl3) 
(173.9 & 173.6 appear as two peaks due to hindered rotation),  172.8, (172.0 & 171.8 
appear as two peaks due to hindered rotation), 162.9, (155.1 & 154.9 appear as two peaks 
due to hindered rotation), 131.2, 131.2, 130.9, 127.5, (120.1 & 119.9 appear as two peaks 
due to hindered rotation), 113.6, 80.9, 66.7, 57.5, 55.4, (49.6 & 48.1 appear as two peaks 
due to hindered rotation), (47.1 & 46.1 appear as two peaks due to hindered rotation), 
43.6, 28.3, 23.6. IR (Neat Film, NaCl) 2974, 2937, 1698, 1604, 1578, 1511, 1453, 1416, 
1392, 1366, 1324, 1280, 1256, 1169, 1139, 1103, 1031, 1001, 983, 929, 840, 768, 733 

















1,6-dicarboxylate (A2.4h). Sodium hydride (60% in mineral oil, 25 mg, 1.1 equiv) was 
added to a solution of anisoyl allyl ester (250 mg, 1.0 equiv) in THF (5.8 mL, 0.1 M) at 
0 °C. After stirring for 30 min at 0 °C, propargyl bromide (80% wt/wt in toluene, 125 µL, 
2 equiv) was added. The reaction mixture was heated to 50 °C and stirred for 16 h, 
turning yellow in minutes. The reaction was quenched with aqueous NaHCO3 (10 mL) 
and extracted with EtOAc (3 x 5 mL). The combined organic phases were dried over 
anhydrous Na2SO4, decanted, and concentrated under reduced pressure. The crude 
product was purified by automated silica gel flash chromatography (Teledyne ISCO, 0 → 
50% acetone/hexanes) to give propargyl allyl ester A2.4h as a clear oil (220 mg, 81% 
yield). 1H NMR (500 MHz, Chloroform-d) δ 7.68 (dt, J = 11.9, 4.8 Hz, 2H), 6.84 (d, J 
= 8.6 Hz, 2H), 5.99 (ddt, J = 17.3, 10.4, 6.0 Hz, 1H), 5.54 – 5.27 (m, 2H), 4.79 (dd, J = 
14.0, 5.8 Hz, 2H), 4.33 – 3.96 (m, 3H), 3.82 (s, 4H), 3.78 – 3.56 (m, 1H), 3.48 (dt, J = 
13.3, 3.1 Hz, 1H), 3.17 – 3.01 (m, 1H), 3.01 – 2.88 (m, 1H), 2.08 (t, J = 2.8 Hz, 1H), 1.42 
(d, J = 14.3 Hz, 9H); 13C NMR (126 MHz, cdcl3) δ (173.7 & 173.2 appear as two peaks 
due to hindered rotation), (170.5 & 170.3 appear as two peaks due to hindered rotation), 
(169.7 & 169.2 appear as two peaks due to hindered rotation), 163.0, (155.5 & 154.9 
appear as two peaks due to hindered rotation), 131.1, 131.0, 127.1, 120.2, 120.0, 113.5, 
(81.1 & 81.0 appear as two peaks due to hindered rotation), (78.9 & 78.6 appear as two 
peaks due to hindered rotation), 72.3, 67.3, (60.7 & 60.4 appear as two peaks due to 
hindered rotation), 55.4, (47.0 & 46.5 appear as two peaks due to hindered rotation), 
(46.1 & 46.0 appear as two peaks due to hindered rotation), 43.0, 28.3, (27.0 & 26.8 
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appear as two peaks due to hindered rotation). HRMS (MM: ESI-APCI): m/z calc’d for 




dicarboxylate (A2.4e). Sodium hydride (60% in mineral oil, 32 mg, 1.1 equiv) was 
added to a solution of anisoyl allyl ester (320 mg, 1.0 equiv) in THF (7.4 mL, 0.1 M) at 
0 °C. After stirring for 30 min at rt, Selectfluor (315 mg 1.2 equiv) was added. The 
reaction mixture was heated to 50 °C and stirred for 16 h. The reaction was quenched 
with aqueous NaHCO3 (10 mL) and extracted with EtOAc (3 x 5 mL). The combined 
organic phases were dried over anhydrous Na2SO4, decanted, and concentrated under 
reduced pressure. The crude product was purified by automated silica gel flash 
chromatography (Teledyne ISCO, 0 → 50% acetone/hexanes) to give fluorinated allyl 
ester A2.4e as a clear oil (290 mg, 87% yield). 1H NMR (400 MHz, Chloroform-d) δ 
7.66 – 7.58 (m, 2H), 6.90 – 6.82 (m, 2H), 5.91 (ddt, J = 16.3, 10.9, 5.7 Hz, 1H), 5.42 – 
5.32 (m, 1H), 5.29 (d, J = 9.6 Hz, 1H), 4.71 (dt, J = 21.0, 13.8 Hz, 3H), 4.52 – 4.40 (m, 
1H), 4.39 – 4.19 (m, 2H), 3.94 (ddd, J = 21.1, 14.6, 9.4 Hz, 1H), 3.82 (s, 3H), 3.77 – 3.56 
(m, 1H), 3.22 – 3.09 (m, 1H), 1.47 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 172.5, 169.6 
(dd, J = 48.2, 25.4 Hz), 164.9 (d, J = 25.8 Hz), 163.4, 154.9, 131.2, 130.8, 126.0, 119.7, 
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(d, J = 92.2 Hz), 43.3, 28.2. IR (Neat Film, NaCl) cm-1; HRMS (MM: ESI-APCI): m/z 
calc’d for C22H28FN2O7 [M+H]+: 451.1875, found 451.1877. 
 
A2.3.4  General Procedure for Allylic Alkylation Optimization Screen 
In a nitrogen-filled glovebox, an oven-dried 1 dram vial was charged with 
Pd2(pmdba)3 (4 mol %), ligand (10 mol %), solvent (1 mL), and a magnetic stir bar. The 
vial was stirred at ambient glovebox temperature (27 °C) for 30 min and then substrate 
A2.4a (20 mg, 1.0 equiv) was added as a solution in solvent (1.8 mL, total concentration 
0.014 M). The vial was sealed with a teflon cap and heated to 40 °C. When complete 
consumption of the starting material was observed by thin layer chromatography, the 
reaction mixture was removed from the glovebox and concentrated under reduced 
pressure. The residue was purified by silica gel flash chromatography to afford the 
oxodiazepane A2.5a.  
A2.3.5 General Procedure for Pd-Catalyzed Decarboxylative Allylic 
Alkylation Reactions 
Please note The absolute configuration for all other products has been inferred by 
analogy.4,6–10 For respective SFC conditions, please refer to the section Determination of 
Enantiomeric Excess. 
In a nitrogen-filled glovebox, an oven-dried 1 dram vial or 20 mL scintillation 
vial was charged with Pd2(pmdba)3 or Pd2(dba)3 (4 mol %), (S)-(CF3)3-tBu-PHOX (10 
mol %), methylcyclohexane, and a magnetic stir bar. The vial was stirred at ambient 
glovebox temperature (27 °C) for 30 min and then the substrate (1.0 equiv) was added as 
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a solution in methylcyclohexane (total concentration 0.014 M). The vial was sealed with 
a teflon cap and heated to 40 °C. When complete consumption of the starting material 
was observed by thin layer chromatography, the reaction mixture was removed from the 
glovebox and concentrated under reduced pressure. The residue was purified by silica gel 
flash chromatography to afford the desired oxopiperazine.  
A2.3.6 Experimental Procedures and Spectroscopic data for the Pd-





diazepane-1-carboxylate (A2.5f). Following the general procedure, allyl ester A2.4f (53 
mg, 1.0 equiv) in MeCy (1 mL) was added to a solution of Pd2(dba)3 (3.7 mg, 4 mol %) 
and (S)-(CF3)3-tBu-PHOX (5.9 mg, 10 mol %) in MeCy (7.1 mL). Purification by 
automated silica gel flash chromatography (0 →  50% EtOAc/hexanes) gave methyl 
carbamate oxodiazepane A2.5f as a white foam (37 mg, 76% yield, 93% ee).  1H NMR 
(400 MHz, Chloroform-d) δ 7.71 – 7.31 (m, 5H), 5.74 (ddt, J = 15.7, 10.5, 7.4 Hz, 1H), 
5.21 – 5.05 (m, 2H), 4.38 (dd, J = 15.2, 5.3 Hz, 1H), 4.09 – 3.13 (m, 7H), 2.67 – 2.09 (m, 
2H), 1.47 (d, J = 24.6 Hz, 18H); 13C NMR (101 MHz, CDCl3) δ (179.3 and 178.8 appear 
as two peaks due to hindered rotation), 174.5, 156.2, (155.9 and 155.0 appear as two 
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hindered rotation), 131.7, 128.5, 127.7, 120.0, (81.3 and 81.1 appear as two peaks due to 
hindered rotation), 79.5, 54.7, 48.8, (47.2 and 46.7 appear as two peaks due to hindered 
rotation), 46.2, (42.6 and 41.1 appear as two peaks due to hindered rotation), (38.7 and 
37.1 appear as two peaks due to hindered rotation), 28.5, 28.4. IR (Neat Film, NaCl) 
2977, 1687, 1502, 1422, 1391, 1365, 1322, 1282, 1245, 1168, 978, 916, 753 cm-1; 
HRMS (MM: ESI-APCI): m/z calc’d for C26H37N3O6 [M+H]+: 488.2755, found 
488.2747; [α]D23.2 –3.70 (c 1.85, CHCl3); SFC conditions: 20% IPA, 2.5 mL/min, 




1-carboxylate (A2.5h). Following the general procedure, allyl ester A2.4h (70 mg, 1.0 
equiv) in MeCy (1 mL) was added to a solution of Pd2(dba)3 (5.4 mg, 4 mol %) and (S)-
(CF3)3-tBu-PHOX (8.8 mg, 10 mol %) in MeCy (7.3 mL). Note: Reaction performed at 
50 °C because no reaction occurred at 40 °C. Purification by automated silica gel flash 
chromatography (Teledyne ISCO, 0 →  40% acetone/hexanes) gave propargyl 
oxodiazepane A2.5h as a clear oil (28 mg, 44% yield, 94% ee); 1H NMR (400 MHz, 
Chloroform-d) δ 7.59 (d, J = 8.2 Hz, 2H), 6.96 – 6.80 (m, 2H), 5.93 – 5.63 (m, 1H), 5.30 
– 5.10 (m, 2H), 4.28 (d, J = 15.2 Hz, 1H), 3.83 (s, 7H), 3.50 (d, J = 11.6 Hz, 1H), 2.60 
(dq, J = 30.2, 17.2, 16.6 Hz, 4H), 2.20 – 1.99 (m, 1H), 1.55 (d, J = 38.4 Hz, 9H); 13C 
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to hindered rotation), 132.1, 130.7, 127.9, 120.0, 113.7, (81.1 & 80.9 appear as two peaks 
due to hindered rotation), 80.5, 72.0, 55.5, 52.6, (49.1 & 46.9 appear as two peaks due to 
hindered rotation), 47.6, (43.0 & 42.33 appear as two peaks due to hindered rotation), 
(39.11 & 37.4 appear as two peaks due to hindered rotation), 28.5, (26.5 & 25.9 appear as 
two peaks due to hindered rotation). IR (Neat Film, NaCl) 3283, 2972, 2922, 1692, 1603, 
1511, 1454, 1418, 1365, 1322, 1255, 1169, 1031, 980, 926, 839, 766, 670 cm-1; HRMS 
(MM: ESI-APCI): m/z calc’d for C24H31N2O5 [M+H]+: 427.2227, found 427.2238; 
[α]D22.1 –7.69 (c 1.0, CHCl3); SFC conditions: 10% IPA, 2.5 mL/min, Chiralpak AD-H 
column, λ = 254 nm, tR (min): major = 11.163, minor = 10.615. 
 
 
tert-butyl (S)-6-allyl-4-benzoyl-6-benzyl-5-oxo-1,4-diazepane-1-carboxylate (A2.5a). 
Following the general procedure, allyl ester A2.4a (42 mg, 1.0 equiv) in MeCy (1 mL) 
was added to a solution of Pd2(dba)3 (3.7 mg, 4 mol %) and (S)-(CF3)3-tBu-PHOX (6.0 
mg, 10 mol %) in MeCy (6.2 mL). Purification by silica gel flash chromatography (0 → 
20% EtOAc/hexanes) gave benzyl oxodiazepane A2.5a as a light pink oil (28 mg, 86% 
yield, 89% ee); 1H NMR (400 MHz, Chloroform-d) δ 7.56 – 7.40 (m, 3H), 7.40 – 7.32 
(m, 2H), 7.32 – 7.19 (m, 3H), 7.19 – 7.00 (m, 2H), 5.88 (s, 1H), 5.26 – 5.07 (m, 2H), 4.26 
– 4.03 (m, 1H), 3.94 (d, J = 15.4 Hz, 1H), 3.73 (d, J = 42.2 Hz, 1H), 3.54 (d, J = 15.3 Hz, 
1H), 3.40 (s, 2H), 3.09 (dd, J = 61.0, 13.7 Hz, 1H), 2.94 – 2.34 (m, 3H), 1.48 (s, 10H); 
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hindered rotation), 136.6, 136.3, 133.0, 131.5, 130.8, 128.5, 128.4, 127.8, 127.1, (120.0 
& 119.6 appear as two peaks due to hindered rotation), 80.8, (54.2 & 53.8 appear as two 
peaks due to hindered rotation), 49.1, 47.3, 46.8, (42.5 & 42.0 appear as two peaks due to 
hindered rotation), (41.4 & 40.3 appear as two peaks due to hindered rotation), 28.5. IR 
(Neat Film, NaCl) 3062, 2975, 2928, 1693, 1682, 1601, 1452, 1415, 1392, 1365, 1322, 
1283, 1246, 1156, 1044, 978, 917, 865, 728, 697 cm-1; HRMS (MM: ESI-APCI): m/z 
calc’d for C27H33N2O4 [M+H]+: 449.2435, found 449.2429; [α]D22.4 +14.19 (c .66, 
CHCl3); SFC conditions: 20% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 254 nm, 





carboxylate (A2.5e). Following the general procedure, allyl ester A2.4e (45 mg, 1.0 
equiv) in MeCy (1 mL) was added to a solution of Pd2(dba)3 (3.7 mg, 4 mol %) and (S)-
(CF3)3-tBu-PHOX (5.9 mg, 10 mol %) in MeCy (6.1 mL). Purification by automated 
silica gel flash chromatography (0 →  50% acetone/hexanes) gave fluorinated 
oxodiazepane A2.5e as a clear pink oil (45 mg, 83% yield, 86% ee); 1H NMR (400 MHz, 
Chloroform-d) δ 7.61 – 7.53 (m, 2H), 6.92 – 6.84 (m, 2H), 5.93 – 5.78 (m, 1H), 5.30 – 
5.21 (m, 2H), 4.35 (t, J = 16.0 Hz, 1H), 4.22 – 4.02 (m, 2H), 3.96 – 3.85 (m, 1H), 3.84 (s, 
3H), 3.40 – 3.19 (m, 2H), 2.94 – 2.78 (m, 1H), 2.71 – 2.48 (m, 1H), 1.47 (s, 9H); 13C 
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97.8 (dd, J = 193.7, 52.5 Hz), 81.1, 55.5, 49.8 (dd, J = 33.5, 23.3 Hz), (47.5 & 46.94 
appear as two peaks due to hindered rotation), 43.2, 39.8 (dd, J = 32.1, 21.8 Hz), 28.3. IR 
(Neat Film, NaCl) 2977, 2932,1696, 1603,1578, 1511, 1448, 1413, 1366, 1327, 1256, 
1169, 1152, 1029, 1000, 977, 923, 835, 766 cm-1; HRMS (MM: ESI-APCI): m/z calc’d 
for C21H28FN2O5 [M+H]+: 407.1977, found 407.1973; [α]D22.5 +46.99 (c 1.7, CHCl3); 
SFC conditions: 20% IPA, 2.5 mL/min, Chiralpak OD-H column, λ = 254 nm, tR (min): 
major = 2.692, minor = 3.253. 
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Figure A3.2 Infrared spectrum (Thin Film, NaCl) of compound A2S1. 
 
Figure A3.3 13C NMR (101 MHz, CDCl3) of compound A2S1. 
 





































Figure A3.5 Infrared spectrum (Thin Film, NaCl) of compound A2S3. 
 
Figure A3.6 13C NMR (101 MHz, CDCl3) of compound A2S3. 
 





































Figure A3.8 Infrared spectrum (Thin Film, NaCl) of 
compound A2S4. 
Figure A3.9  13C NMR (101 MHz, CDCl3) of compound A2S4. 
 





































Figure A3.11 Infrared spectrum (Thin Film, NaCl) of compound A2.4f. 
 
Figure A3.12  13C NMR (101 MHz, CDCl3) of compound A2.4f. 
 






































Figure A3.14 Infrared spectrum (Thin Film, NaCl) of compound A2.4g. 
 
Figure A3.15 13C NMR (101 MHz, CDCl3) of compound A2.4g. 
 






































Figure A3.17 Infrared spectrum (Thin Film, NaCl) of compound A2.4h. 
 
Figure A3.18 13C NMR (101 MHz, CDCl3) of compound A2.4h. 
 






































Figure A3.20 Infrared spectrum (Thin Film, NaCl) of compound A2.4i. 
 
Figure A3.21 13C NMR (101 MHz, CDCl3) of compound A2.4i. 
 






































Figure A3.23 Infrared spectrum (Thin Film, NaCl) of compound A2.4j. 
 
Figure A3.24 13C NMR (101 MHz, CDCl3) of compound A2.4j. 
 






































Figure A3.26 Infrared spectrum (Thin Film, NaCl) of compound A2.4l. 
 
Figure A3.27 13C NMR (101 MHz, CDCl3) of compound A2.4l. 
 






































Figure A3.29 Infrared spectrum (Thin Film, NaCl) of compound A2.5f. 
 
Figure A3.30 13C NMR (101 MHz, CDCl3) of compound A2.5f. 
 






































Figure A3.32 Infrared spectrum (Thin Film, NaCl) of compound A2.5g. 
 
Figure A3.33 13C NMR (101 MHz, CDCl3) of compound A2.5g. 
 






































Figure A3.35 Infrared spectrum (Thin Film, NaCl) of compound A2.5h. 
 
Figure A3.36  13C NMR (101 MHz, CDCl3) of compound A2.5h. 
 






































Figure A3.38 Infrared spectrum (Thin Film, NaCl) of compound A2.5l. 
 
Figure A3.39 13C NMR (101 MHz, CDCl3) of compound A2.5l. 
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Stereoselective Synthesis of α,α-Disubstituted Amino Acids via 
Decarboxylative Alkylation of Imidazolinones 
 
A4.1   INTRODUCTION AND BACKGROUND 
 
Unnatural amino acids exhibit tremendous biological and chemical utility. They 
function as chemical intermediates and building blocks for peptide therapeutics, are 
heavily featured in biological studies of unnatural peptides and proteins, and are found in 
natural products1 (Figure A4.1). For example, alpha-disubstituted amino acids can alter 
peptide conformation and protein structure due increased conformational rigidity, thus 
serving as useful tools to probe the biological effects of protein structure.2,3 Because of 
their conformational effects and their enhanced resistance to chemical and enzymatic 
degradation, alpha-disubstituted amino acids are featured in a number of experimental 
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Figure A4.1 Biological important of disubstituted amino acids 
 
Given the biological utility of disubstituted amino acids, researchers have 
developed myriad methods to synthesize chiral alpha-disubstituted amino acids. Here we 
cover just a few of the most prevalent strategies (Scheme A4.1); the interested reader is 
directed to a number of more comprehensive reviews.1,7–9 Classical approaches include 
enzymatic resolution of racemic mixtures, and installation of chiral auxiliaries. Seebach 
has pioneered the diastereoselective alkylation of cyclic oxazoline scaffolds, which are 
formed upon cyclization of an amino acid with a chiral aldehyde (Scheme A4.1A).10,11 
The rigid cyclic structure enables highly diastereoselective alkylations; however, the 
substrate scope is limited by the availability of substituted amino acid precursors as well 
as the relatively harsh basic reaction conditions. In a modern twist on Seebach’s 
diastereoselective functionalization method Clayden recently developed an innovative N-
to-C aryl migration strategy to generate alpha-arylated amino acids (Scheme A4.1B).12 
Other popular chiral auxiliary strategies involve appending a removable chiral scaffold to 
either the carboxylic acid or the amine of an acyclic amino acid substrate, in the latter 
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In the realm of asymmetric catalysis, modern approaches include enantioselective 
Mannich reactions, Strecker reactions (Scheme A4.1D),14 phase transfer conditions 
(Scheme A4.1E)15,16 and allylic alkylation reactions (Scheme A4.2).  
Scheme A4.1 Synthetic methods for disubstituted amino acids 
 
The cyclic azlactone scaffold (Scheme A4.2A) is commonly used in asymmetric 
catalysis to generate functionalized precursors that can be hydrolyzed to provide chiral 
alpha-disubstituted amino acids.17,18 Transition metal catalyzed allylic alkylation 
approaches, pioneered by Trost and others, allow access to unique alpha-disubstituted 
amino acids containing a synthetically versatile allyl handle (Scheme A4.2A).19–21  
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However, these methods display limited substrate variation as the cyclic substrates are 
synthesized from existing amino acids. In a series of significant advances, mild allylic 
alkylation conditions using acyclic Schiff base scaffolds were recently developed Scheme 
A4.2B &C).22–24 Compared to previous acyclic strategies,25 these new developments 
feature broader substrate scope; however, their substrate variation is still limited by 
beginning from synthetically and commercially available amino acids.  
Scheme A4.2 Transition metal catalyzed asymmetric allylic alkylation methods  
 
In the Stoltz laboratories, we previously attempted to optimize the DAAA of 
various oxazole and oxazolidine substrates (Scheme S4.3), which could theoretically be 
directly hydrolyzed to afford chiral amino acids.26 However, a series of conditions using 
Trost and PHOX ligands with various solvents resulted in low enantioselectivity. These 
poor results were consistent with our previous experience performing decarboxylative 
alkylation on lactone substrates. Furthermore, we believe the stabilized aromatic 
character of the prochiral decarboxylated intermediate contributes to the poor 
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C. Allylic Alkylation via Chiral Aldehyde Catalysis  (Guo 2019, JACS)
R2
Substrate scope limited by starting material availability
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enantioselectivity. Overcoming initial disappointments, we eventually identified a 
successful DAAA scaffold that when hydrolyzed, would result in a disubstituted amino 
acid. In the following section, we detail these efforts to significantly expand upon the 
substrate scope of chiral disubstituted amino acid synthesis via decarboxylative 
asymmetric allylic alkylation.  
Scheme A4.3 Previous attempts toward the decarboxylative alkylation of cyclic amino acid scaffolds 
 
A4.2   SYNTHESIS OF CYCLIC AMINO ACID SCAFFOLDS 
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A. Poor results from decarboxylative alkylation of an oxazole
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A. Failed route toward imidazolinone A4.5
B. Successful literature route toward imidazolinone A4.5
C. More concise route toward Boc-imidazolinone A4.8
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In light of our unsuccessful DAAA attempts with oxazole type scaffolds, we 
sought an alternative cyclic core; the imidazolinone core A4.5 (Scheme A4.4) is logically 
the next simplest scaffold on which to perform DAAA explorations, with hydrolysis 
ultimately yielding a chiral disubstituted amino acid. We thus sought to synthesize a 
model substrate based on the imidazolinone core. Initial attempts to cyclize glycinamide 
with formaldehyde (Scheme A4.4A) were unsuccessful. Looking to the literature, we 
found a multi-step patent route starting from glycinamide.27 Benzylation, followed by 
cyclization with formaldehyde affords hydroxyimidazolinone A4.3. Formaldehyde is then 
eliminated by heating under vacuum to yield benzyl-protected A4.4, with hydrogenolysis 
finally leading to imidazolinone A4.5. While this patent route proved reliable, we 
nevertheless sought a more concise route; Boc-azetidinone A4.6 is commercially 
available at <$1.25/gram, and Beckmann rearrangement would directly afford Boc-
imidazolinone A4.8. After screening a variety of conditions, we eventually found that 
Beckmann rearrangement of the oxime sulfonate under reflux provided the product A4.8 
in rather low yields of around 20%. We are currently exploring other Beckmann 
rearrangement conditions to improve the yield.  
With Boc-imidazolinone A4.8 in hand, we next sought to synthesize the 
dicarbonyl compound A4.10, which would serve as a divergent point of entry to a variety 
of novel DAAA substrates. Benzoylation to give A4.9 was facile. However, acylation 
with allyl cyanoformate proved more difficult.  At -78 °C, enolate formation by slowly 
adding a solution of A4.9 into a solution of LHMDS led to significant amounts of self-
cleavage of the benzoyl protecting group, significantly lowering the yield of dicarbonyl 
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A4.10. Fortunately, performing the deprotonation at -114 °C, at which point the THF 
reaction solvent began to solidify, avoided degradation and afforded A4.10 in 90% yield.   
Scheme A4.5 Synthesis of the imidazolinone DAAA substrate 
 
A4.3  DECARBOXYLATIVE ASYMMETRIC ALLYLIC ALKYLATION OF 
IMIDAZOLINONES  
 
With dicarbonyl A4.10 in hand, we next synthesized a range of DAAA substrates. 
Using methyl and aminomethyl substrate A4.11a and A4.11b for initial optimization 
attempts, we found that in line with previous results on six and seven-membered 
diazaheterocycles, a nonpolar solvent mixture of 2:1 hexanes/toluene or 2:1 
methylcyclohexane/toluene provided high enantioselectivity (Table A4.1, entries 2 & 3). 
In contrast, pure toluene resulted in lower ee (entry 1). To our delight, we achieved a 91% 
ee in our first screening attempt.  
 
 
Entry Solvent ee 
1 Toluene 80 
2 2:1 MeCy/Toluene 91 
3 2:1 Hexanes/Toluene 91 
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With the methyl model substrate A4.11b, we found that (S)-(CF3)3-tBu-PHOX 
was the optimal ligand (Table A4.2, entry 3). ANDEN-Ph-Trost ligand in dioxane (entry 
2) resulted in lowered enantioselectivity and longer reaction times; however, the entry 
should be repeated using 2:1 toluene/hexanes to provide a direct comparison to the other 
entries. While conducting the reaction at 40 °C resulted in higher enantioselectivity, the 
reaction was incomplete even after 72 hours, with significant amounts of starting material 
remaining. 
 
Entry Ligand Solvent Temp °C ee 
1 (S)-(CF3)3-tBu-PHOX 2:1 Hexanes/Toluene 40 96a 
2 (S,S)-ANDEN-Ph-Trost Dioxane 60 70a,b 
2 (S)-(CF3)3-tBu-PHOX 2:1 Hexanes/Toluene 60 94 
[a] Incomplete conversion after 72 h. [b] 0.5 M concentration. Reactions performed on 10 mg scale 
 
With these initial results in hand, we examined the DAAA of additional substrates 
(Table A4.3). The benzyl, benzyloxymethyl, and propargyl substrates A4.11c-d provided 
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Table A4.3 Initial Substrate Scope 
 
Reactions performed on 10 mg scale 
 
A4.4  CONCLUSIONS 
 In summary, we report the enantioselective synthesis of unprecedented gem-
disubstituted imidazolinones using the venerable Pd-catalyzed decarboxylative 
asymmetric allylic alkylation. The versatile (S)-(CF3)3-t-Bu-PHOX ligand performs well, 
yielding products in ee’s up to >99%. Future directions include further exploration of the 
substrate scope of this reaction and product transformations. These novel chiral 
imidazolinones are anticipated to find utility in the design of novel alpha-disubstituted 
amino acids. 
 
A4.5  EXPERIMENTAL SECTION 
A4.5.1  MATERIALS AND METHODS 
Unless otherwise stated, reactions were performed in flame-dried glassware under 
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60 °C: 94% ee, 12 h
40 °C: 98% ee, 36 h
A4.12e
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40°C:  91% ee, 4 h
A4.11 A4.12
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by passage through an activated alumina column under argon. Boc-azetidinone S4.6 was 
obtained from Combi-Blocks. Commercially obtained reagents were used as received. 
Chemicals were purchased from Sigma Aldrich/Strem/Alfa Aesar/Combi-Blocks and 
used as received.   
Reaction temperatures were controlled by an IKAmag temperature modulator. 
Glove box manipulations were performed under a nitrogen atmosphere. Thin-layer 
chromatography (TLC) was performed using E. Merck silica gel 60 F254 precoated 
plates (0.25 mm) and visualized by UV fluorescence quenching, iodine on silica, 
ninhydrin, or KMnO4 staining. SiliaFlash P60 Academic Silica gel (particle size 0.040–
0.063 mm) was used for flash chromatography.  
Analytical SFC was performed with a Mettler SFC supercritical CO2 analytical 
chromatography system utilizing a Chiralpak IC column (4.6 mm x 25 cm) obtained from 
Daicel Chemical Industries, Ltd. with visualization at 254 nm. Reverse Phase Preparatory 
HPLC was performed with a Teledyne ISCO ACCQPrep HP125 preparative liquid 
chromatography system equipped with a RediSep Prep C18 5 µm column (20 x 250 mm).  
1H NMR spectra were recorded on a Varian Inova 600 MHz or 500 MHz 
spectrometer or a Bruker Avance HD 400 MHz spectrometer and are reported relative to 
residual CHCl3 (δ 7.26 ppm) or CH3OH (δ 3.31 ppm). 13C NMR spectra were recorded on 
a Varian Inova 500 MHz spectrometer or a Bruker Avance HD 400 MHz spectrometer 
and are reported relative to residual CDCl3 (δ 77.16 ppm) or CD3OD (δ 49.00 ppm). Data 
for 1H NMR are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = 
pentet, sept = septuplet, m = multiplet, br s = broad singlet. Data for 13C NMR are 
reported in terms of chemical shifts (δ ppm). Some reported spectra include minor 
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solvent impurities of water (δ 1.56 or 4.87 ppm), ethyl acetate (δ 4.12, 2.05, 1.26 ppm), 
methylene chloride (δ 5.30 ppm), acetone (δ 2.17 ppm), grease (δ 1.26, 0.86 ppm), and/or 
silicon grease (δ 0.07 ppm), which do not impact product assignments.  
IR spectra were obtained using a Perkin Elmer Paragon 1000 spectrometer using 
thin films deposited on NaCl plates and reported in frequency of absorption (cm-1). High 
resolution mass spectra (HRMS) were obtained from an Agilent 6200 Series TOF with an 
Agilent G1978A Multimode source in electrospray ionization (ESI+), atmospheric 
pressure chemical ionization (APCI+), or mixed ionization mode (MM: ESI-APCI+). 
Optical rotations were measured with a Jasco P-2000 polarimeter operating on the 
sodium D-line (589 nm), using a 100 mm pathlength cell and are reported as: [α]DT 
(concentration in g/100 mL, solvent). Stereochemistry is assigned by analogy to previous 
results. 28–33 
A4.5.2  EXPERIMENTAL PROCEDURES AND SPECTROSCOPIC DATA 
A4.5.2.1 Procedures for the Synthesis of Imidazolinone Allylic Alkylation 
Substrates 
 
tert-butyl 4-oxoimidazolidine-1-carboxylate (S4.8). Can be prepared by two separate 
procedures. Procedure A: To a solution of imidazolinone S4.527 (1.47 g, 1 equiv) in THF 
(170 mL, 0.1 M) was added NEt3 (2.38 mL, 1 equiv) followed by Boc2O (3.72 g, 1 equiv) 
portionwise. The solution was stirred for 4 h at rt and then concentrated. The crude 
residue was purified by automated silica gel flash chromatography (Teledyne ISCO, 0 → 
20% MeOH/CH2Cl2) to provide S4.8 as a clear oil (2.5g, 79% yield). Procedure B: To a 
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concentration) was added a solution of NaOAc (6.72 g, 2 equiv) and NH2OH-HCl (4.06 g, 
2 equiv) in H2O (60 mL, 0.25 M total concentration). The solution was stirred at 50 °C 
for 2 h, and then extracted with CH2Cl2 (3x).  The combined organic layers were 
backwashed with NaHCO3 (1x) dried over Na2SO4, concentrated, and then placed under 
high vacuum to remove AcOH. The crude oxime was then dissolved in 260 mL of 3:2 
DME/H2O. K2CO3 (8.92 g, 2.5 equiv) and TsCl (5.9 g, 1.5 equiv) were added. The 
reaction was refluxed for 3 h until complete consumption of starting material was 
observed by TLC (5% MeOH/CH2Cl2). DME was concentrated off. The aqueous layer 
was extracted with EtOAc (6x). The combined organic layers were dried over Na2SO4 
and concentrated. The crude imidazolinone was purified by automated silica gel flash 
chromatography (0 → 30% MeOH/CH2Cl2) to provide the Boc-imidazolinone S4.8. 1H 
NMR (400 MHz, Chloroform-d) δ 7.66 (d, J = 52.9 Hz, 1H), 4.76 (d, J = 11.0 Hz, 2H), 
3.87 (d, J = 15.1 Hz, 2H), 1.47 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 172.1, 153.1, 
152.7, 81.2, (59.0, 58.8 two peaks due to hindered rotation), (47.5, 47.0 two peaks due to 




tert-butyl 3-benzoyl-4-oxoimidazolidine-1-carboxylate (S4.9). S4.8 (1.4 g, 1 equiv) in 
THF (75 mL), 0.1 M at −78 °C was added dropwise nBuLi (3.61 mL, 2.5 M solution in 
hexane, 1.2 equiv). The resulting yellow solution was stirred for 5 min at −78 °C. 
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yellow solution. The reaction was stirred for 10 min at −78 °C, quenched by addition of 
saturated aqueous NH4Cl, and diluted with ethyl acetate. The layers were separated and 
the aqueous layer was extracted with ethyl acetate (3 × 100 mL). The combined organic 
layers were dried over anhydrous Na2SO4, decanted, and concentrated under reduced 
pressure. The crude product was purified by automated silica gel flash column 
chromatography (0 → 80% EtOAc/hexanes) to give protected imidazolinone as a white 
solid. 1H NMR (400 MHz, Chloroform-d) δ 7.68 – 7.61 (m, 2H), 7.61 – 7.51 (m, 1H), 
7.48 – 7.39 (m, 2H), 5.29 (s, 2H), 4.17 (s, 2H), 1.51 (s, 9H). 13C NMR (101 MHz, 
CDCl3) δ 168.6, 167.5, 152.6, 133.0, 132.7, 129.1, 128.0, 81.8, 61.8, 49.3, 28.4. IR 
(Neat Film, NaCl) 2979, 1763, 1708, 1476, 1448, 1410,1367, 1305, 1212, 1163, 1127, 
894, 858, 767, 727, 704, 661 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C15H22N3O4 
[M+NH4]+: 308.1605, found 308.1600. 
 
 
 5-allyl 1-(tert-butyl) 3-benzoyl-4-oxoimidazolidine-1,5-dicarboxylate (A4.10). To a 
solution of LHMDS (1.52 g, 1.1 equiv) in THF (15 mL 0.1 M total concentration) was 
slowly added A4.9 (2.4 g, 1.0 equiv) in THF (68 mL, 0.1 M total concentration) at 
−114 °C. The resulting light orange reaction mixture (slurry/frozen) was stirred for 5 min 
at −114 °C. Then, allyl cyanoformate (368 µL, 1.2 equiv) was added dropwise at −114 °C, 
giving a light yellow solution. After stirring for 20 min at −96 °C, the reaction was 
quenched with 1 M HCl (10 mL) and diluted with ethyl acetate (20 mL). The aqueous 
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dried over anhydrous Na2SO4 and solid NaHCO3, decanted, and concentrated under 
reduced pressure The crude product was purified by automated silica gel flash 
chromatography (Teledyne ISCO, 0% → 80% EtOAc/hexanes) to give dicarbonyl A4.10 
as a clear oil; 1H NMR (400 MHz, Chloroform-d) δ 7.65 – 7.57 (m, 2H), 7.57 – 7.51 (m, 
1H), 7.42 (t, J = 7.8 Hz, 2H), 5.98 – 5.82 (m, 1H), 5.41 – 5.31 (m, 3H), 5.26 (dd, J = 15.2, 
10.4 Hz, 1H), 4.80 – 4.63 (m, 2H), 1.52 (s, 4H), 1.46 (s, 4H); 13C NMR (101 MHz, 
CDCl3) δ (168.42, 168.20 two peaks due to hindered rotation), (165.70, 165.55 two peaks 
due to hindered rotation), (163.49, 163.24 two peaks due to hindered rotation), (152.14, 
151.89 two peaks due to hindered rotation), 132.99, 132.63, (131.00, 130.94 two peaks 
due to hindered rotation), 129.18, 128.14, (119.79, 119.18 two peaks due to hindered 
rotation), (82.75, 82.61 two peaks due to hindered rotation), 67.16, 63.46, (63.01, 61.50 
two peaks due to hindered rotation), (28.34, 28.23 two peaks due to hindered rotation). 
IR (Neat Film, NaCl) 2977, 1747, 1715, 1449, 1405, 1369,1302, 1250, 1167, 1135, 986, 
938, 769, 725, 696, 668 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C19H26N3O6 
[M+NH4]+: 392.1816, found 392.1822.  
 
5-allyl 1-(tert-butyl) 3-benzoyl-5-methyl-4-oxoimidazolidine-1,5-dicarboxylate 
(A4.11b). Sodium hydride (60% in mineral oil, 32 mg, 1.2 equiv) was added to a solution 
of dicarbonyl A4.10 (250 mg, 1.0 equiv) in THF (6.7 mL, 0.1 M) at rt. After stirring for 
30 min at rt, MeI (208 µL, 5 equiv) was added. The reaction mixture was stirred for 2 h. 
The reaction was quenched with aqueous NH4Cl (10 mL) and extracted with EtOAc (3 x 
5 mL). The combined organic phases were dried over anhydrous Na2SO4, decanted, and 
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gel flash chromatography (Teledyne ISCO, 0 → 50% acetone/hexanes) to give methyl 
allyl ester A4.11b as a clear oil; 1H NMR (400 MHz, Chloroform-d) δ 7.71 – 7.50 (m, 
3H), 7.42 (t, J = 7.6 Hz, 2H), 5.89 (dtt, J = 15.9, 10.3, 5.7 Hz, 1H), 5.46 – 5.15 (m, 4H), 
4.80 – 4.50 (m, 2H), 1.81 (d, J = 21.1 Hz, 3H), 1.50 (s, 9H). 13C NMR (101 MHz, 
CDCl3) δ (168.6, 168.3 two peaks due to hindered rotation), 167.4, 167.2, (152.3, 152.2 
two peaks due to hindered rotation), 132.9, 132.7, (131.2, 130.9 two peaks due to 
hindered rotation), 129.1, 128.1, (119.6, 119.0 two peaks due to hindered rotation), (82.6, 
82.4 two peaks due to hindered rotation), (68.4, 68.2 two peaks due to hindered rotation), 
67.1, (61.1, 61.0 two peaks due to hindered rotation), (28.3, 28.2 two peaks due to 
hindered rotation), (20.4, 19.8 two peaks due to hindered rotation); IR (Neat Film, NaCl) 
2978, 1772, 1740, 1713, 1601, 1476, 1449, 1385,1369, 1304, 1244, 1161, 1123, 1066, 
912, 858, 769, 732, 702, 667 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C20H28N3O6 




dicarboxylate (A4.11d). Sodium hydride (60% in mineral oil, 32 mg, 1.2 equiv) was 
added to a solution of dicarbonyl A4.10 (250 mg, 1.0 equiv) in THF (6.7 mL, 0.1 M) at rt. 
After stirring for 30 min at rt, BOMCl (185 µL, 2 equiv) was added. The reaction mixture 
was stirred for 2 h. The reaction was quenched with aqueous NH4Cl (10 mL) and 
extracted with EtOAc (3 x 5 mL). The combined organic phases were dried over 
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product was purified by automated silica gel flash chromatography (Teledyne ISCO, 0 → 
40% acetone/hexanes) to give benzyloxymethyl allyl ester A4.11d as a clear oil; 1H 
NMR (400 MHz, Chloroform-d) δ 7.69 – 7.48 (m, 3H), 7.47 – 7.17 (m, 7H), 5.87 (dddt, 
J = 17.3, 10.4, 8.8, 5.8 Hz, 1H), 5.51 – 5.12 (m, 4H), 4.84 – 4.44 (m, 4H), 4.42 – 4.03 (m, 
2H), 1.52 (s, 5H), 1.38 (s, 5H); 13C NMR (101 MHz, CDCl3) δ (168.5, 168.3 two peaks 
due to hinded rotation), (166.0, 165.7 two peaks due to hinded rotation), (165.3, 165.21 
two peaks due to hinded rotation), (151.9, 151.5 two peaks due to hinded rotation), (137.7, 
137.3 two peaks due to hindered rotation), 132.9, 132.7, (131.1, 130.8 two peaks due to 
hindered rotation), 129.2, (128.68, 128.5 two peaks due to hindered rotation), 128.1, 
128.0, 127.9, (127.6 127.4 two peaks due to hindered rotation), (119.8, 119.2 two peaks 
due to hindered rotation), (82.5, 82.4 two peaks due to hindered rotation), 73.7, (72.0, 
71.8 two peaks due to hindered rotation), (69.5, 69.0 two peaks due to hindered rotation), 
67.0, 61.6, (28.4, 28.2 two peaks due to hindered rotation). IR (Neat Film, NaCl) 2975, 
1771,1744, 1713, 1450, 1389, 1369,1308, 1236, 1158, 1068, 858, 795, 744, 696, 668 cm-
1; HRMS (MM: ESI-APCI): m/z calc’d for C27H34N3O7 [M+NH4]+: 512.2398, found 
512.2395.   
 
5-allyl 1-(tert-butyl) 3-benzoyl-5-benzyl-4-oxoimidazolidine-1,5-dicarboxylate 
(A4.11c). Sodium hydride (60% in mineral oil, 32 mg, 1.2 equiv) was added to a solution 
of dicarbonyl A4.10 (250 mg, 1.0 equiv) in THF (6.7 mL, 0.1 M) at rt. After stirring for 
30 min at rt, BnBr (169 µL, 2 equiv) was added. The reaction mixture was stirred for 5 h, 
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and extracted with EtOAc (3 x 5 mL). The combined organic phases were dried over 
anhydrous Na2SO4, decanted, and concentrated under reduced pressure. The crude 
product was purified by automated silica gel flash chromatography (Teledyne ISCO, 10 
→ 30% acetone/hexanes) to give benzyl allyl ester A4.11c as a clear oil; 1H NMR (400 
MHz, Chloroform-d) δ 7.62 – 7.47 (m, 1H), 7.47 – 7.27 (m, 7H), 7.18 (ddd, J = 7.1, 5.3, 
1.8 Hz, 2H), 5.92 (dddt, J = 17.2, 10.4, 7.9, 5.8 Hz, 1H), 5.44 – 5.19 (m, 3H), 5.16 (d, J = 
7.0 Hz, 1H), 4.79 (ddt, J = 13.1, 5.7, 1.4 Hz, 1H), 4.74 – 4.59 (m, 2H), 4.40 (d, J = 7.0 Hz, 
1H), 3.82 (d, J = 13.9 Hz, 1H), 3.67 – 3.49 (m, 1H), 1.56 (d, J = 2.8 Hz, 10H). 13C NMR 
(101 MHz, CDCl3) δ 168.3, 168.0, 166.7, 166.6, 166.26, 166.1, 152.1, 151.8, 134.8, 
134.2, 132.8, 132.7, 131.3, 130.9, 130.3, 129.0, 128.8, 128.67, 128.0, 128.0, 127.9, 127.7, 
119.7, 119.1, 82.9, 82.4, 72.9, 67.2, 61.3, 38.0, 37.2, 28.4, 28.4. IR (Neat Film, NaCl) 
2977, 1770, 1712, 1602, 1449, 1393, 1294, 1230, 1147, 1074, 1009, 768, 701 cm-1; 
HRMS (MM: ESI-APCI): m/z calc’d for C26H32N3O6 [M+NH4]+: 482.2286, found 
482.2284.   
 
5-allyl 1-(tert-butyl) 3-benzoyl-4-oxo-5-(prop-2-yn-1-yl)imidazolidine-1,5-
dicarboxylate (A4.11e). Sodium hydride (60% in mineral oil, 32 mg, 1.2 equiv) was 
added to a solution of dicarbonyl A4.10 (250 mg, 1.0 equiv) in THF (6.7 mL, 0.1 M) at rt. 
After stirring for 15 min at rt, propargyl bromide (80% wt/wt in toluene, 252 µL, 4 equiv) 
was added. The reaction mixture was stirred for 1 h, turning light orange and cloudy in 
minutes. The reaction was quenched with aqueous NaHCO3 (10 mL) and extracted with 
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decanted, and concentrated under reduced pressure. The crude product was purified by 
automated silica gel flash chromatography (Teledyne ISCO, 0 → 30% acetone/hexanes) 
to give propargyl allyl ester A4.11e as a clear oil; 1H NMR (400 MHz, Chloroform-d) δ 
7.67 (dt, J = 8.5, 1.5 Hz, 2H), 7.61 – 7.51 (m, 1H), 7.51 – 7.34 (m, 2H), 5.86 (dtt, J = 
17.3, 10.4, 5.8 Hz, 1H), 5.42 (dd, J = 18.4, 7.0 Hz, 1H), 5.37 – 5.18 (m, 3H), 4.82 – 4.48 
(m, 2H), 3.46 (dd, J = 17.2, 2.7 Hz, 1H), 3.38 – 3.09 (m, 2H), 2.12 (dt, J = 5.4, 2.6 Hz, 
1H), 1.49 (d, J = 20.7 Hz, 9H). 13C NMR (101 MHz, CDCl3) δ 168.42, 168.17, 165.88, 
165.83, 165.68, 165.59, 151.97, 151.53, 133.06, 132.52, 131.00, 130.69, 129.22, 128.13, 
119.93, 119.35, 82.98, 82.76, 78.24, 77.57, 77.16, 72.37, 71.80, 71.13, 70.88, 67.36, 
67.33, 62.01, 28.31, 28.20, 24.20, 23.29. IR (Neat Film, NaCl) 3280, 2977, 1771, 1746, 
1713, 1601, 1449, 1391, 1370, 1295, 1228, 1151, 1058, 1018, 858, 790, 769, 739, 701, 
665 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C22H28N3O6 [M+NH4]+: 430.1973, 
found 430.1969.   
 
A4.5.2.2 General Procedure for Allylic Alkylation Optimization Screen 
In a nitrogen-filled glovebox, an oven-dried 1 dram vial was charged with 
Pd2(pmdba)3 (4 mol %), ligand (10 mol %), solvent (1 mL), and a magnetic stir bar. The 
vial was stirred at ambient glovebox temperature (27 °C) for 30 min and then substrate 
(10 mg, 1.0 equiv) was added as a solution in solvent (total concentration 0.014 M). The 
vial was sealed with a teflon cap and heated to 40 or 60 °C. When complete consumption 
of the starting material was observed by thin layer chromatography, the reaction mixture 
was removed from the glovebox and concentrated under reduced pressure. The residue 
was purified by silica gel flash chromatography to afford the imidazolinone.  
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A4.5.2.3 General Procedure for Pd-Catalyzed Decarboxylative Allylic 
Alkylation Reactions 
Please note The absolute configuration for all other products has been inferred by 
analogy.28–33 For respective SFC conditions, please refer to the section Determination of 
Enantiomeric Excess. 
In a nitrogen-filled glovebox, an oven-dried 1 dram vial or 20 mL scintillation 
vial was charged with Pd2(pmdba)3 or Pd2(dba)3 (4 mol %), (S)-(CF3)3-tBu-PHOX (10 
mol %), 2:1 hexanes/toluene, and a magnetic stir bar. The vial was stirred at ambient 
glovebox temperature (27 °C) for 30 min and then the substrate (10 mg, 1.0 equiv) was 
added as a solution in 2:1 hexanes/toluene (total concentration 0.014 M). The vial was 
sealed with a teflon cap and heated to 40 or 60 °C. When complete consumption of the 
starting material was observed by thin layer chromatography, the reaction mixture was 
removed from the glovebox and concentrated under reduced pressure. The residue was 
purified by silica gel flash chromatography to afford the desired imidazolinone.  
 
A4.5.2.4 Experimental Procedures and Spectroscopic data for the Pd-
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tert-butyl (R)-5-allyl-3-benzoyl-5-benzyl-4-oxoimidazolidine-1-carboxylate (A4.12c). 
IR (Neat Film, NaCl) 2927, 1757, 1707,1389, 1367, 1295, 1167, 701, 660 cm-1; HRMS 
(MM: ESI-APCI): m/z calc’d for C25H29N2O4 [M+H]+: 421.2122, found 421.2108.  
 
 
 tert-butyl (S)-5-allyl-3-benzoyl-5-methyl-4-oxoimidazolidine-1-carboxylate (A4.12b). 
Following the general procedure, allyl ester A4.11b (46 mg, 1.0 equiv) in 2:1 Hex/Tol 
(7.5 mL) was added to a solution of Pd2(pmdba)3 (5.2 mg, 4 mol %) and (S)-(CF3)3-tBu-
PHOX (7 mg, 10 mol %) in 2:1 Hex/Tol (1.0 mL). Reaction performed at 60 °C. 
Purification by automated silica gel flash chromatography (Teledyne ISCO, 0 → 20% 
acetone/hexanes) gave methyl imidazolinone A4.12b as a clear oil (94% ee); 1H NMR 
(400 MHz, Chloroform-d) δ 7.68 – 7.50 (m, 3H), 7.43 (t, J = 7.6 Hz, 2H), 5.70 (ddt, J = 
17.3, 9.9, 7.5 Hz, 1H), 5.31 – 5.13 (m, 3H), 5.07 (dd, J = 13.8, 7.7 Hz, 1H), 3.16 (dd, J = 
13.7, 7.8 Hz, 1H), 2.48 (ddd, J = 20.5, 13.6, 7.4 Hz, 1H), 1.76 – 1.40 (m, 13H); 13C 
NMR (101 MHz, CDCl3) δ 172.6, 168.7, 168.5, 152.7, 151.7, 133.2, 132.7, 132.1, 131.8, 
129.0, 128.0, 120.4, 81.8, 81.3, 77.4, 66.1, 65.7, 60.8, 60.7, 41.3, 40.0, 28.5, 28.5, 23.6, 
22.6; IR (Neat Film, NaCl) 3076, 2977, 2931, 1759, 1702, 1602,1477, 1449, 1388,1368, 
1296, 1262,1227, 1168,1124, 1059, 997, 964, 928, 906, 879, 859, 823.08 95.51 792, 773, 
732, 703, 661, 614 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for C19H25N2O3 [M+H]+: 
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Figure A5.2 Infrared spectrum (Thin Film, NaCl) of compound A4.8 
 
Figure A5.3 13C NMR (101 MHz, CDCl3) of compound A4.8 
 





































Figure A5.5 Infrared spectrum (Thin Film, NaCl) of compound A4.9. 
 
Figure A5.4 13C NMR (101 MHz, CDCl3) of compound A4.9 
 





































Figure A5.8 Infrared spectrum (Thin Film, NaCl) of compound A4.11b 
 
Figure A5.9 13C NMR (101 MHz, CDCl3) of compound A4.11b 
 





































Figure A5.11 Infrared spectrum (Thin Film, NaCl) of compound A4.11d 
 
Figure A5.12 13C NMR (101 MHz, CDCl3) of compound A4.11d 
 





































Figure A5.14 Infrared spectrum (Thin Film, NaCl) of compound A4.11c 
 
Figure A5.15 13C NMR (101 MHz, CDCl3) of compound A4.11c 
 





































Figure A5.17 Infrared spectrum (Thin Film, NaCl) of compound A4.11e 
 
Figure A5.18 13C NMR (101 MHz, CDCl3) of compound A4.11e 
 





































Figure A5.20 Infrared spectrum (Thin Film, NaCl) of compound A4.10 
 
Figure A5.21 13C NMR (101 MHz, CDCl3) of compound A4.10 
 






































Figure A5.23 Infrared spectrum (Thin Film, NaCl) of compound A4.12b 
 
Figure A5.24  13C NMR (101 MHz, CDCl3) of compound A4.12b 
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gem-Disubstituted Morpholine Analogues of Linezolid 
 
 
2.1  Introduction 
Figure 2.1 N-Heterocycles are valuable components of small molecule drugs. 
 
Traditionally, small molecule pharmaceuticals are rich in flat, aromatic motifs; 
however, studies have shown that increased sp3 character is associated with improved 
target specificity.1,2 One method of enhancing sp3 character in small molecule drugs 
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pyrrolidine, and morpholine, which rank amongst the most common N-heterocycles in 
small molecule drugs (Figure 2.1A).3  
Figure 2.2 Substitution patterns of common saturated heterocycles found in small molecule drugs 
 
The native sp3 complexity imparted by these saturated N-heterocycles can be 
further augmented by substituting the carbon atoms of the ring. Functionalizing these ring 
systems with carbon gem-disubstitutions—also termed quaternary centers—would 
potentially result in a number of improvements in the drug-like properties of such 
molecules, such as enhanced solubility, permeability, potency, and efficacy (Figure 
2.1C). Interestingly however, a 2014 analysis found that a majority of piperidine and 
pyrrolidine-containing drugs contained one or more C-substitutions (Figure 2.2a).3 In 
contrast, gem-disubstituted heterocyclic drugs are relatively rare (Figure 2.2b). For 
example, an analysis of the drugbank.ca structural database reveals that of all 139 FDA 
approved non-natural product derived piperazine and morpholine-containing small 
molecule drugs, none contain a chiral gem-disubstituted piperazine or morpholine.4 And 
in 69 pyrrolidine containing drugs, only three chiral gem-disubstituted molecules exist. 
Only in the most common N-heterocycle, piperidine, are gem-disubstitutions more 








































a) Monosubstitution patterns of common saturated heterocycles found in small molecule drugs 1
b) Disubstitution patterns of common saturated heterocycles found in small molecule drugs 2
297
Chapter 2 – gem-Disubstituted Morpholine Analogues of Linezolid 
  
	
disubstituted. The dearth of gem-disubstituted heterocycles in the pharmacopeia is 
partially due to the difficulty of preparing such heterocycles in a high yielding, 
enantioselective manner. In recent years, however, powerful methods have been 
developed to enantioselectively synthesize gem-disubstituted heterocycles. For instance, 
our laboratory has pioneered the development of Pd-catalyzed decarboxylative 
asymmetric allylic alkylation methodologies to synthesize a range of gem-disubstituted 
lactams of ring size 5 to 7 (Figure 1c).5–8 Such lactams can be deprotected and 
reductively transformed into the corresponding gem-disubstituted N-heterocycles.  
While such gem-disubstituted heterocycles are rare in small molecule 
pharmaceuticals, they hold the potential to further enhance the drug-like properties of 
small molecules (Figure 2.3).  
Figure 2.3 Biological properties altered by hypothetical gem-disubstitution of the antibiotic linezolid. 
 
 
2.2  Results 
 
Given this potential, we sought to investigate the practical utility of gem-
disubstituted heterocycles in bioactive small molecules. After surveying various N-
heterocyclic drugs for cases in which physicochemical attributes could be improved upon 
heterocyclic gem-disubstitution, we selected the morpholine-containing oxazolidinone 
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inhibits bacterial ribosome assembly by binding to the 50S subunit of the ribosome.9 
Linezolid and the recently approved oxazolidinone Tedizolid are important last resort 
antibiotics that are active against drug-resistant pathogens like methicillin-resistant 
Staphylococcus aureus (MRSA),10 vancomycin-resistant Enterococcus faecalis (VRE),11 
and multi-drug resistant Mycobacterium tuberculosis (MDR-TB).12 
Figure 2.4 Summary of oxazolidinone antibiotics 
 
Because the bacterial and human mitochondrial ribosomes are highly 
homologous, oxazolidinone antibiotics bind a commonly conserved site and thus also 
inhibit mitochondrial protein synthesis (MPS).13,14 This off-target binding is thought to be 
responsible for the more significant side-effects of linezolid, including myelosuppression, 
hyperlactatemia, and peripheral neuropathy.15 Similarly, other ribosome-targeting 
antibiotics such as clindamycin and chloramphenicol also exhibit corresponding 
myelotoxic side effects.16,17 If a structure-activity-relationship (SAR) could be 
determined for linezolid’s mitochondrial binding ability, then new oxazolidinones could 
be designed with reduced MPS inhibition. In fact, reducing myelotoxic side effects while 
maintaining antibacterial potency is often cited as one of the greatest challenges in new 
oxazolidinone design.18  
   Linezolid (Pfizer 2000)
• Member of the oxazolidinone class of antibiotics
• Inhibits gram+ bacterial growth
• Binds bacterial ribosome, preventing protein translation
• Commonly treats pneumonia, skin & soft tissue infections
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Fortunately, the modular structure of oxazolidinones enables chemical 
modification of all three rings, A, B, and C, facilitating SAR studies for mitochondrial 
ribosome binding (Figure 2.3). Some patterns have already been emerged. In 2006, 
McKee identified several oxazolidinones that more potently inhibit MPS yet display MIC 
values comparable to that of linezolid (Table 2.1).19 In these cases, the morpholine ring 
was replaced with other heterocycles, suggesting the C-ring may be the greatest 
determinant of MPS inhibition. In spite of these initial results, there are no known reports 
of a potent oxazolidinone featuring reduced MPS inhibition. 
 
Table 2.1. MIC and MPS IC50 values for linezolid analogues 
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We thus initiated a medicinal chemistry project seeking to modify the morpholine 
C-ring of linezolid with the goal of reducing MPS inhibition. Importantly, crystal 
structure studies note that the morpholine ring does not make significant interactions with 
the binding pocket, suggesting that the ring can be modified without compromising 
binding.20 Because increased molecular complexity is associated with reduced ligand 
promiscuity, we hypothesized that gem-disubstitution of the morpholine ring could 
potentially increase selectivity for the bacterial ribosome and reduce off-target side 
effects such as MPS inhibition (Figure 2.3). To test this hypothesis, we began by 
identifying a modular route to enable the synthesis of a library of gem-disubstituted 
linezolid analogs (Scheme 2.1). Cross-coupling of a gem-disubstituted morpholine with 
aryl halide 2.7 was identified as an efficient route. Thus, aryl halide 2.7 was synthesized 
by adapting a patent procedure.21 Briefly, (S)-epichlorohydrin (2.2) was coupled with 4-
chlorobenzaldehyde (2.1) and ammonia to give imine 3. To forge the oxazolidinone 
intermediate 2.5, imine 2.3 was then subjected to a base-catalyzed coupling reaction with 
carbamate 2.4,22 which itself was made by addition of benzyl chloroformate to 3-
fluoroaniline. Finally, imine hydrolysis, N-acetylation, and iodination provided the aryl 
iodide 2.7. 2.7 was cross-coupled under copper-catalyzed Ullmann conditions23 with a 
variety of gem-disubstituted morpholines resulting in linezolid analogues 2.12-2.19 
(Figure 2.5). Notably, this synthetic route will facilitate future efforts to modify the C 
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Scheme 2.1. Synthesis of gem-disubstituted linezolid analogues via Cu-catalyzed Ullmann coupling 
 
[a] (S)-epichlorohydrin, NH4OH (aq). THF, 40 °C, 12 h, 55% yield; [b] LiOt-Bu, CH2Cl2, rt to 40 °C, 87% yield; [c] 1N HCl, 
H2O/EtOAc; [d] Ac2O, CH2Cl2, 96% yield over 2 steps; [e] NIS, TFA, rt, 92% yield; f. Substituted morpholine 2.11a-p, CuBr 
(10 mol %), BINOL (20 mol %), K3PO4, DMF, 80 °C. 
 
Scheme 2.2. Synthesis of gem-disubstituted morpholines by benzoyl cleavage and reduction of 
morpholinone decarboxylative alkylation products  
 
Two analogues 2.13 and 2.14 were prepared using substituted morpholines 2.10 and 2.11, 
which were synthesized via a decarboxylative alkylation protocol and subsequent 
deprotective and reductive transformations (Scheme 2.2).6 Other analogues including the 
gem-dimethyl compound 2.12 and spiro compounds 2.15-2.19 were prepared from 
commercially available di-substituted morpholines. We note that all analogs were 





























































i. LiOH/H2O, i-PrOH, rt
ii. LAH, THF, 50 °C, 2h
2.10: R = Me, 90% yield
2.11: R = CH2OBn, 76% yield
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Figure 2.5. gem-Disubstituted linezolid analogues synthesized via Ullmann coupling 
 
Additionally, analogues synthesized via Ullman coupling could be further derivatized 
(Scheme 2.3). Taking advantage of the versatile allyl handle of 2.13, hydroboration-
oxidation afforded hydroxyl analogue 2.20, which could be acetyl-protected to give 
analogue 2.21.  Additionally, a Lemieux–Johnson oxidation provided the aldehyde 
intermediate, which was reductively aminated with dimethylamine to provide analogue 
2.23. Catalytic hydrogenation afforded the reduced analogue 2.22. Similarly, the 
benzyloxy analogue 2.14 could also be hydrogenated using catalytic Pd(OH)2 on carbon 
to provide the hydroxyl analogue 2.24. Finally, Boc-spiro compound 2.16 was 
deprotected using HCl resulting in spiropiperidine 2.25; subsequent acetyl protection 
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Scheme 2.3. Additional analogues synthesized by derivatization 
 
With a diverse set of gem-disubstituted linezolid analogues in hand, we proceeded with 
broth microdilution assays against S. aureus to determine minimum inhibitory 
concentration (MIC) values (Table 2.2). The initial three compounds, 2.12, 2.13, 2.24, 
were noticeably less potent than linezolid, suggesting that bulky alkyl di-substitution on 
the morpholino ring reduces activity. Similarly, bulky hydroxyl-substituted analogue 2.20 
and protected alcohols 2.21 and 2.14 were also inactive. In contrast, hydroxyl analogue 
2.25 retained a moderate amount of activity, displaying 48% growth inhibition at the 


















2.25: R = H, 32% yield 











































































40% yield over two steps
a, bc
2.20: R = H, 19% yield




40% yield over 2 steps
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and 2.25, featuring methylamino, dimethyl amino, and spiroamine functionalities, were 
uniformly inactive up to 64 µM concentrations. Interestingly, when the basic nitrogen of 
2.25 was masked as an amide as in 2.27, an 18% growth inhibition at the maximal tested 
concentration of 16 µM was achieved, suggesting that positively charged substituted 
morpholines are not tolerated. Finally, we were excited to observe increased growth 
inhibition when the spirofuran 2.18 and spirotetrahydropyran 2.19 analogues were tested, 
with 2.19 displaying the greatest potency of all analogues examined.  
Table 2.2. MIC values against ATCC 8235-4 (MSSA) or ATCC 43300 (MRSA) 
 
[a] MIC: the lowest concentration of molecule preventing visible growth. [b] Tested against ATCC 43300 (MRSA). [c] Tested 
against ATCC 8235-4 (MSSA).  [d] 16 μM was the maximal concentration tested. 
 
 
Since stereoisomers often exhibit differing biological activity, we used chiral HPLC to 
obtain both diastereomers of 2.19, and then assigned their absolute stereochemistry using 
vibrational circular dichroism (VCD) and optical rotation calculations, both of which 
were in agreement (Figure 2.6). Notably a eudysmic difference between the two 
diastereomers 2.19a and 2.19b was observed, with the more active diastereomer 2.19a 
























16 uM: 18% inhib.b,d
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Figure 2.6. Diastereomers of analogue 2.19. Absolute configuration of the spirocyclic stereocenter 
determined by both VCD and optical rotations (See Appendix 6 for details).  
 
We further investigated the bioactivity of 2.19a against other strains of S. aureus, 
determining the MIC values to be consistent against a range of MSSA and MRSA strains 
(Table 2.3).  
Table 2.3. MIC values of lead analogue 2.19a against various S. aureus strains 
 
We next examined the pharmacokinetic properties of 2.19a and 2.19b, 
determining most properties were slightly lower but comparable to that of linezolid 
(Table 2.4). For instance, 2.19a and 2.19b demonstrated slightly lower aqueous solubility 
and stability at low pH. Microsomal stability for was also lower than that of linezolid, 
perhaps due to the metabolic susceptibility of the tetrahydropyran ring. Initial safety data 
including cytotoxicity and cytochrome P450 isoform inhibition were satisfactory. One 
interesting difference was MPS inhibition, in which linezolid displayed a relatively potent 
8 µM IC50. In contrast, 2.19a displayed an IC50 value of 30 µM. This finding correlates 
with the relative MIC values of linezolid and 2.19a; in this case, MPS inhibition is also 
roughly three-fold less potent, suggesting that the spirotetrahydropyran ring of 2.19a 
maintains moderate binding affinity to the bacterial ribosome while reducing inhibition of 
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Table 4. Pharmacokinetic properties, inhibitory activity, and physicochemical properties  
 
[a] Metabolic stability performed with mouse liver microsomes 
[b] Cytotoxicity against HepG2 cells using CellTiter Glo 
[c] Measured against CYP1A2, 2C9, 2C19, 2D6, 3A4 
[d] MitoBiogenesis In-Cell ELISA assay for COXI and SDH-A mitochondrial proteins 
 
2.3  CONCLUSIONS 
In conclusion, we identified a gem-disubstituted morpholine analogue of linezolid 
bearing a spirotetrahydropyran substitution, 2.19a, that displays slightly reduced potency 
compared to linezolid against various S. aureus strains while also having reduced 
mitochondrial inhibition. These results contribute to the existing SAR of MPS inhibition 
(Table 2.1). Although the mitochondrial and bacterial ribosomes share homology, they 
have structural differences that may be exploited to design molecules with reduced 
selectivity for the mitochondrial ribosome.13 Our research further contributes to the body 
of data suggesting that the morpholine ring is a key structural component whose 
modification can reduce mitochondrial inhibition while maintaining bacterial ribosome 
inhibition. Continued efforts are needed to identify a molecule as potent as linezolid but 
with reduced MPS inhibition. This ability of gem-disubstituted heterocycles to alter 
selectivity for a target such as the bacterial ribosome highlights one of the many useful 
properties of heterocyclic substitution. Efforts such as those underway in our laboratory 
2.19a 2.19bLinezolid
Aq. solubility (μg/mL)
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to incorporate gem-disubstituted heterocycles into other small molecule scaffolds will 
undoubtedly shed light on the broader medicinal utility of gem-disubstituted heterocycles.  
 
2.4  EXPERIMENTAL SECTION 
2.4.1  MATERIALS AND METHODS 
Unless otherwise stated, reactions were performed in flame-dried glassware under 
an argon or nitrogen atmosphere using dry, deoxygenated solvents. Solvents were dried 
by passage through an activated alumina column under argon. Commercially obtained 
reagents were used as received. Chemicals were purchased from Sigma 
Aldrich/Strem/Alfa Aesar/Combi-Blocks/Enamine/PharmaBlock and used as received.  
From Combi-Blocks: (S)-epichlorohydrin, 2,2-dimethylmorpholine. From Enamine: 1,8-
dioxa-4-azaspiro[5.5]undecane, tert-butyl 1-oxa-4,8-diazaspiro[5.5]undecane-8-
carboxylate, 6-oxa-2,9-diazaspiro[4.5]decane, 2,6-dioxa-9-azaspiro[4.5]decane. From 
PharmaBlock: tert-butyl 8-oxo-6-oxa-2,9-diazaspiro[4.5]decane-2-carboxylate. 
Reaction temperatures were controlled by an IKAmag temperature modulator. 
Glove box manipulations were performed under a nitrogen atmosphere. Thin-layer 
chromatography (TLC) and preparatory TLC was performed using E. Merck silica gel 60 
F254 precoated plates (0.25 mm) and visualized by UV fluorescence quenching or 
KMnO4 staining. SiliaFlash P60 Academic Silica gel (particle size 0.040–0.063 mm) was 
used for flash chromatography.  
Analytical SFC was performed with a Mettler SFC supercritical CO2 analytical 
chromatography system utilizing a Chiralpak IC column (4.6 mm x 25 cm) obtained from 
Daicel Chemical Industries, Ltd. with visualization at 254 nm. Reverse Phase Preparatory 
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HPLC was performed with a Teledyne ISCO ACCQPrep HP125 preparative liquid 
chromatography system equipped with a RediSep Prep C18 5 µm column (20 x 250 mm).  
1H NMR spectra were recorded on a Varian Inova 600 MHz or 500 MHz 
spectrometer or a Bruker Avance HD 400 MHz spectrometer and are reported relative to 
residual CHCl3 (δ 7.26 ppm) or CH3OH (δ 3.31 ppm). 13C NMR spectra were recorded on 
a Varian Inova 500 MHz spectrometer or a Bruker Avance HD 400 MHz spectrometer 
and are reported relative to residual CDCl3 (δ 77.16 ppm) or CD3OD (δ 49.00 ppm). Data 
for 1H NMR are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = 
pentet, sept = septuplet, m = multiplet, br s = broad singlet. Data for 13C NMR are 
reported in terms of chemical shifts (δ ppm). Some reported spectra include minor 
solvent impurities of water (δ 1.56 or 4.87 ppm), ethyl acetate (δ 4.12, 2.05, 1.26 ppm), 
methylene chloride (δ 5.30 ppm), acetone (δ 2.17 ppm), grease (δ 1.26, 0.86 ppm), and/or 
silicon grease (δ 0.07 ppm), which do not impact product assignments.  
1H NMR spectra were recorded on a Varian Inova 600 MHz or 500 MHz 
spectrometer or a Bruker Avance HD 400 MHz spectrometer and are reported relative to 
residual CHCl3 (δ 7.26 ppm) or CH3OH (δ 3.31 ppm). 13C NMR spectra were recorded on 
a Varian Inova 500 MHz spectrometer or a Bruker Avance HD 400 MHz spectrometer 
and are reported relative to residual CDCl3 (δ 77.16 ppm) or CD3OD (δ 49.00 ppm). Data 
for 1H NMR are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = 
pentet, sept = septuplet, m = multiplet, br s = broad singlet. Data for 13C NMR are 
reported in terms of chemical shifts (δ ppm). Some reported spectra include minor 
solvent impurities of water (δ 1.56 or 4.87 ppm), ethyl acetate (δ 4.12, 2.05, 1.26 ppm), 
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methylene chloride (δ 5.30 ppm), acetone (δ 2.17 ppm), grease (δ 1.26, 0.86 ppm), and/or 
silicon grease (δ 0.07 ppm), which do not impact product assignments.  
IR spectra were obtained using a Perkin Elmer Paragon 1000 spectrometer using 
thin films deposited on NaCl plates and reported in frequency of absorption (cm-1). High 
resolution mass spectra (HRMS) were obtained from an Agilent 6200 Series TOF with an 
Agilent G1978A Multimode source in electrospray ionization (ESI+), atmospheric 
pressure chemical ionization (APCI+), or mixed ionization mode (MM: ESI-APCI+). 
Optical rotations were measured with a Jasco P-2000 polarimeter operating on the 
sodium D-line (589 nm), using a 100 mm pathlength cell and are reported as: [α]DT 
(concentration in g/100 mL, solvent).  
MIC values were obtained in collaboration with UCLA (P.L.B. and J.F.M.) and 
the CO-ADD. Pharmacokinetic data was obtained with WuXi AppTec, a contract 
research organization.  
 
2.4.2  EXPERIMENTAL PROCEDURES AND SPECTROSCOPIC DATA 
2.4.2.1 Determination of Absolute Configuration of 2.19a and 2.19b. 
 
Diastereomers SI1a and SI1b: To a solution of (S)-(−)-1-Phenylethanol (599 uL, 
1.1 equiv) in THF (4.5 mL, 1M), was added CDI (794 mg, 1.1 equiv). The solution was 
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equiv) were added and the solution was stirred for 5 min. Then 1,8-dioxa-4-
azaspiro[5.5]undecane was added and the solution was stirred for 16 h before quenching 
with NH4Cl. Following extraction with EtOAc (3x10 mL) and backwashing with 
NaHCO3 (5 mL), the combined organic layers were dried over Na2SO4 and concentrated. 
The crude product was purified by silica gel flash chromatography (33% 
EtOAc:Hexanes). The diastereomers were then separated by chiral preparative HPLC 
(CHIRALPAK IC Column 20 x 150 mm), 30% iPrOH:Hexanes. The diastereomer SI1a 
which results in the more potent analogue 2.19a elutes first from the chiral column. 
 
(R) and (S)-1,8-dioxa-4-azaspiro[5.5]undecane, enantiopure SI2a and SI2b: To a 
solution of carbamate SI1a or SI1b (460 mg, 1 equiv) in 1:1 EtOAc/MeOH (16 mL, 0.1 
M) under nitrogen was added Pd/C (10%, 80 mg, 0.05 equiv). The reaction vessel was 
evacuated and filled with hydrogen three times and then left to stir for 12 h at room 
temperature. Following completion as determined by TLC, the reaction was filtered 
through celite, rinsed with EtOAc, and then concentrated to afford the enantiopure 
amines SI2a or SI2b, which were used in subsequent reactions without further 
purification. 
 
(R) and (S)-1-(1,8-dioxa-4-azaspiro[5.5]undecan-4-yl)ethan-1-one (Acylated 
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added NEt3 (106 uL, 1.5 equiv) and Ac2O (53 uL, 1.1 equiv). The reaction was stirred at 
rt for 1 h and then purified by automated silica gel flash chromatography (Teledyne 
ISCO): MeOH/CH2Cl2 (0 → 30%) to afford the acylated amine SI3a or SI3b as a clear 
oil (65 mg, 65% yield); 1H NMR (400 MHz, Chloroform-d) δ 3.84 – 3.21 (m, 10H), 
2.09 (d, J = 5.2 Hz, 3H), 1.88 – 1.48 (m, 4H); 13C NMR (101 MHz, CDCl3) δ (169.6 & 
169.4 appear as two peaks due to hindered rotation), (71.1 & 70.9 appear as two peaks 
due to hindered rotation), (70.2 & 69.4 appear as two peaks due to hindered rotation), 
(68.5 & 68.4 appear as two peaks due to hindered rotation), (60.4 & 60.1 appear as two 
peaks due to hindered rotation), (51.1 & 41.7 appear as two peaks due to hindered 
rotation) (46.8 & 46.6 appear as two peaks due to hindered rotation), (30.9 & 29.8 appear 
as two peaks due to hindered rotation), (22.8 & 22.0 appear as two peaks due to hindered 
rotation), (21.2 & 21.11 appear as two peaks due to hindered rotation). IR: See VCD 
section; HRMS (MM: ESI-APCI) m/z calc’d for C10H21N2O3 [M+NH4]+: 217.1547, 
found 217.1552. [α]D22.7 –22.00 (c 1.0, CHCl3) for (S) ent. [α]D22.4 +17.38 (c 21.0, CHCl3) 
for (R) ent. 
Note: We elected to acylate these amines to facilitate absolute stereochemistry 
determination by both VCD and optical rotations. 
Method 1 – Vibrational Circular Dichroism (VCD) 
Experimental Protocol.  Solutions of SI3a and SI3b (65 mg/mL) were prepared 
in CDCl3 and loaded into a front-loading SL-4 cell (International Crystal Laboratories) 
possessing BaF2 windows and 100 µm path length.   Infrared (IR) and VCD spectra were 
acquired on a BioTools ChiralIR-2X VCD spectrometer as a one-hour block of 3120 
scans for each enantiomer.  A 15-minute acquisition of neat (+)-α-pinene control 
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(separate 75 µm BaF2 cell)  yielded a VCD spectrum in agreement with literature spectra.  
IR and VCD spectra were background-corrected using a 5-minute block acquisition of the 
empty instrument chamber under gentle N2 purge.  The resultant VCD spectra of SI3a 
and SI3b were enantiomer subtracted (half-difference). 
Computational Protocol.  The arbitrarily chosen (R) enantiomer of compound 
SI3b was subjected to an exhaustive initial molecular mechanics-based conformational 
search (MMFF94 force field, 0.08 Å geometric RMSD cutoff, and 30 kcal/mol energy 
window) as implemented in MOE 2018.1 (Chemical Computing Group, Montreal, CA).  
All conformers retained the (R) configuration.  All MMFF94 conformers were then 
subjected to geometry optimization, harmonic frequency calculation, and VCD rotational 
strength evaluation using density functional theory.  All quantum mechanical calculations 
utilized the B3PW91 functional, cc-pVTZ basis, and implicit IEFPCM chloroform 
solvation model as implemented in the Gaussian 16 program system (Rev. B.01; Frisch 
et al., Gaussian, Inc., Wallingford, CT).  Resultant harmonic frequencies were scaled by 
0.98. All structurally unique conformers were Boltzmann weighted by relative free 
energy at 298.15 K.  The predicted IR and VCD frequencies and intensities were 
convolved using Lorentzian line shapes (γ = 4 cm-1) and summed using the respective 
Boltzmann weights to yield the final predicted IR and VCD spectra of the (R) enantiomer 
of SI3b.  The predicted VCD of the corresponding (S) enantiomer was generated by 
inversion of sign.  From the agreement between the predicted and measured IR and VCD 
spectra in the useful range (1150-1325 cm-1; see below) the absolute configuration of the 
N-acylated derivative of the desired, more active spirocyclic amine tail group was 
established as (S). 
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Experimental (left) and computed (right) IR and VCD spectra for SI3a and SI3b. 
Method 2 – Optical Rotation (OR) 
Computational Protocol.  The ensemble of unique B3PW91/cc-PVTZ conformers of the 
(R) enantiomer of SI3b generated in Method 1 above were subjected to optical rotation 
calculation at 589.0 nm using the B3LYP hybrid density functional, the large and diffuse 
6-311++G(2df,2pd) basis set, and the IEFPCM implicit chloroform solvent model.  From 
the computed B3PW91/cc-pVTZ free energies at 298.15 K and IEFPCM-B3LYP/6-
31++G(2df,2pd) optical rotations, a Boltzmann-weighted OR value of +33.6° was 
determined for the (R)-configuration of the above N-acylated derivative.   (Thus -33.6° 
for the (S) configuration).   As the measured specific rotations (CHCl3 solvent, 22.7 °C, c 
= 1.0, 100 mm path length) were found to be +17.4° (less potent enantiomer) and -20.0° 
(more potent enantiomer) the OR-based assignment is therefore in accord with the VCD-
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based assignment above (more active = (S), less active = (R).  Individual free energies 
and optical rotational signatures are provided in the accompanying Microsoft Excel file.  
 
2.4.2.2 Experimental	Procedures	for	Biological	Assays	
Broth microdilution method A (Performed by the CO-ADD) 
Samples were provided by the collaborator and stored frozen at -20 °C. Samples 
were prepared in DMSO and water to a final testing concentration of 32 µg/mL or 20 µM 
(unless otherwise indicated in the data sheet) and serially diluted 1:2 fold 8 times. Each 
sample concentration was prepared in 384-well plates, non-binding surface plate (NBS; 
Corning 3640) for each bacterial/fungal strain or Tissue-culture treated (TC-treated; 
Corning 3712/3764) black for mammalian cell types, all in duplicate (n=2), and keeping 
the final DMSO concentration to a maximum of 0.5% DMSO. All sample preparation 
was done using liquid handling robots. 
Whole cell growth inhibition assays against S. aureus ATCC 43300 MRSA were 
conducted as an 8-point dose response to determine the Minimum Inhibitory 
Concentration (MIC), in duplicate (n=2). All bacteria were cultured in Cation-adjusted 
Mueller Hinton broth (CAMHB) at 37 °C overnight. A sample of each culture was then 
diluted 40-fold in fresh broth and incubated at 37 °C for 1.5-3 h. The resultant mid-log 
phase cultures were diluted (CFU/mL measured by OD600), then added to each well of the 
compound containing plates, giving a cell density of 5Å~105 CFU/mL and a total volume 
of 50 µL. All the plates were covered and incubated at 37 °C for 18 h without shaking. 
Inhibition of bacterial growth was determined measuring absorbance at 600 nm (OD600), 
using a Tecan M1000 Pro monochromator plate reader. The percentage of growth 
inhibition was calculated for each well, using the negative control (media only) and 
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positive control (bacteria without inhibitors) on the same plate as references. The 
percentage of growth inhibition was calculated for each well, using the negative control 
(media only) and positive control (bacteria without inhibitors) on the same plate. The 
MIC was determined as the lowest concentration at which the growth was fully inhibited, 
defined by an inhibition ≥ 80%. In addition, the maximal percentage of growth inhibition 
is reported as DMax , indicating any compounds with partial activity. 
 
Broth microdilution method B (Performed by UCLA, P.L.B and J.F.M.) 
A broth microdilution method was used to estimate the MIC of synthesized 
compounds against Staphylococcus aureus ATCC 8235-4 (MSSA), 43300 (MSSA), 
29213 (MRSA), and 25293 (MSSA). Compounds were diluted in Luria-Bertani (LB) 
broth to concentrations ranging from 4 µM to 22 µM (in 2 µM steps) in 96 well plates 
(100 µl per well). DMSO-treated wells (carrier-only) were used as negative controls, and 
linezolid-treated wells were used as positive controls. Wells at the edge of the plate were 
not used to avoid broth evaporation during incubation. Overnight cultures of S. aureus 
8235-4 were diluted 1:200 in experimental plates, and plates were sealed with a plastic 
cover and tape. Inoculated plates were gently shaken (150 RPM) at 37 °C for 16hrs, at 
which point the optical density at 600nm (OD600) for each well was determined using an 
Epoch microplate spectrophotometer (BioTek Instruments). MIC was defined as the 
concentration at which at least 90% of S. aureus growth was inhibited, relative to DMSO-













(S)-1-chloro-3-((4-chlorobenzylidene)amino)propan-2-ol (2.3). To a solution of 
benzaldehyde (25 g, 1 equiv) in THF (180 mL, 1M) was added aqueous ammonia (28 wt 
%, 18 mL, 1.5 equiv). The mixture was stirred at rt for 20 min. Then, (S)-epichlorohydrin 
(13.9 mL, 1.0 equiv) was added. The reaction was stirred at 30 °C for 4 h, then at 40 °C 
for 12 h. with a reflux condenser attached. Then, another 18 mL aq. NH3 was added and 
stirring was continued at 40 °C for another 12 h.  The solvent was concentrated under 
reduced pressure. 50 mL PhMe was added and then removed under reduced pressure to 
azeotrope remaining volatiles. The aqueous solution was then extracted with EtOAc 
(3x50 mL). The combined organic layers were dried over Na2SO4 and concentrated under 
reduced pressure. The crude product was recrystallized using hot hexanes, rinsed with 
hexanes, and isolated as white needles (22.7 g, 55% yield). Product identity matched 
previously reported characterization data.24 
 
 
benzyl (3-fluorophenyl)carbamate (2.4). To a solution of 3-fluoroaniline (5 g, 1 equiv) 
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solution was stirred at rt for 5 h and then quenched with 200 mL sat. Na2CO3. The layers 
were separated and the organic layer was washed with Na2CO3 (2x). The combined 
aqueous layers were extracted with CH2Cl2 (4x). The combined organic layers were dried 
over Na2SO4 and concentrated under reduced pressure. The crude mixture was triturated 
with hexanes at rt: after cooling at -20 °C, the white precipitate was isolated by filtration 





(2.5). To a solution of carbamate 2.4 (4 g, 1 equiv) and LiOtBu (3.27 g, 2.5 equiv) in 
CH2Cl2 (22 mL, 0.75 M) was added a solution of imine 2.3 in CH2Cl2 (11 mL, 2.27 M). 
The reaction was refluxed for 16 h, and then allowed to cool to rt before being quenched 
with half saturated brine. The solution was extracted with CH2Cl2 (4x30 mL). Addition 
H2O and CH2Cl2 were added to clear emulsions formed in the separatory funnel. The 
combined organic layers were dried over Na2SO4, filtered over celite to remove 
suspended particles, and then concentrated under reduced pressure. The crude product 
was triturated by adding hot Et2O, which solvated the byproduct, but left the product 
unsolvated. The hot Et2O was allowed to cool to rt and then the product was isolated by 
filtration and rinsed with cold Et2O to provide the imine 2.5 as a white fluffy solid (4.73 
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2H), 7.54 – 7.14 (m, 5H), 6.84 (td, J = 8.2, 2.5 Hz, 1H), 4.97 (dq, J = 8.9, 5.2 Hz, 1H), 
4.29 – 4.04 (m, 2H), 4.04 – 3.79 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 163.21 (d, JCF 
= 245.0 Hz), 163.68, 154.45, 139.94 (d, JCF = 10.7 Hz), 137.44, 134.09, 130.35 (d, JCF = 
9.4 Hz), 129.66, 129.10, 113.43 (d, JCF = 3.0 Hz), 110.85 (d, JCF = 21.2 Hz), 105.90 (d, 
JCF = 26.9 Hz), 71.90, 63.28, 48.27; IR (Neat Film, NaCl) 3746, 2360, 1748, 1646, 
1614, 1495, 1456, 1405, 1224, 1195, 1168, 1087, 837 cm-1; HRMS (MM: ESI-APCI) 
m/z calc’d for C17H15FN2O2 [M+H]+: 333.0801, found 333.0803. [α]D22.7 –99.9 (c 2.0, 
CHCl3). 
 
(S)-N-((3-(3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide (2.6). To a solution 
of imine 2.5 in a 1:1 mixture of EtOAc/H2O (80 mL, 0.17 M) was added concentrated 
HCl (2.26 mL, 2 equiv). The reaction was stirred at rt for 5 h and then slowly quenched 
with NaHCO3(aq). Then, KOH was added until pH = 14. The solution was extracted with 
EtOAc (4x40 mL) and CH2Cl2 (4x40 mL). The combined organic layers were dried over 
Na2SO4 and concentrated under reduced pressure. The crude product was triturated with 
Et2O to afford crude amine, which was used in the next step without purification. 
To a solution of crude amine in CH2Cl2 (45 mL, 0.3 M) was added NEt3 (3.78 mL, 2 
equiv) followed by Ac2O (2.55 mL, 2 equiv). The reaction was stirred for 2 h at rt and 
then quenched with H2O. Following extraction with EtOAc (3x20 mL) and drying with 
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crude product was dissolved in a minimal amount of hot CH2Cl2 and then Et2O was 
added. The solution was left overnight at -20 °C, resulting in crystallization of pure 2.6. 
The solid product (3.28 g, was isolated by filtration and rinsed with Et2O. Product 
identity matched previously reported characterization data. 
 
(S)-N-((3-(3-fluoro-4-iodophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide (2.7). To a 
solution of (S)-N-((3-(3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide (2.6) 
(2.9 g, 1 equiv) in TFA (12 mL, 1M) was added NIS (2.72 g, 1.05 equiv) portion-wise. 
The reaction was stirred for 1 h at rt. While stirring, the exothermic reaction turned 
pinked. Next, the TFA was concentrated off under reduced pressure. The crude mixture 
was diluted with Na2S2O3 (10%), and then KOH was added until pH = 14. Next the 
solution was diluted to ~700 mL volume with H2O. Extraction with CH2Cl2 (4x50 mL) 
and EtOAc (4x50 mL) was followed by drying with Na2SO4 and concentration of the 
combined organic layers under reduced pressure. The crude product was then purified by 
silica gel flash chromatography (5 → 10% MeOH/CH2Cl2) to afford the desired iodinated 
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2-allyl-2-((benzyloxy)methyl)morpholine (2.11). Prepared according to literature 
procedure.6 Product identity matched previously reported characterization data.6 
 
 
2-allyl-4-benzoyl-2-methylmorpholin-3-one.6 Prepared according to an adapted 
procedure from our publications:6,28 In the glove box, in a 100 mL Schlenck bomb, 
Pd(OAc) (2.7 mg, 0.005 equiv), GlyPHOX29,30 (16 mg, 0.02 equiv), and MTBE (5 mL) 
were added. The solution was stirred at rt for 30 min. Then, allyl 4-benzoyl-2-methyl-3-
oxomorpholine-2-carboxylate6 dissolved in 10 mL toluene was added. The reaction was 
heated to 60 °C for 5 h, at which time TLC analysis showed complete consumption of 
starting material. The solution was loaded onto a silica gel flash column and purified (10 
→ 20% EtOAc/Hexanes) to afford racemic 2-allyl-4-benzoyl-2-methylmorpholin-3-one 
as a white solid (620 mg, 98% yield). Product identity matched previously reported 
characterization data.6 
 
2-allyl-2-methylmorpholine (10). To a solution of 2-allyl-4-benzoyl-2-
methylmorpholin-3-one (620 mg, 1 equiv) in iPrOH (60 mL, 0.04 M) was added LiOH-
H2O (150 mg, 1.5 equiv) dissolved in H2O (16 mL, 0.15 M). The reaction was stirred at 
room temperature for 2 h and then concentrated into SiO2. The dry-loaded crude product 
was purified by silica gel flash chromatography (2.5 → 5% MeOH/CH2Cl2) to afford the 
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To a solution of deprotected lactam (370 mg, 1 equiv) in THF (24 mL, 0.1 M) was added 
LAH (271 mg, 3 equiv) portionwise at 0 °C. The reaction was then heated to 50 °C for 2 
h. A Fieser workup was performed: the reaction was diluted with Et2O (12 mL) at 0 °C, 
then the following were slowly and sequentially added at 0 °C: 270 uL H2O, 270 uL 15% 
aq. NaOH, and lastly 800 uL H2O. The suspension was stirred at 0 °C for 15 min and 
then MgSO4 was added. The mixture was allowed to warm to rt and then filtered over 
celite, rinsing with EtOAc. The solvent was concentrated under reduced pressure. The 
crude product was purified by silica gel flash chromatography (5 → 10% MeOH/CH2Cl2) 
to yield racemic 2.10 as a clear oil (305 mg, 90% yield over two steps); 1H NMR (600 
MHz, Chloroform-d) δ 5.80 (dddd, J = 14.6, 12.9, 6.1, 3.8 Hz, 1H), 5.14 – 5.02 (m, 2H), 
3.67 (dq, J = 5.7, 3.3, 2.7 Hz, 2H), 2.79 (q, J = 4.4, 4.0 Hz, 2H), 2.74 – 2.57 (m, 2H), 
2.48 (dt, J = 12.1, 5.5 Hz, 1H), 2.21 (dt, J = 12.7, 5.9 Hz, 1H), 2.06 (d, J = 7.5 Hz, 1H), 
1.26 – 1.10 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 133.6, 117.9, 72.1, 61.6, 54.3, 46.0, 
41.7, 22.0; IR (Neat Film, NaCl) 3335, 3074,2973, 2938, 2868, 2818, 2741,2360, 1639, 
1455, 1375, 1324, 1259, 1200, 1177, 1130, 1084, 997, 914, 852, 797, 750, 669 cm-1; 
HRMS (MM: ESI-APCI) m/z calc’d for C8H16NO [M+H]+: 142.1226, found 142.1229. 
 
 
2-methyl-6-oxa-2,9-diazaspiro[4.5]decane (SI5). To a solution of tert-butyl 8-oxo-6-
oxa-2,9-diazaspiro[4.5]decane-2-carboxylate (100 mg, 1 equiv) in THF (3.9 mL, 0.1 M) 
at 0 °C was slowly added LAH (59 mg, 4 equiv). The reaction was stirred at 60 °C for 6 h 
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reaction was diluted two-fold with Et2O at 0 °C, then the following were slowly and 
sequentially added at 0 °C: 60 uL H2O, 60 uL 15% aq. NaOH, and lastly 180 uL H2O. 
The suspension was stirred at 0 °C for 15 min and then MgSO4 was added. The mixture 
was allowed to warm to rt and then filtered over celite, rinsing with EtOAc. The solvent 








To a flame-dried one-dram vial equipped with a Teflon screw cap and a stir bar was 
added CuBr (0.1 - 0.3 equiv), BINOL (0.1 - 0.3 equiv), aryl iodide 2.7 (1 equiv), and 
K3PO4 (2 equiv). The vial was cycled into a glovebox and then DMF (0.2 M final 
concentration) was added to the vial, followed by the amine (2 equiv). The reaction was 
stirred at 80 °C for 24-72 hours until complete consumption of starting material was 
noted by LC-MS analysis. In some cases, conversion of the starting material stopped, at 
which point 0.2 equiv of CuBr and 0.2 equiv of BINOL was added to the reaction, which 
then proceeded to completion. The reaction was diluted with EtOAc and filtered through 
a plug of silica, rinsing with 10% MeOH/EtOAc. The solution was concentrated in vacuo 
until all DMF solvent was removed. The crude material was purified by by silica gel flash 























CuBr (20 mol %)
BINOL (20 mol %) 
K3PO4, DMF,  80 °C
24-72 h
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oxooxazolidin-5-yl)methyl)acetamide (2.19a). Prepared according to the general 
procedure using: CuBr (2.3 mg, 0.016 mmol, 0.2 equiv), BINOL (4.5 mg, 0.016 mmol, 
0.2 equiv), aryl iodide 2.7 (30 mg, 0.079 mmol, 1 equiv), K3PO4 (34 mg, 0.16 mmol, 2 
equiv), enantiopure (S)-1,8-dioxa-4-azaspiro[5.5]undecane (SI2a) (18 mg, 0.16 mmol, 
2 equiv), and 400 uL DMF. The crude residue was purified by silica gel flash 
chromatography (2 → 3 → 5% MeOH/CH2Cl2) to yield spirotetrahydropyran analogue 
2.19a (8 mg, 28% yield) as a clear oil: 1H NMR (400 MHz, CDCl3) δ 7.40 (dd, J = 14.1, 
2.6 Hz, 1H), 7.04 (ddd, J = 8.8, 2.6, 1.1 Hz, 1H), 6.88 (t, J = 9.1 Hz, 1H), 6.39 (t, J = 6.2 
Hz, 1H), 4.76 (dddd, J = 8.8, 6.7, 5.5, 3.3 Hz, 1H), 4.00 (t, J = 9.0 Hz, 1H), 3.91 (t, J = 
4.9 Hz, 2H), 3.85 – 3.77 (m, 1H), 3.74 (dd, J = 9.2, 6.7 Hz, 1H), 3.71 – 3.54 (m, 5H), 
3.09 – 2.94 (m, 2H), 2.92 (s, 2H), 2.01 (s, 3H), 1.95 – 1.78 (m, 3H), 1.58 (dddd, J = 14.3, 
11.4, 6.8, 2.4 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 171.3, 155.6 (d, JCF = 246.5 Hz), 
154.5, 136.9 (d, JCF = 9.0 Hz), 133.0 (d, JCF = 10.3 Hz), 119.2 (d, JCF = 4.0 Hz), 114.0 (d, 
J = 3.4 Hz), 107.6 (d, J = 26.1 Hz), 72.1, 71.7, 70.0, 68.7, 61.0, 56.9, 50.8, 47.8, 42.0, 
31.0, 23.2, 22.4; IR (Neat Film, NaCl) 3312, 3073, 2953, 2846, 2244, 1748, 1660, 1517, 
1486, 1446, 1416, 1374, 1324, 1279, 1225, 1196, 1097, 1044, 985, 910, 871, 809, 732, 
674, 646 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C20H27FN3O5 [M+H]+: 

















oxooxazolidin-5-yl)methyl)acetamide (2.19b). Prepared according to the general 
procedure using: CuBr (2.3 mg, 0.016 mmol, 0.2 equiv), BINOL (4.5 mg, 0.016 mmol, 
0.2 equiv), aryl iodide 2.7 (30 mg, 0.079 mmol, 1 equiv), K3PO4 (34 mg, 0.16 mmol, 2 
equiv), enantiopure (R)-1,8-dioxa-4-azaspiro[5.5]undecane (SI2b) (18 mg, 0.16 mmol, 
2 equiv), and 400 uL DMF. The crude residue was purified by silica gel flash 
chromatography (2 → 3 → 5% MeOH/CH2Cl2) to yield spirotetrahydropyran analogue 
2.19b (10 mg, 32% yield) as a clear oil: 1H NMR (400 MHz, Chloroform-d) δ 7.43 (dd, 
J = 14.1, 2.6 Hz, 1H), 7.06 (ddd, J = 8.8, 2.7, 1.1 Hz, 1H), 6.91 (t, J = 9.1 Hz, 1H), 6.06 
(t, J = 6.2 Hz, 1H), 4.76 (dddd, J = 8.9, 6.7, 5.8, 3.2 Hz, 1H), 4.02 (t, J = 9.0 Hz, 1H), 
3.93 (t, J = 4.9 Hz, 2H), 3.81 (d, J = 11.7 Hz, 1H), 3.78 – 3.55 (m, 6H), 3.08 – 2.96 (m, 
2H), 2.94 (s, 2H), 2.02 (s, 3H), 1.96 – 1.77 (m, 3H), 1.59 (dddd, J = 15.1, 12.8, 6.9, 2.4 
Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 171.1, 155.6 (d, J = 246.6 Hz), 154.3, 136.81 
(d, J = 8.9 Hz), 133.06 (d, J = 10.4 Hz), 119.27 (d, J = 4.0 Hz), 113.99 (d, J = 3.5 Hz), 
107.62 (d, J = 26.2 Hz), 71.9, 71.7, 70.0, 68.7, 60.9, 56.9, 50.8, 47.7, 42.1, 31.0, 23.3, 
22.5; IR (Neat Film, NaCl) 3318, 3067, 2927, 2850, 1748, 1667, 1516, 1486, 1416, 
1374, 1326, 1277, 1225, 1097, 939, 870, 815, 733 cm-1; HRMS (MM: ESI-APCI) m/z 

















5-yl)methyl)acetamide (2.18). Prepared according to the general procedure using: CuBr 
(7.5 mg, 0.052 mmol, 0.3 equiv), BINOL (15.0 mg, 0.052 mmol, 0.3 equiv), aryl iodide 
2.7 (66 mg, 0.17 mmol, 1 equiv), K3PO4 (74 mg, 0.35 mmol, 2 equiv), 2,6-dioxa-9-
azaspiro[4.5]decane (50 mg, 0.35 mmol, 2 equiv), and 873 uL DMF. The crude residue 
was purified by reverse phase preparatory HPLC (0 → 100% MeCN/H2O gradient over 
10 minutes, 30x250 mm C18 column, 60 mL/min flow rate) to yield spirotetrahydrofuran 
analogue 2.18 (35 mg, 51% yield) as a clear oil. Note: HPLC H2O solvent contained 
0.25% TFA: 1H NMR (400 MHz, Chloroform-d) δ (Note TFA appears in the 1H and 
13C NMR) 7.41 (dd, J = 14.0, 2.6 Hz, 1H), 7.05 (ddd, J = 8.8, 2.6, 1.1 Hz, 1H), 6.92 (t, J 
= 9.0 Hz, 1H), 4.82 (dddd, J = 8.8, 6.4, 5.1, 3.6 Hz, 1H), 4.14 – 3.83 (m, 7H), 3.79 (dd, J 
= 9.3, 6.4 Hz, 1H), 3.75 – 3.65 (m, 2H), 3.03 (d, J = 5.2 Hz, 4H), 2.24 – 2.13 (m, 2H), 
2.13 – 2.00 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 171.4, 155.6 (d, J = 246.6 Hz), 
154.5, 136.4 (d, J = 9.0 Hz), 133.3 (d, J = 10.4 Hz), 119.1 (d, J = 4.0 Hz), 114.0 (d, J = 
3.3 Hz), 107.6 (d, J = 26.1 Hz), 82.6, 75.5, 72.1, 67.6, 63.1, 57.9, 50.1, 47.7, 42.0, 36.4, 
23.2; IR (Neat Film, NaCl) 3304, 3070, 2955, 2870, 1751, 1662, 1517, 1446, 1415, 
1374, 1326, 1278, 1227, 1195, 1083, 1060, 992, 919, 731 cm-1; HRMS (MM: ESI-
APCI) m/z calc’d for C19H25FN3O5 [M+H]+: 394.1773 found 394.1779. [α]D2.8 –5.54 (c 

















yl)methyl)acetamide (2.12). Prepared according to the general procedure using: CuBr 
(2.3 mg, 0.016 mmol, 0.2 equiv), BINOL (4.5 mg, 0.016 mmol, 0.2 equiv), aryl iodide 
2.7 (30 mg, 0.079 mmol, 1 equiv), K3PO4 (34 mg, 0.16 mmol, 2 equiv), dimethyl 
morpholine (18 mg, 0.16 mmol, 2 equiv), and 400 uL DMF. The crude residue was 
purified by silica gel flash chromatography (2 → 3 → 5% MeOH/CH2Cl2) to yield 
dimethyl analogue 2.12 (8 mg, 28% yield) as a clear oil: 1H NMR (400 MHz, CDCl3) δ 
7.42 (dd, J = 14.2, 2.6 Hz, 1H), 7.05 (ddd, J = 8.8, 2.6, 1.1 Hz, 1H), 6.88 (t, J = 9.1 Hz, 
1H), 6.16 (t, J = 6.2 Hz, 1H), 4.76 (dddd, J = 8.9, 6.7, 5.7, 3.3 Hz, 1H), 4.01 (t, J = 9.0 
Hz, 1H), 3.92 – 3.85 (m, 2H), 3.80 – 3.65 (m, 2H), 3.61 (dt, J = 14.7, 6.1 Hz, 1H), 3.01 – 
2.93 (m, 2H), 2.81 (s, 2H), 2.02 (s, 3H), 1.34 (s, 6H); 13C NMR (101 MHz, CDCl3) δ 
171.2, 155.6 (d, JCF = 247.5 Hz), 154.45, 137.1 (d, JCF = 9.1 Hz), 132.71 (d, JCF = 10.1 
Hz), 119.02 (d, JCF = 4.0 Hz), 114.03 (d, JCF = 4.0 Hz), 107.7 (d, JCF = 133.3 Hz), 72.0, 
71.6, 61.4, 60.89, 60.86, 50.5, 47.8, 42.1, 24.8, 23.3; δ IR (Neat Film, NaCl) 3300, 2971, 
1748, 1659, 1517, 1415, 1366, 1325, 1272, 1224, 1194, 1100, 987, 862, 752 cm-1; 
HRMS (MM: ESI-APCI) m/z calc’d for C18H25FN3O4 [M+H]+: 366.1824, found 
















yl)methyl)acetamide (2.13). Prepared according to the general procedure using: CuBr 
(9.1 mg, 0.064 mmol, 0.3 equiv), BINOL (18 mg, 0.064 mmol, 0.3 equiv), aryl iodide 2.7 
(80 mg, 0.21 mmol, 1 equiv), K3PO4 (90 mg, 0.42 mmol, 2 equiv), methallyl morpholine 
2.10 (60 mg, 0.42 mmol, 2 equiv), and 1.1 mL DMF. The crude residue was purified by 
reverse phase preparatory HPLC (50 → 70% MeCN/H2O gradient over 7 minutes, 
30x250 mm C18 column, 60 mL/min flow rate) to yield methallyl analogue 2.13 (45 mg, 
54% yield) as a light brown oil; 1H NMR (400 MHz, CDCl3) δ 7.40 (dd, J = 14.1, 2.6 
Hz, 1H), 7.04 (dd, J = 8.8, 2.6 Hz, 1H), 6.90 (t, J = 9.1 Hz, 1H), 6.74 (t, J = 6.2 Hz, 1H), 
5.93 – 5.78 (m, 1H), 5.17 – 5.07 (m, 2H), 4.85 – 4.75 (m, 1H), 4.05 (t, J = 9.0 Hz, 1H), 
3.91 (td, J = 4.6, 2.8 Hz, 2H), 3.81 – 3.59 (m, 3H), 3.05 – 2.95 (m, 2H), 2.90 (dd, J = 
11.6, 1.1 Hz, 1H), 2.79 (dd, J = 11.6, 1.0 Hz, 1H), 2.66 (dd, J = 14.1, 7.1 Hz, 1H), 2.34 
(ddt, J = 14.1, 7.5, 1.2 Hz, 1H), 2.07 (s, 3H), 1.29 (s, 3H): 13C NMR (101 MHz, CDCl3) 
δ 172.9 (C=O), 155.6 (d, JCF = 247.5 Hz), 154.9 (C=O), 137.1 (d, JCF = 8.1 Hz), 133.4, 
132.5 (d, JCF = 10.1 Hz), 119.2 (d, JCF = 4.0 Hz), 118.3, 114.3 (d, JCF = 4.0 Hz), 107.9 (d, 
JCF = 26.3 Hz), 73.5, 72.0, 61.1, 59.7, 50.4, 47.9, 42.3, 41.5, 22.9, 22.4; δ IR (Neat Film, 
NaCl) 3300, 3077, 2976, 2822, 1752, 1662, 1546, 1517, 1486, 1445, 1415, 1377, 1326, 
1269, 1222, 1196, 1172, 1086, 995, 918, 867, 817, 750, 703 cm-1; HRMS (MM: ESI-
APCI) m/z calc’d for C20H27FN3O4 [M+H]+: 392.1980, found 392.1976 [α]D23.0 –4.55 (c 















yl)methyl)acetamide (2.22). To a solution of methallyl analogue 2.13 (12 mg, 0.031 
mmol, 1 equiv) in MeOH (300 uL, 0.1 M) was added Pd/C (10% wt/wt, 3.3 mg, 0.1 
equiv). The reaction vial was evacuated and backfilled with H2 three times, and then 
sparged with H2 for 5 min. The reaction was stirred for 7 h and then the Pd/C was filtered 
off through a plug of celite, rinsing with EtOAc. The solution was concentrated under 
reduced pressure and purified by silica gel flash chromatography (2 → 5% 
MeOH/CH2Cl2) to yield the methyl-propyl analogue 2.22 as a clear oil (10 mg, 83% 
yield); 1H NMR (400 MHz, Chloroform-d) δ 7.41 (ddd, J = 14.2, 2.5, 0.9 Hz, 1H), 7.04 
(ddq, J = 8.8, 2.6, 1.0 Hz, 1H), 6.89 (t, J = 9.1 Hz, 1H), 6.52 – 6.28 (m, 1H), 4.78 (dddd, 
J = 8.9, 6.6, 5.8, 3.2 Hz, 1H), 4.03 (t, J = 9.0 Hz, 1H), 3.86 (tdd, J = 11.6, 5.7, 4.3 Hz, 
2H), 3.79 – 3.67 (m, 2H), 3.63 (dt, J = 14.7, 6.1 Hz, 1H), 3.05 – 2.92 (m, 2H), 2.83 (q, J 
= 11.5 Hz, 2H), 2.06 (s, 3H), 1.84 (ddd, J = 12.9, 10.3, 6.0 Hz, 1H), 1.55 – 1.31 (m, 3H), 
1.29 (s, 3H), 0.95 (t, J = 7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.2, 155.6 (d, 
JCF = 246.7 Hz), 154.6, 137.2 (d, JCF = 8.8 Hz), 132.5 (d, JCF = 10.3 Hz), 119.1 (d, JCF = 
4.2 Hz), 114.1 (d, JCF = 3.3 Hz), 107.8 (d, JCF = 26.3 Hz), 73.6, 71.9, 61.0, 60.1, 60.1, 
50.4, 50.4, 47.8, 42.2, 39.6, 23.0, 22.0, 16.4, 14.8.  IR (Neat Film, NaCl) 3297, 3074, 
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1101,1087, 994, 919, 867, 750 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for 




oxooxazolidin-5-yl)methyl)acetamide (2.20). In a glovebox, to a solution of methallyl 
analogue 2.13 (20 mg, 0.051 mmol, 1 equiv) in THF (500 uL, 0.1 M), was added 9-BBN 
dimer (25 mg, 0.10 mmol, 2 equiv). The reaction was stirred for 3 h at ambient 
temperature amd then taken out of the glovebox. Then, a solution of NaBO3⋅4H2O in H2O 
(500 uL) was added and the mixture was stirred for 2 h before being concentrated down. 
The crude residue was purified by reverse phase preparatory HPLC (0 → 100% 
MeCN/H2O gradient over 10 minutes, 30x250 mm C18 column, 60 mL/min flow rate) to 
yield hydroxyl analogue 2.20 (4 mg, 19% yield) as a clear oil; 13C NMR (101 MHz, 
CDCl3) δ 172.0, 155.6 (d, J = 246.7 Hz), 154.6, 137.0 (d, J = 8.9 Hz), 132.7 (d, J = 10.4 
Hz), 119.1 (dd, J = 4.1, 1.9 Hz), 114.1 (d, J = 3.3 Hz), 107.7 (d, J = 26.1 Hz), 73.6, 72.9, 
71.9, 68.6, 63.4, 61.2, 61.1, 60.3, 60.3, 60.1, 60.1, 50.3, 50.2, 50.3, 47.8, 42.2, 34.8, 32.6, 
26.3, 23.1, 22.2, 22.1, 21.4. IR (Neat Film, NaCl) 3314, 2937, 1783, 1747, 1666, 1517, 
1486, 1416, 1379, 1223, 1168, 1100, 866, 820, 745, 667 cm-1; HRMS (MM: ESI-APCI) 

















methylmorpholin-2-yl)propyl acetate (2.21). To a solution of hydroxyl analogue 2.20 
(4 mg, 1 equiv) in CH2Cl2 (200 uL, 0.05 M) was added NEt3 (4 uL, 3 equiv) and AcCl (1 
uL, 2 equiv). The solution was stirred at rt for 4 h, then concentrated, and purified by 
silica gel flash chromatography (3 → 5% MeOH/CH2Cl2) to give acetylated analogue 
2.21 as a clear oil (3 mg, 68% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.42 (ddd, J 
= 14.2, 2.5, 0.9 Hz, 1H), 7.06 (dddt, J = 8.7, 2.7, 1.9, 1.0 Hz, 1H), 6.88 (t, J = 9.1 Hz, 
1H), 6.11 (t, J = 6.3 Hz, 1H), 4.76 (dddd, J = 8.9, 6.6, 5.7, 3.2 Hz, 1H), 4.47 – 4.32 (m, 
1H), 4.10 (td, J = 6.6, 5.2 Hz, 1H), 4.02 (t, J = 9.0 Hz, 1H), 3.88 – 3.80 (m, 2H), 3.76 – 
3.66 (m, 2H), 3.65 – 3.58 (m, 1H), 2.97 (t, J = 4.9 Hz, 2H), 2.86 (d, J = 11.6 Hz, 1H), 
2.80 (dd, J = 11.5, 1.6 Hz, 1H), 2.04 (d, J = 11.9 Hz, 6H), 1.86 (d, J = 6.7 Hz, 2H), 1.75 – 
1.70 (m, 1H), 1.57 – 1.51 (m, 1H), 1.30 (d, J = 2.6 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 171.0, 171.2, 156.8, 154.4, 136.9 (dd, JCF = 12.6, 9.0 Hz), 132.8 (t, JCF = 10.5 
Hz), 119.1 (t, JCF = 3.5 Hz), 114.0 (d, JCF = 3.3 Hz), 107.6 (d, JCF = 26.2 Hz), 73.0, 71.9, 
68.7, 65.0, 61.1, 60.1, 50.3, 47.8, 42.1, 23.2, 22.6, 22.1, 21.1. IR (Neat Film, NaCl) 
3311, 3063, 2962, 1747, 1667, 1516, 1415, 1371, 1222,1169, 1087, 1036, 919, 867, 803, 
737, 703 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C22H31FN3O6 [M+H]+: 

















5-yl)methyl)acetamide (SI4). To a solution of methallyl analogue 2.13 (54 mg, 1 equiv) 
in 2:1 THF/H2O (14 mL, 0.01 M) was added a solution of OsO4 in PhMe (87 uL, 0.079 
M, 0.05 equiv) followed by NaIO4 (89 mg, 3 equiv) The reaction was stirred for 16 h at 
ambient temperature, and was then quenched with Na2S2O3. The mixture was extracted 
with EtOAc (5x) and the combined organic layers were dried over Na2SO4. The residue 
was purified by silica gel chromatography (10 → 20% → 30% MeOH/CH2Cl2) to yield 
dimethylamino analogue SI4 (15 mg, 94% yield) as a yellow oil. 1H NMR (400 MHz, 
Chloroform-d) δ 9.89 (t, J = 2.9 Hz, 1H), 7.42 (dd, J = 14.1, 2.6 Hz, 1H), 7.06 (ddd, J = 
8.8, 2.6, 1.2 Hz, 1H), 6.89 (t, J = 9.1 Hz, 1H), 6.21 (t, J = 6.2 Hz, 1H), 4.76 (dddd, J = 
8.9, 6.7, 5.7, 3.3 Hz, 1H), 4.07 – 3.78 (m, 3H), 3.78 – 3.56 (m, 3H), 3.10 – 3.02 (m, 2H), 
3.02 – 2.89 (m, 2H), 2.82 (d, J = 11.7 Hz, 1H), 2.63 (dd, J = 15.4, 2.9 Hz, 1H), 2.02 (s, 
3H), 1.44 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 201.9, 171.2, 155.7 (d, J = 246.5 Hz), 
154.4, 136.4 (d, J = 9.1 Hz), 133.2 (d, J = 10.4 Hz), 119.3 (d, J = 3.9 Hz), 114.0 (d, J = 
3.3 Hz), 107.6 (d, J = 26.1 Hz), 72.7, 72.0, 61.4, 60.0, 50.3, 49.5, 47.7, 42.0, 23.7, 23.2; 
IR (Neat Film, NaCl) 3316, 2937, 1748, 1659, 1517, 1415,1379,1279, 1225,1085, 868, 
751 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C19H25FN3O5 [M+H]+: 394.1773, 
















oxooxazolidin-5-yl)methyl)acetamide (2.23). To a solution of aldehyde SI4 (15 mg, 
0.038 mmol, 1 equiv) in THF (400 uL, 0.1 M) was added dimethylamine (95 uL, 0.19 
mmol, 5 equiv) and AcOH (2 uL, 0.038 mmol, 1 equiv). The solution was stirred for 5 
min, and then NaBH(OAc)3 (16 mg, 0.076 mmol, 2 equiv) was added. The reaction was 
stirred for 3 h at ambient temperature, and was then concentrated onto SiO2. The silica 
loaded crude residue was purified by silica gel chromatography (10 → 20% → 30% 
MeOH/CH2Cl2) to yield dimethylamino analogue 2.23 (15 mg, 94% yield) as a clear oil; 
1H NMR (600 MHz, CDCl3) δ 7.41 (dt, J = 14.1, 2.8 Hz, 1H), 7.05 (dt, J = 9.0, 2.7 Hz, 
1H), 6.86 (t, J = 9.1 Hz, 1H), 6.43 (t, J = 6.2 Hz, 1H), 4.76 (dtd, J = 9.3, 6.2, 3.4 Hz, 1H), 
4.00 (t, J = 8.9 Hz, 1H), 3.84 (h, J = 6.8 Hz, 2H), 3.75 (dd, J = 9.1, 6.6 Hz, 1H), 3.68 
(ddd, J = 14.6, 6.2, 3.4 Hz, 1H), 3.60 (dt, J = 14.6, 6.1 Hz, 1H), 3.02 – 2.92 (m, 4H), 2.86 
(d, J = 11.6 Hz, 1H), 2.80 (d, J = 11.6 Hz, 1H), 2.66 (s, 6H), 2.46 – 2.38 (m, 1H), 2.01 (d, 
J = 8.8 Hz, 3H), 1.91 – 1.82 (m, 1H), 1.32 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
171.38, 155.62 (d, J = 246.1 Hz), 154.49, 136.54 (d, J = 9.1 Hz), 133.13 (d, J = 10.5 Hz), 
119.19 (d, J = 4.0 Hz), 114.05 (d, J = 3.2 Hz), 107.60 (d, J = 26.3 Hz), 72.2, 72.0, 61.3, 
60.1, 53.0, 50.25, 47.8, 43.2, 42.1, 31.3, 23.2, 22.3. IR (Neat Film, NaCl) 3250, 2924, 
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867,749, 674 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C21H32FN4O4 [M+H]+: 
423.2402, found 423.2393 [α]D24.0 –3.59 (c 1.0, CHCl3). 
 
N-(((5S)-3-(3-fluoro-4-(6-oxa-2,9-diazaspiro[4.5]decan-9-yl)phenyl)-2-oxooxazolidin-
5-yl)methyl)acetamide (2.27). Prepared according to the general procedure using: CuBr 
(2.3 mg, 0.016 mmol, 0.2 equiv), BINOL (4.5 mg, 0.016 mmol, 0.2 equiv), aryl iodide 
2.7 (30 mg, 0.079 mmol, 1 equiv), K3PO4 (34 mg, 0.16 mmol, 2 equiv), 6-oxa-2,9-
diazaspiro[4.5]decane (38 mg, 0.16 mmol, 2 equiv), and 400 uL DMF. The crude residue 
was filtered through a silica column (2 → 3 → 5 → 10% MeOH/CH2Cl2) to yield a 
mixture of Boc-protected spirocyclic analogue 2.15 and starting material aryl iodide 2.7, 
which  was carried forward to the next step: To 2.3 mL MeOH at 0 °C was added AcCl 
(230 uL), generating HCl in situ. This HCl solution was stirred for 5 min at 0°C and then 
transferred by syringe into a 20 mL scintillation vial containing Boc analogue 2.15. The 
reaction was stirred for 1 h at ambient temperature and then the solvent was concentrated 
under reduced pressure onto SiO2. The silica-loaded residue was purified by silica gel 
flash chromatography (5 → 10 → 20% MeOH/CH2Cl2) to yield spiropyrrolidine 
analogue 2.27 as a light yellow oil (12 mg, 40% yield over 2 steps). 1H NMR (400 MHz, 
CD3OD) δ 7.53 (dd, J = 14.5, 2.5 Hz, 1H), 7.19 (ddd, J = 8.8, 2.6, 1.0 Hz, 1H), 7.08 (t, J 
= 9.2 Hz, 1H), 4.83 – 4.73 (m, 1H), 4.12 (t, J = 9.0 Hz, 1H), 3.94 (dd, J = 5.4, 4.3 Hz, 
2H), 3.80 (dd, J = 9.2, 6.3 Hz, 1H), 3.72 (dd, J = 12.6, 1.6 Hz, 1H), 3.56 (d, J = 5.0 Hz, 



























CuBr (20 mol %)
BINOL (20 mol %) 
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2.97 (m, 3H), 2.42 – 2.29 (m, 1H), 2.17 – 2.00 (m, 2H), 1.96 (s, 3H); 13C NMR (101 
MHz, CD3OD) δ 174.1, 156.9 (d, J = 244.3 Hz), 156.6, 137.2 (d, J = 10.1 Hz), 135.5 (d, 
J = 10.6 Hz), 120.7 (d, J = 4.0 Hz), 115.5 (d, J = 3.0 Hz), 108.4 (d, J = 26.3 Hz), 82.2, 
73.5, 63.5, 57.5, 52.6, 51.5, 49.2, 45.3, 43.1, 34.5, 22.4 (Note: A 1H-13C HSQC 
experiment revealed the chemical shift of a methylene carbon to be at 49.2 ppm, obscured 
by MeOD resonance); IR (Neat Film, NaCl) 3287, 2924, 2282, 1754, 1667, 1548, 1516, 
1415, 1377, 1325, 1278, 1226, 1083, 989, 869, 751 cm-1; HRMS (MM: ESI-APCI) m/z 





oxooxazolidin-5-yl)methyl)acetamide (2.17). Prepared according to the general 
procedure using: CuBr (2.3 mg, 0.2 equiv), BINOL (4.6 mg, 0.2 equiv), aryl iodide 2.7 
(30 mg, 1 equiv), K3PO4 (34 mg, 2 equiv), 2-methyl-6-oxa-2,9-diazaspiro[4.5]decane 
(SI5) (25 mg, 2 equiv), and 400 uL DMF. The crude residue was purified by silica gel 
flash chromatography (5 → 10 → 20 MeOH/CH2Cl2) to yield N-methyl spiropyrrolidine 
analogue 2.17 (15 mg, 47% yield) as a light yellow oil; 1H NMR (400 MHz, CDCl3) δ 
7.45 (dd, J = 14.1, 2.6 Hz, 1H), 7.08 (ddd, J = 8.8, 2.6, 1.1 Hz, 1H), 6.90 (t, J = 9.0 Hz, 
1H), 6.05 (t, J = 6.2 Hz, 1H), 4.77 (dddd, J = 8.9, 6.7, 5.9, 3.3 Hz, 1H), 4.02 (td, J = 9.0, 
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3.25 (s, 1H), 3.11 (d, J = 11.6 Hz, 2H), 3.01 (t, J = 10.5 Hz, 5H), 2.66 (s, 3H), 2.20 (m, 
2H), 2.02 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.1, 155.8 (d, J = 246.5 Hz), 154.4, 
136.0 (d, J = 9.1 Hz), 133.6 (d, J = 10.4 Hz), 119.4 (d, J = 3.7 Hz), 114.0 (d, J = 3.4 Hz), 
107.6 (d, J = 26.2 Hz), 81.7, 72.0, 63.4, 62.8, 57.84, 55.0, 50.4, 47.8, 42.4, 42.1, 35.4, 
23.3; IR (Neat Film, NaCl) 3264, 2925, 2283, 1747, 1666, 1516, 1444, 1377, 1325, 
1225, 1082, 869, 752 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C20H28FN4O4 




oxooxazolidin-5-yl)methyl)acetamide (2.25). Prepared according to the general 
procedure using: CuBr (2.1 mg, 0.015 mmol, 0.2 equiv), BINOL (4.2 mg, 0.015 mmol, 
0.2 equiv), aryl iodide 2.7 (28 mg, 0.074 mmol, 1 equiv), K3PO4 (31 mg, 0.15 mmol, 2 
equiv), tert-butyl 1-oxa-4,8-diazaspiro[5.5]undecane-8-carboxylate (38 mg, 0.15 mmol, 2 
equiv), and 370 uL DMF. The crude residue was filtered through a silica column (40% 
MeCN/CH2Cl2) to yield a mixture of Boc-protected spirocyclic analogue 2.16 and 
starting material aryl iodide 2.7, which was carried forward to the next step: To 2.2 mL 
MeOH at 0 °C was added AcCl (220 uL), generating HCl in situ. This HCl solution was 
stirred for 5 min at 0°C and then transferred by syringe into a 20 mL scintillation vial 
containing Boc analogue 2.16. The reaction was stirred for 1 h at ambient temperature 
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loaded residue was purified by silica gel flash chromatography (1 → 2 → 5 → 10 → 
100% MeOH/CH2Cl2 with 1% NH4OH) to yield spiropiperidine analogue 2.25 as a light 
yellow oil (12 mg, 32% yield over two steps): 1H NMR (600 MHz, CD3OD) δ 7.51 (dd, 
J = 14.4, 2.5 Hz, 1H), 7.18 (ddd, J = 8.8, 2.6, 1.0 Hz, 1H), 7.06 (t, J = 9.2 Hz, 1H), 4.83 – 
4.77 (m, 1H), 4.14 (t, J = 9.0 Hz, 1H), 3.98 (ddd, J = 11.4, 8.0, 3.2 Hz, 1H), 3.91 (ddd, J 
= 11.9, 5.0, 3.4 Hz, 1H), 3.88 – 3.80 (m, 2H), 3.56 (d, J = 5.1 Hz, 2H), 3.38 – 3.32 (m, 
2H), 3.13 – 3.06 (m, 1H), 3.06 – 2.97 (m, 4H), 2.86 (d, J = 12.0 Hz, 1H), 2.20 – 2.14 (m, 
1H), 2.14 – 2.01 (m, 1H), 1.97 (s, 3H), 1.81 – 1.76 (m, 1H), 1.63 (td, J = 13.7, 4.3 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 171.3, 155.6 (d, J = 246.3 Hz), 154.6, 136.8 (d, J = 
9.0 Hz), 133.0 (d, J = 10.4 Hz), 119.2 (d, J = 5.6 Hz), 114.0 (t, J = 3.8 Hz), 107.6 (d, J = 
26.1 Hz), 72.1, 69.8, 60.9, 58.5, 50.7, 47.8, 46.13, 42.1, 31.6, 29.8, 23.3, 21.3; IR (Neat 
Film, NaCl) 3275, 2931, 2359, 1748, 1668, 1540, 1517, 1417, 1374, 1286, 1224, 1195, 
1084, 867, 732 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C20H28FN4O4 [M+H]+: 




oxooxazolidin-5-yl)methyl)acetamide (2.26). To a solution of spiropiperidine 2.25 (12 
mg, 1 equiv) in MeCN was added NEt3 (12 uL, 3 equiv) followed by DMAP (0.4 mg, 0.1 
equiv), and then Ac2O (4 uL, 1.5 equiv). The reaction was stirred at rt for 2 h, 
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MeOH/CH2Cl2) to afford acetylated analogue 2.26 as a clear oil (10 mg, 77% yield). 1H 
NMR (400 MHz, Chloroform-d) δ 7.42 (dddd, J = 20.9, 14.2, 2.6, 1.6 Hz, 1H), 7.05 
(ttd, J = 8.8, 2.6, 1.1 Hz, 1H), 6.94 – 6.82 (m, 1H), 6.34 – 6.17 (m, 1H), 4.86 (dd, J = 
14.0, 6.1 Hz, 1H), 4.81 – 4.70 (m, 1H), 4.11 (ddd, J = 12.0, 8.9, 3.0 Hz, 1H), 4.05 – 3.82 
(m, 2H), 3.82 – 3.43 (m, 6H), 3.23 – 2.64 (m, 5H), 2.15 – 2.05 (m, 3H), 2.02 (s, 3H), 1.89 
– 1.83 (m, 1H), 1.74 – 1.66 (m, 2H), 1.60 – 1.50 (m, 1H); 13C NMR (101 MHz, CDCl3) 
δ (Note: multiple peaks observed due to the presence of rotamers) 171.2, 171.2, 169.9, 
169.3, 156.9, 156.8, 154.5, 154.4, 136.8, 136.7, 136.7, 136.6, 136.4, 136.3, 133.5, 133.4, 
132.9, 132.8, 119.4, 119.4, 119.2, 114.0, 114.0, 113.9, 107.7, 107.6, 107.5, 107.4, 107.3, 
72.0, 71.9, 71.2, 70.8, 61.6, 61.3, 58.3, 56.5, 51.4, 51.1, 51.1, 50.3, 47.7, 47.3, 45.9, 45.8, 
42.3, 42.1, 42.1, 42.1, 33.1, 33.0, 23.2, 21.7, 21.4, 20.9; IR (Neat Film, NaCl) cm-1; 
HRMS (MM: ESI-APCI) m/z calc’d for C22H30FN4O5 [M+H]+: 449.2195, found 
449.2193 [α]D24.4 –11.08 (c 0.7, CHCl3). 
 
N-(((5S)-3-(4-(2-allyl-2-((benzyloxy)methyl)morpholino)-3-fluorophenyl)-2-
oxooxazolidin-5-yl)methyl)acetamide (2.14). Prepared according to the general 
procedure using: CuBr (2.3 mg, 0.016 mmol, 0.2 equiv), BINOL (4.5 mg, 0.016 mmol, 
0.2 equiv), aryl iodide 2.7 (30 mg, 0.079 mmol, 1 equiv), K3PO4 (34 mg, 0.16 mmol, 2 
equiv), benzyloxy morpholine6 (18 mg, 0.16 mmol, 2 equiv), and 400 uL DMF. The 
crude residue was purified by silica gel flash chromatography (2 → 3 → 5% 
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NMR (400 MHz, CDCl3) δ 7.46 – 7.34 (m, 1H), 7.33 (d, J = 4.4 Hz, 3H), 7.33 – 7.23 
(m, 1H), 7.04 (dd, J = 8.8, 1.8 Hz, 1H), 6.88 (t, J = 9.1 Hz, 1H), 6.29 (t, J = 6.1 Hz, 1H), 
5.82 (ddt, J = 17.5, 10.3, 7.3 Hz, 1H), 5.15 – 5.04 (m, 2H), 4.76 (qd, J = 7.8, 6.6, 5.0 Hz, 
1H), 4.56 (s, 2H), 4.05 – 3.49 (m, 7H), 3.06 – 2.87 (m, 4H), 2.77 (dt, J = 15.0, 7.5 Hz, 
1H), 2.46 (dd, J = 14.3, 7.6 Hz, 1H), 2.01 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 
171.4, 155.7 (d, J = 246.7 Hz), 154.5, 138.4, 137.0 (d, J = 9.0 Hz), 133.3, 132.9 (d, J = 
10.3 Hz), 128.5, 127.8, 127.7, 119.3 (d, J = 4.0 Hz), 118.3, 114.0 (d, J = 3.3 Hz), 107.6 
(d, J = 26.1 Hz), 74.9, 73.7, 72.0, 71.0, 61.4, 56.1, 50.5, 47.8, 42.1, 37.2, 23.2; IR (Neat 
Film, NaCl) 3288, 2921, 2364, 1749, 1654, 1516, 1416, 1373, 1324, 1274, 1224, 1103, 
747 cm-1; HRMS (MM: ESI-APCI) m/z calc’d for C27H33FN3O5 [M+H]+: 498.2399, 




oxooxazolidin-5-yl)methyl)acetamide (2.24). In a 1 dram vial open to the air, benzyloxy 
analogue 2.14 (20 mg, 0.04 mmol, 1 equiv) was dissolved in MeOH (400 uL, 0.1M). 
Pd(OH)2/C (20 wt. %, 4.2 mg, 0.006 mmol, 0.15 equiv) was then added. The vial was 
then sealed with a septum cap and evacuated and filled using a balloon containing H2 
three times. The solvent was then sparged with H2 for 5 min and stirred for 16 h until 
TLC analysis showed the starting material had been consumed. The Pd(OH)2/C was 
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under reduced pressure onto SiO2. The silica-loaded residue was purified by silica gel 
flash chromatography (2 → 3 → 10% MeOH/CH2Cl2) to yield hydroxyl analogue 2.24 
(14 mg, 88% yield) as a clear oil: 1H NMR (400 MHz, CDCl3) δ 7.42 (dt, J = 14.1, 2.4 
Hz, 1H), 7.05 (dtd, J = 8.9, 2.4, 1.1 Hz, 1H), 6.90 (t, J = 9.1 Hz, 1H), 6.27 (t, J = 6.3 Hz, 
1H), 4.77 (dddd, J = 8.9, 6.7, 5.6, 3.3 Hz, 1H), 4.01 (t, J = 9.0 Hz, 1H), 3.92 (t, J = 4.9 
Hz, 2H), 3.79 – 3.70 (m, 2H), 3.74 – 3.63 (m, 2H), 3.61 (dt, J = 14.7, 6.0 Hz, 1H), 3.07 – 
2.97 (m, 2H), 2.99 – 2.85 (m, 2H), 2.02 (s, 3H), 1.83 (ddd, J = 14.0, 11.6, 5.6 Hz, 1H), 
1.60 (ddd, J = 14.0, 11.1, 5.8 Hz, 1H), 1.44 – 1.21 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 171.3, 155.7 (d, J = 246.4 Hz), 154.5, 136.9 (d, J = 9.1 Hz), 
133.1 (d, J = 10.4 Hz), 119.3 (d, J = 4.0 Hz), 114.0 (d, J = 2.5 Hz), 107.6 (d, J = 26.2 
Hz), 75.3, 72.0, 64.8, 61.42, 55.4, 50.4, 47.8, 42.1, 35.3, 23.3, 16.4, 14.9; IR (Neat Film, 
NaCl) 3316, 2957, 1747,1659, 1547, 1516, 1416, 1375, 1268, 1229, 1090, 743 cm-1; 
HRMS (MM: ESI-APCI) m/z calc’d for C20H29FN3O5 [M+H]+: 410.2086, found 
410.2086 [α]D22.3 –11.50 (c 1.0, CHCl3). 
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Figure A6.2 Infrared spectrum (Thin Film, NaCl) of compound 2.5 
 
Figure A6.3 13C NMR (101 MHz, CDCl3) of compound 2.5 
 



































Figure A6.5 Infrared spectrum (Thin Film, NaCl) of compound 2.10. 
 
Figure A6.6 13C NMR (101 MHz, CDCl3) of compound 2.10. 
 




































Figure A6.8 Infrared spectrum (Thin Film, NaCl) of compound 2.12. 
 
Figure A6.9  13C NMR (101 MHz, CDCl3) of compound 2.12. 
 




































Figure A6.11  Infrared spectrum (Thin Film, NaCl) of compound 2.13. 
 
 Figure A6.12  13C NMR (101 MHz, CDCl3) of compound 2.13. 
 




































Figure A6.14  Infrared spectrum (Thin Film, NaCl) of compound 2.14. 
 
Figure A6.15   13C NMR (101 MHz, CDCl3) of compound 2.14. 
 





































Figure A6.17   Infrared spectrum (Thin Film, NaCl) of compound 2.17 
 
Figure A6.18    13C NMR (101 MHz, CDCl3) of compound 2.17 
 





































Figure A6.20    Infrared spectrum (Thin Film, NaCl) of compound 2.18 
 
 Figure A6.21   13C NMR (101 MHz, CDCl3) of compound 2.18. 
 





































Figure A6.23   Infrared spectrum (Thin Film, NaCl) of compound 2.19a. 
 
Figure A6.21    13C NMR (101 MHz, CDCl3) of compound 2.19a. 
 






































Figure A6.26   Infrared spectrum (Thin Film, NaCl) of compound 2.19b. 
 
 Figure A6.27  13C NMR (101 MHz, CDCl3) of compound 2.19b. 
 





































Figure A6.29  Infrared spectrum (Thin Film, NaCl) of compound 2.21. 
 
 Figure A6.30 13C NMR (101 MHz, CDCl3) of compound 2.21. 
 






































Figure A6.32 Infrared spectrum (Thin Film, NaCl) of compound 2.22. 
 
Figure A6.33  13C NMR (101 MHz, CDCl3) of compound 2.22. 
 






































Figure A6.35 Infrared spectrum (Thin Film, NaCl) of compound 2.23. 
 
Figure A6.36  13C NMR (101 MHz, CDCl3) of compound 2.23. 
 






































Figure A6.38  Infrared spectrum (Thin Film, NaCl) of compound  2.24. 
 
 Figure A6.39  13C NMR (101 MHz, CDCl3) of compound 2.24. 
 






































Figure A6.41  Infrared spectrum (Thin Film, NaCl) of compound 2.25. 
 
Figure A6.42   13C NMR (101 MHz, CDCl3) of compound 2.25. 
 





































Figure A6.44   Infrared spectrum (Thin Film, NaCl) of compound 2.26. 
 
Figure A6.45   13C NMR (101 MHz, CDCl3) of compound 2.26. 
 






































Figure A6.47 Infrared spectrum (Thin Film, NaCl) of compound 2.27. 
 
 Figure A6.48   13C NMR (101 MHz, CD3OD) of compound 2.27. 
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Figure A6.49   HSQC of compound 2.27 revealing one peak obscured by CD3OD. 






































































































Figure A6.53   Infrared spectrum (Thin Film, NaCl) of compound SI4. 
 
Figure A6.54  13C NMR (101 MHz, CDCl3) of compound SI4. 
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Decarboxylative Asymmetric Allylic Alkylation of Tertiary Alcohols  
 
 
A7.1   INTRODUCTION AND BACKGROUND 
Enantioenriched tertiary  alcohols are valuable motifs found in myriad bioactive 
natural products and pharmaceuticals, such as the alkaloid chemotherapeutic (−)-
vinblastine1 and the neurotrophic sesquiterpene (+)-jiadifenin2 (Figure A7.1). Due to the 
molecular prevalence of chiral tertiary alcohols, diverse methods3 have been developed to 
enable the stereoselective α-hydroxylation of a wide range of carbonyl compounds, 
including acyclic compounds,4,5,6 oxindoles,7,8 pyrazolones,9 and cycloalkanones10 
(Scheme A7.1). Aside from chiral oxidants such as oxaziridines introduced during 
Davis’s pivotal 1981 studies,11 α-hydroxylation methods can be broadly categorized 
under either transition metal catalysis or organic catalysis. In the realm of organic 
catalysis, a number of terminal oxidants have been coupled with structurally diverse 
chiral organic catalysts such BINOL-derived phosphoric acids,12 guanidine-
bisureas,13,14,15 cinchona alkaloids,6,9 aminobenzamides,5 and photocatalysts composed of 
a bisoxazoline-diarylketone photosensitizer conjugate16  (Scheme A7.1a). Similarly, 
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numerous chiral transition metal complexes also facilitate -hydroxylation,3 including 
systems such as Cu-phenanthroline,17 Zr-Salen,10 and Ti-TADDOLato.18 
Contrasting with these traditional enantioselective hydroxylation methods, in 
which the hydroxyl group is introduced in the enantiodetermining step, is a conceptually 
unique approach involving allylic alkylation of α-hydroxy compounds. In this case, 
alkylation of a prochiral hydroxyenolate would engender stereoselectivity. Of particular 
interest to our group were initial reports by Trost19,20 utilizing a Pd-catalyzed 
decarboxylative allylic alkylation protocol to synthesize protected tertiary α-hydroxy 
ketones and aldehydes (Scheme A7.1b). Trost found that depending on the choice of 
bisphosphine ligand, isomeric products A7.3 or A7.4 could be almost exclusively 
attained. Later, Trost21 again reported a decarboxylative alkylation approach toward the 
synthesis of MOM-protected tetralones (Scheme A7.1c). However, no examples of 
unprotected alcohols were shown. In a more recent 2017 advance, Zhang22 demonstrated 
that a dual catalyst system involving Trost’s Zn/ProPhenol system and an Ir catalyst 
could effect the C-alkylation of unprotected alcohols (Scheme A7.1d). It was 
hypothesized that the bidentate/η 2 binding mode of the Zn catalyst reduced the 
nucleophilicity of the hydroxyl group, precluding O-allylation pathways. Most recently, 
Zhang8 utilized a single iridium-phosphoramidite catalyst in the asymmetric allylic 
alkylation of oxindoles, showing the Zn/ProPhenol partner was not needed. We wondered 
if subjecting similar tertiary alcohols to decarboxylative allylic alkylation conditions 
using a simple single catalyst system consisting of Pd-PHOX could likewise enable 
effective C-alkylation (Scheme A7.1e).  
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Scheme A7.1 Approaches toward tertiary α-hydroxy carbonyl compounds 
 
 
Our investigations were stimulated by an unexpected result23 during the course of 
our studies on the decarboxylative allylic alkylation of N4-Boc piperazinones, in which 
we were pleased to obtain α-fluorinated substrate A7.1 via electrophilic fluorination of 
the 1,3 dicarbonyl precursor (Scheme A7.2). However, upon subjecting A7.1 to the 
optimized Pd-catalyzed alkylation conditions, the α-tertiary hydroxypiperazinone A7.2 
was instead obtained in a moderate 50% yield and 77% ee. The presence of adventitious 
water could produce this unexpected result; if fluoride anion is eliminated during the 






































X = NBz, CH2





X = NBz, CH2
n = 1, 2, 3
R2OH
Pd/L
a) Traditional methods toward chiral alpha tertiary compounds
b) Decarboxylative alkylation of protected allyl enol carbonates (Trost)
R = TBS, Bz, Ac
c) Synthesis of protected chiral alpha tertiary hydroxylated tetralones (Trost)
d) Allylic alkylation of alpha hydroxy indanones (Zhang)
e) Decarboxylative alkylation of cyclic carbonyl compounds (this research)
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To extend upon this finding, we began by exploring the decarboxylative 
alkylation of tetralone A7.3 (Table A7.1). Upon subjecting A7.3 to standard Pd-catalyzed 
decarboxylative alkylation conditions using electron-deficient PHOX ligand L1, a 5/1 
mixture of the desired product A7.4a and the isomer A7.4b were obtained, both with low 
ee. In contrast, the more electron-rich PHOX ligand L2 increased the proportion of 
isomer A7.4b (1/3.6), with an improved ee of 68% for A7.4a. The bisphosphine ligands 
L3 and L4 provided even more of the isomer A7.4b, with ratios of 1/25 and 1/24, 
respectively. Interestingly, A7.4b was attained with an ee of 98% using L3.  
 




Table A7.1 Attempts to optimize reaction conditions for model substrate A7.3   
 






1 L1 5/1 (50) 40 10 
2 L2 1/3.6 (61) 68 10 
3 L3 1/25 (76) 1 98 
4 L4 1/24 (75) 4 20 
Pd2(dba)3 (4 mol %)
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[a] Ratio determined by 400 MHz 1H NMR spectroscopy of the purified mixture. [b] Isolated yield for the mixture of A7.4a 
and A7.4b. [c] The ee values were determined by chiral SFC analysis. pmdba =  bis(4-methoxybenzylidene)acetone 
 
We then subjected the isomeric tetralone substrate A7.5 to allylic alkylation 
conditions with ligands L1 and L3, achieving product ratios of 1.4/1 and <1/25, 
respectively (Table A7.2). Together, these results suggest there is an equilibration of Pd-
bound enolates leading to the observed ratios of products. 
Table A7.2 Investigation into reaction outcomes for isomeric tetralone A7.5  
	
Entry Ligand Ratio A7.4a/4b (Yield 
%)a,b 
ee A7.4a (%)c ee A7.4b (%)c 
1 L1 1.4/1 (70) 86 1 
2 L3 <1/25 (65) − 10 
[a] Ratio determined by 400 MHz 1H NMR spectroscopy of the purified mixture. [b] Isolated yield for the mixture of 4a and 
4b. [c] The ee values were determined by chiral SFC analysis.  
 
We can rationalize these results with a relative rate argument considering the rate 
of alkylation versus equilibration of Pd-bound hydroxyenolates I and II (Scheme A7.3): 
If equilibration is faster than alkylation, as may be the case with electron rich ligands L3 
and L4, then more of the isomer A7.4b should be formed as intermediate II is more 
stable both electronically and sterically. In contrast, if alkylation is faster than 
equilibration, as may be the case for the electron deficient PHOX ligand L1, then A7.3 
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As mixtures of isomeric products may be uniquely obtained in unsaturated α-
hydroxy systems such as tetralones, we elected to examine simpler carbocyclic 
substrates, beginning with cyclohexanone A7.6a (Table A7.3). Of the previously utilized 
ligands, the electron deficient L1 provided the best results, affording tertiary alcohol 
A7.7a in a moderate 70% ee. Similarly, a methallyl variant A7.7b and cycloheptanone 
A7.7c were also attained in modest ee. The cyclopentanone A7.7d was obtained in a 
disappointing 30% ee, suggesting significant influence of conformation on 
stereoselectivity. In contrast, we were excited to obtain the novel tertiary α-
hydroxypiperidinone A7.7e in 92% ee. Hydroxylactam A7.7e represents an oxidized 
derivative of the medicinally prevalent 3-hydroxypiperidine, which is found in 
pharmaceuticals like the chemotherapeutic vinblastine and the antihypertensive agent 
Benidipine.24  Unfortunately, a variety of other heterocyclic substrates including 
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[a] Reported yields are for the isolated products. [b] Reaction performed at rt. [c] Reaction performed at 40 °C. [d] ee value 
determined by chiral GC analysis. [e] ee value determined by chiral SFC analysis. dba = dibenzylideneacetone. 
 
Encouraged by these results, we next explored whether a primary hydroxyl group 
could be tolerated in the Pd-catalyzed decarboxylative alkylation conditions (Scheme 
A7.4). Our initial test substrate A7.8 was amenable using L3 to provide the desired 
primary hydroxyl product A7.9 in moderate yield and an ee of 93%. Unfortunately, a 
variety of other primary alcohol substrates including lactams, and carbocyclic motifs 
were either unreactive, or provided a low-yielding mixture of β-elimination and 

















Pd2(dba)3 (4 mol %)
L1 (10 mol %)
toluene (0.033 M)
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Scheme A7.4 Decarboxylative alkylation of a primary alcohol.a,b 
 
 
[a] Reported yield is for the isolated product. [b] ee value determined by chiral SFC analysis. 
 
 
A7.2  CONCLUSIONS 
In summary, we report initial results using the decarboxylative allylic alkylation 
reaction to synthesize chiral tertiary α-hydroxy compounds. While a novel tertiary 
hydroxypiperidinone was obtained in high ee, other carbocyclic compounds still require 
optimization with an appropriate catalyst-ligand combination. Nevertheless, this research 
provides proof of concept that Pd-catalysts are effective in the decarboxylative C-
alkylation of unprotected alcohol-containing substrates and can lead to high yield and 
high enantioselectivities in certain limited cases.  
A7.3  EXPERIMENTAL SECTION 
A7.3.1  MATERIALS AND METHODS 
Unless otherwise stated, reactions were performed in flame-dried glassware under 
an argon or nitrogen atmosphere using dry, deoxygenated solvents. Solvents were dried 
by passage through an activated alumina column under argon. Commercially obtained 
reagents were used as received. Chemicals were purchased from Sigma 
Aldrich/Strem/Alfa Aesar/Combi-Blocks and used as received.   
Reaction temperatures were controlled by an IKAmag temperature modulator. 
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chromatography (TLC) was performed using E. Merck silica gel 60 F254 precoated 
plates (0.25 mm) and visualized by UV fluorescence quenching, iodine on silica, or 
KMnO4 staining. SiliaFlash P60 Academic Silica gel (particle size 0.040–0.063 mm) was 
used for flash chromatography.  
Analytical SFC was performed with a Mettler SFC supercritical CO2 analytical 
chromatography system utilizing a Chiralpak IC column (4.6 mm x 25 cm) obtained from 
Daicel Chemical Industries, Ltd. with visualization at 254 nm. Automated silica gel flash 
chromatography was performed with a Teledyne ISCO CombiFlash EZ Prep system.  
1H NMR spectra were recorded on a Varian Inova 600 MHz or 500 MHz 
spectrometer or a Bruker Avance HD 400 MHz spectrometer and are reported relative to 
residual CHCl3 (δ 7.26 ppm). 13C NMR spectra were recorded on a Varian Inova 500 
MHz spectrometer or a Bruker Avance HD 400 MHz spectrometer and are reported 
relative to residual CDCl3 (δ 77.16 ppm). Data for 1H NMR are reported as follows: s = 
singlet, d = doublet, t = triplet, q = quartet, p = pentet, sept = septuplet, m = multiplet, br 
s = broad singlet. Data for 13C NMR are reported in terms of chemical shifts (δ ppm). 
Some reported spectra include minor solvent impurities of water (δ 1.56 or 4.87 ppm), 
ethyl acetate (δ 4.12, 2.05, 1.26 ppm), methylene chloride (δ 5.30 ppm), acetone (δ 2.17 
ppm), grease (δ 1.26, 0.86 ppm), and/or silicon grease (δ 0.07 ppm), which do not impact 
product assignments.  
IR spectra were obtained using a Perkin Elmer Paragon 1000 spectrometer using 
thin films deposited on NaCl plates and reported in frequency of absorption (cm-1). High 
resolution mass spectra (HRMS) were obtained from an Agilent 6200 Series TOF with an 
Agilent G1978A Multimode source in electrospray ionization (ESI+), atmospheric 
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pressure chemical ionization (APCI+), or mixed ionization mode (MM: ESI-APCI+). 
Optical rotations were measured with a Jasco P-2000 polarimeter operating on the 
sodium D-line (589 nm), using a 100 mm pathlength cell and are reported as: [α]DT 
(concentration in g/100 mL, solvent). Stereochemistry is assigned by analogy to previous 
results.1 
 
A7.3.2  EXPERIMENTAL PROCEDURES AND SPECTROSCOPIC DATA 
A7.3.2.1 Experimental	 Procedures	 and	 Spectroscopic	 Data	 for	 the	
Synthesis	 of	 Tertiary	 Alcohol	 Allylic	 Alkylation	 Substrates	 and	
Corresponding	Decarboxylative	Alkylation	Products	
A) General Procedure for synthesis of allylic alkylation substrates using CeCl3-7H2O 
A solution of the β-ketoester (1 equiv) and CeCl3-7H2O (0.05 equiv) in iPrOH (0.1 M) 
was evacuated and filled with O2 three times. The solution was stirred at room 
temperature, changing color from light yellow to dark yellow/dark green over the course 
of the reaction. When TLC analysis showed the starting material had been completely 
consumed, the solvent was removed under reduced pressure and the crude product was 
purified by silica gel  flash chromatography to afford the desired alcohol. 
 
B) General Procedure for synthesis of allylic alkylation substrates using samarium(III) 
trifluoromethanesulfonate 
 
To an orange solution of iodine (0.02 equiv) and samarium (III) triflate (0.05 equiv) in a 
1:5 mixture of H2O/THF (0.1 M) was added the β-ketoester substrate (1 equiv). The 
393
Appendix 7 – Decarboxylative Asymmetric Allylic Alkylation of Tertiary Alcohols  
  
solution was evacuated and filled with O2 three times, sparged with O2 for 5 minutes, and 
then allowed to stir until TLC analysis showed the starting material had been completely 
consumed. If the orange color faded to yellow, then another bolus of iodine was added 
iodine (0.02 equiv) as needed to restore the orange color. The reaction was then quenched 
with sodium thiosulfate and extracted with EtOAc (3x). NaCl was added to clear the 
emulsion formed during extraction. The combined organic layers were dried over 
Na2SO4, concentrated under reduced pressure onto silica gel, and purified by silica gel 
flash chromatography to afford the desired alcohol. 
 
C) General Procedure for Pd-Catalyzed Decarboxylative Allylic Alkylation Reactions 
Please note Racemic products were synthesized according to the general procedure, using 
achiral GlyPHOX ligand instead of a chiral ligand.3 The absolute configuration for all 
other products has been inferred by analogy.1 SFC and chiral GC conditions are listed at 
the end of the experimental procedure for each compound.  
In a nitrogen-filled glovebox, an oven-dried 1 dram vial or 20 mL scintillation 
vial was charged with Pd2(pmdba)3 or Pd2(dba)3 (4 mol %), ligand (10 mol %), toluene, 
and a magnetic stir bar. The vial was stirred at ambient glovebox temperature (27 °C) for 
30 min and then the substrate (1.0 equiv) was added as a solution in toluene (total 
concentration 0.033 M). The vial was sealed with a teflon cap stirred at ambient 
temperature or at 40 °C. When complete consumption of the starting material was 
observed by thin layer chromatography, the reaction mixture was removed from the 
glovebox and concentrated under reduced pressure. The residue was purified by silica gel 
flash chromatography to afford the desired tertiary hydroxyl product. 
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2-allyl 1-(tert-butyl) 4-benzoyl-2-fluoro-3-oxopiperazine-1,2-dicarboxylate (A7.1). 
Sodium hydride (60% in mineral oil, 11 mg, 0.28 mmol, 1.1 equiv) was added to a 
solution of 2-allyl 1-(tert-butyl) 4-benzoyl-3-oxopiperazine-1,2-dicarboxylate4Ref (100 
mg, 0.26 mmol, 1.0 equiv) in THF (0.1 M) at 0 °C. After stirring for 30 min at 0 °C, 
Selectfluor (109 mg, 0.31 mmol, 1.2 equiv) was added. The reaction mixture was allowed 
to warm to room temperature and stirred for 16 h. The reaction was quenched with 
aqueous NH4Cl (10 mL) and extracted with EtOAc (3 x 5 mL). The combined organic 
phases were dried over anhydrous Na2SO4, decanted, and concentrated under reduced 
pressure onto silica gel. After purification by silica gel flash chromatography 
(Et2O/toluene 3% → 5%), the fluorinated ester A7.2 was isolated as a colorless oil (70 
mg, 67% yield): 1H NMR (400 MHz, CDCl3) δ 7.67 – 7.48 (m, 3H), 7.48 – 7.29 (m, 
2H), 5.93 (ddt, J = 17.3, 10.4, 5.9 Hz, 1H), 5.46 – 5.21 (m, 2H), 4.84 – 4.63 (m, 2H), 4.21 
(m, 1H), 4.15 – 3.92 (m, 2H), 3.83 (m, 1H), 1.49 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 
171.7, 163.3 (d, JCF = 36 Hz), 162.5 (d, JCF = 29 Hz), 152.5, 133.8, 132.9, 130.9, 128.5, 
128.2, 119.9, 95.4 (d, JCF = 227 Hz), 84.7, 67.7, 42.9, 41.2, 28.1; IR (Neat Film, NaCl) 
3426, 3064, 2982, 2936, 1787, 1724, 1704, 1651, 1600, 1584, 1451, 1382, 1368, 1359, 
1322, 1274, 1233, 1157, 1082, 1045, 1012, 993, 942, 849, 800, 774, 756, 725, 696, 624 
cm-1; HRMS (MM: ESI-APCI) m/z calculated for [C20H27FN3O6] ([M+NH4]+): 
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tert-butyl (R)-2-allyl-4-benzoyl-2-hydroxy-3-oxopiperazine-1-carboxylate (A7.2). 
Following general procedure B, fluorinated allyl ester A7.1 (10 mg, 0.025 mmol, 1.0 
equiv) in hexanes/toluene (2:1, 1.3 mL) was added to a solution of Pd2(dba)3 (0.9 mg, 
0.0098 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (1.5 mg, 0.0025 mmol, 10 mol %) in 
hexanes/toluene (2:1, 0.5 mL). The reaction was stirred at 40 °C for 16 h. Purification by 
flash chromatography (10 → 15% EtOAc/hexanes) gave hydroxypiperazinone A7.2 as a 
yellow oil (5 mg, 50% yield, 77% ee): 1H NMR (400 MHz, CDCl3) δ 7.70 – 7.58 (m, 
2H), 7.58 – 7.48 (m, 1H), 7.41 (dd, J = 8.3, 6.9 Hz, 2H), 5.74 (ddt, J = 17.5, 10.2, 7.4 Hz, 
1H), 5.28 – 5.08 (m, 3H), 4.00 (t, J = 4.0 Hz, 2H), 3.86 (ddt, J = 11.0, 7.8, 3.9 Hz, 1H), 
3.62 (dt, J = 13.9, 5.6 Hz, 1H), 3.2 (dd, J = 13.7, 7.2 Hz, 1H), 3.06 (dd, J = 13.7 fHz, 7.5 
Hz, 1H), 1.54 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 172.3, 169.8, 154.5, 134.8, 132.2, 
131.6, 128.4, 128.2, 120.4, 88.1, 82.6, 43.8, 42.4, 42.1, 28.5; IR (Neat Film, NaCl) 
3375, 2978, 1714, 1600, 1513, 1394, 1368, 1253, 1172, 1028, 987, 833, 735 cm-1; 
HRMS (MM: ESI-APCI): m/z calc’d for C19H25N2O5 [M+H]+: 361.1758, found 
361.1751; [α]D23.4 +5.2 (c 0.33, CHCl3); SFC conditions: 20% IPA, 2.5 mL/min, 















allyl 2-hydroxy-1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate (A7.3). 
Following general procedure B: to a solution of iodine (11 mg, 0.04 mmol, 0.02 equiv) 
and samarium (III) triflate (65 mg, 0.11 mmol, 0.05 equiv) in a 1:5 mixture of H2O/THF 
(24 mL) was added allyl 1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate (500 mg, 
2.17 mmol, 1 equiv). The reaction was stirred for 72 h. Purification by silica gel flash 
chromatography (20 → 30% EtOAc/hexanes) afforded alcohol A7.3 as a clear oil (450 
mg, 84% yield): 1H NMR (400 MHz, CDCl3) δ 8.03 (dd, J = 7.8, 1.6 Hz, 1H), 7.51 (ddd, 
J = 9.1, 6.6, 1.6 Hz, 1H), 7.32 (td, J = 7.2, 6.6, 1.6 Hz, 1H), 7.24 (d, J = 7.8 Hz, 1H), 5.80 
(ddtd, J = 16.6, 11.0, 5.6, 1.5 Hz, 1H), 5.23 – 5.08 (m, 2H), 4.62 (d, J = 5.4 Hz, 2H), 4.39 
(s, 1H), 3.10 (d, J = 5.6 Hz, 2H), 2.71 (ddd, J = 13.7, 6.0, 4.3 Hz, 1H), 2.24 (ddd, J = 
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130.3, 129.0, 128.2, 127.2, 127.0, 118.7, 77.8, 66.4, 32.7, 30.2, 25.6; IR (Neat Film, 
NaCl) 3466, 3073, 3026, 2939, 1745 1689, 1649, 1602,1485, 1456, 1377, 1333, 1292, 
1239, 1191, 1159, 1139, 1109, 1035, 996, 970, 944, 919, 806, 744, 690, 661 cm-1; 




allyl 1-hydroxy-2-oxo-1,2,3,4-tetrahydronaphthalene-1-carboxylate (A7.5). To a 
suspension of NaH (60% in mineral oil, 684 mg, 17.1 mmol, 2.5 equiv) in THF (20 mL) 
at 0 °C was added 2-tetralone (1g, 6.84 mmol, 1 equiv) dropwise, producing a yellow-
green solution. The solution was stirred for 30 min at 0 °C before adding diallyl 
carbonate (1.47 mL, 10.3 mmol, 1.5 equiv) dropwise. The reaction was heated to reflux 
for 16 h, resulting in a dark orange-gold color. The reaction was quenched with aq. 
NH4Cl (20 mL) and then extracted with EtOAc (3x15 mL). The combined organic layers 
were dried with Na2SO4 and then concentrated under reduced pressure. Purification of the 
crude reaction mixture with silica gel flash chromatography (0 → 2.5 → 4% 
EtOAc/hexanes) afforded the intermediate allyl β-ketoester, which was then used in the 
following hydroxylation reaction following general procedure A: a solution of the β-
ketoester (400 mg, 1.74 mmol, 1 equiv) and CeCl3-7H2O (32 mg, 0.087 mmol, 0.05 
equiv) in iPrOH (17 mL, 0.1 M) was evacuated and filled with O2 three times. The 
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yellow over the course of the reaction. The solvent was removed under reduced pressure 
and the crude product was purified by silica gel Teledyne ISCO automated flash 
chromatography (0 → 50% Et2O/hexanes) to afford alcohol A7.5 as a clear oil (200 mg, 
47% yield): 1H NMR (400 MHz, CDCl3) δ 7.70 – 7.60 (m, 1H), 7.38 – 7.27 (m, 2H), 
7.27 – 7.17 (m, 1H), 5.80 (ddt, J = 17.0, 10.6, 5.6 Hz, 1H), 5.23 – 5.16 (m, 1H), 5.15 (dq, 
J = 12.9, 1.6 Hz, 1H), 4.61 (t, J = 1.4 Hz, 1H), 4.60 – 4.57 (m, 2H), 3.40 – 3.27 (m, 1H), 
3.14 – 2.99 (m, 2H), 2.74 – 2.59 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 206.9, 169.1, 
136.0, 134.6, 130.9, 129.0, 128.0, 127.5, 126.5, 119.1, 79.8, 66.8, 34.6, 27.5; IR (Neat 
Film, NaCl) 3455, 3071, 3026, 2946, 1748, 1727, 1651, 1484, 1455, 1360, 1245, 1209, 
1160, 1122, 1070, 1025, 990, 944, 749, 651 cm-1; HRMS (MM: ESI-APCI): m/z calc’d 
for [C14H18NO4] ([M+NH4]+): 264.1230, found 264.1228. 
 
 
Following general procedure B, tetralone A7.3 or A7.5 (20 mg, 0.081 mmol, 1 equiv) in 
toluene (2.0 mL) was added to a solution of Pd2(pmdba)3 (3.6 mg, 0.0032 mmol, 4 mol 
%) and ANDEN (S,S)-L3 (6.6 mg, 0.008 mmol, 10 mol %) or (S)-L1 (4.8 mg, 0.008 
mmol, 10 mol %) in toluene (0.5 mL). Purification by silica gel flash chromatography 
(15% EtOAc/hexanes) gave α-tertiary tetralones A7.4a and A7.4b as a mixture, the ratio 
of which was determined by 1H NMR. Product identities of A7.4a and A7.4b were 
confirmed by comparison to previously reported characterization data. SFC conditions: 
7% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): For 4b: major = 














Note: Based on relative retention times, ANDEN (S,S)-L3 gives the opposite enantiomer 
of the product 4b compared to (S)-L1 and (S)-L2, [(S)-t-BuPHOX/(S)-CF3-t-BuPHOX]. 
 
 
allyl 1-hydroxy-2-oxocyclohexane-1-carboxylate A7.6a.  A solution of allyl 2-
oxocyclohexane-1-carboxylate (1.7 g, 9.33 mmol, 1 equiv) and CeCl3-7H2O (173 mg, 
0.47 mmol, 0.05 equiv) in i-PrOH (93 mL) was evacuated and filled with O2 three times. 
The solution was stirred for 1 hour at room temperature, changing color from clear to 
light pink over the course of the reaction. The solvent was removed under reduced 
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20% EtOAc/hexanes) to afford alcohol 6a as a clear oil (1.11 g, 60% yield): 1H NMR 
(400 MHz, CDCl3) δ 5.89 (ddt, J = 17.2, 10.4, 5.8 Hz, 1H), 5.38 – 5.19 (m, 2H), 4.66 (dt, 
J = 5.8, 1.4 Hz, 2H), 4.35 (s, 1H), 2.71 – 2.59 (m, 2H), 2.55 (ddd, J = 14.1, 11.8, 6.1 Hz, 
1H), 2.13 – 1.96 (m, 1H), 1.96 – 1.77 (m, 2H), 1.77 – 1.58 (m, 2H); 13C NMR (101 
MHz, CDCl3) δ 207.3, 169.8, 131.2, 119.4, 80.8, 66.5, 39.0, 37.8, 27.2, 22.1; IR (Neat 
Film, NaCl) 3780, 3458, 3087, 2947, 2869, 2668, 2403, 1727, 1649, 1452, 1425, 1374, 
1337, 1311, 1247, 1207, 1132, 1116, 1094, 1054, 984, 937, 853, 817, 792, 714, 689, 618 
cm-1; HRMS (MM: ESI-APCI) m/z calculated for [C10H18NO4] ([M+NH4]+): 
216.1230, found 216.1232.  
 
(R)-2-allyl-2-hydroxycyclohexan-1-one (A7.7a). Following general procedure B, 
ketoester A7.6a (15 mg, 0.076 mmol, 1.0 equiv) in toluene (1.8 mL) was added to a 
solution of Pd2(pmdba)3 (3.3 mg, 0.003 mmol, 4 mol %) and (S)-(CF3)3-tBu-PHOX (4.5 
mg, 0.0076 mmol, 10 mol %) in toluene (0.5 mL). The reaction was stirred at ambient 
temperature for 16 h. Purification by flash chromatography (15% EtOAc/hexanes) gave 
α-hydroxycyclohexanone A7.7a as a yellow oil (10 mg, 85% yield, 70% ee): 1H NMR 
(400 MHz, CDCl3) δ 5.72 (ddt, J = 16.6, 10.6, 7.2 Hz, 1H), 5.16 – 5.06 (m, 2H), 3.95 (s, 
1H), 2.59 (ddt, J = 14.0, 7.4, 1.1 Hz, 1H), 2.55 – 2.43 (m, 2H), 2.48 – 2.38 (m, 1H), 2.22 
(dq, J = 13.0, 3.0 Hz, 1H), 2.16 – 2.05 (m, 1H), 1.89 – 1.56 (m, 4H); 13C NMR (101 
MHz, CDCl3) δ 213.7, 131.8, 118.9, 78.9, 41.9, 40.5, 38.4, 27.9, 22.7. IR (Neat Film, 
NaCl) 3475, 3073, 2939, 2864, 1711, 1639, 1441, 1379, 1309, 1242, 1156, 1128, 1078, 
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[M+NH4]+: 172.1332, found 172.1328; [α]D23.0 –10.2 (c 1.0, CHCl3); Chiral GC 
conditions: Astec® CHIRALDEX G-TA column, 100 °C isotherm, tR (min): major = 







2-methylallyl 1-hydroxy-2-oxocyclohexane-1-carboxylate (A7.6b). Note: While 
general procedure A using catalytic CeCl3-7H2O was successful, it led to a mixture that 
was more difficult to purify. Thus, we used general procedure B: to a solution of iodine 
(10 mg, 0.04 mmol, 0.02 equiv) and samarium (III) triflate (60 mg, 0.10 mmol, 0.05 
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1-carboxylateRef (400 mg, 2.0 mmol, 1 equiv). The reaction was stirred for 72 h. 
Purification by silica gel flash chromatography (1 → 2% Et2O/CH2Cl2) afforded alcohol 
A7.6b as a clear oil (240 mg, 55% yield): 1H NMR (400 MHz, CDCl3) δ 5.01 – 4.91 (m, 
2H), 4.65 – 4.54 (m, 2H), 4.36 (s, 1H), 2.74 – 2.60 (m, 2H), 2.55 (ddd, J = 14.0, 11.7, 6.0 
Hz, 1H), 2.04 (ddtd, J = 14.4, 6.4, 4.2, 3.8, 1.9 Hz, 1H), 1.94 – 1.76 (m, 2H), 1.74 (t, J = 
1.2 Hz, 3H), 1.73 – 1.62 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 207.3, 169.9, 139.1, 
114.0, 80.9, 69.2, 39.0, 37.7, 27.2, 22.1, 19.6; IR (Neat Film, NaCl) 3457, 3084, 2947, 
2869, 1722, 1660, 1451, 1378, 1247, 1205, 1116, 1093, 1055, 991, 960, 907, 852, 814, 
785, 686, 619 cm-1; HRMS (MM: ESI-APCI) m/z calculated for [C11H20NO4] 
([M+NH4]+): 230.1387, found 230.1382. 
 
(R)-2-hydroxy-2-(2-methylallyl)cyclohexan-1-one (A7.7b). Following general 
procedure C, alcohol A7.6b (15 mg, 0.071 mmol, 1.0 equiv) in toluene (1.6 mL) was 
added to a solution of [Pd2(pmdba)3] (3.1 mg, 0.0028 mmol, 4 mol %) and (S)-(CF3)3-t-
BuPHOX (4.2 mg, 0.0071 mmol, 10 mol %) in toluene (0.5 mL). Purification by flash 
chromatography (10% EtOAc/hexanes) gave alcohol A7.7b as a clear oil (10 mg, 84% 
yield, 75% ee): 1H NMR (400 MHz, CDCl3) δ 4.86 (dd, J = 2.1, 1.4 Hz, 1H), 4.73 (dd, J 
= 2.0, 1.0 Hz, 1H), 3.94 (s, 1H), 2.65 – 2.47 (m, 3H), 2.43 (dd, J = 13.8, 1.0 Hz, 1H), 
2.24 (dq, J = 13.2, 3.1 Hz, 1H), 2.19 – 2.06 (m, 1H), 1.86 – 1.72 (m, 5H), 1.72 – 1.56 (m, 
2H); 13C NMR (101 MHz, CDCl3) δ 214.1, 141.0, 115.2, 79.5, 45.3, 41.4, 38.7, 28.2, 
24.2, 23.0; IR (Neat Film, NaCl) 3482, 3073, 2941, 2865, 2358, 1709, 1644, 1452, 




Appendix 7 – Decarboxylative Asymmetric Allylic Alkylation of Tertiary Alcohols  
  
(MM: ESI-APCI): m/z calc’d for [C10H20NO2] ([M+NH4]+): 186.1489, found 
186.1482; [α]D23.3 –28.2 (c 0.33, CHCl3); Chiral GC conditions: Astec® CHIRALDEX 






allyl 1-hydroxy-2-oxocycloheptane-1-carboxylate A7.6c.  Following general procedure 
A: A solution of allyl 2-oxocycloheptane-1-carboxylate (500 mg, 2.55 mmol, 1 equiv) 
and CeCl3-7H2O (47 mg, 0.13 mmol, 0.05 equiv) in i-PrOH (25 mL) was stirred for 1 
hour at room temperature, changing color from clear to yellow/golden-green over the 
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(20% Et2O/hexanes) to afford alcohol A7.6c as a clear oil (340 mg, 63% yield): 1H NMR 
(500 MHz, CDCl3) δ 5.86 (ddt, J = 17.3, 10.4, 5.7 Hz, 1H), 5.37 – 5.14 (m, 2H), 4.61 (d, 
J = 5.8 Hz, 2H), 4.30 (d, J = 1.6 Hz, 1H), 2.93 (td, J = 12.0, 2.9 Hz, 1H), 2.56 (ddd, J = 
11.7, 7.2, 2.2 Hz, 1H), 2.34 – 2.18 (m, 1H), 2.18 – 2.02 (m, 1H), 1.95 (tq, J = 6.3, 1.7 Hz, 
1H), 1.88 – 1.72 (m, 2H), 1.46 (qdd, J = 8.1, 3.9, 2.3 Hz, 2H), 1.37 – 1.22 (m, 1H); 13C 
NMR (126 MHz, CDCl3) δ 209.5, 170.3, 131.2, 119.2, 83.6, 66.5, 40.0, 34.5, 30.2, 27.2, 
23.7; IR (Neat Film, NaCl) 3790, 3471, 2928, 2857, 2350, 1746, 1722, 1712, 1681, 
1453, 1370, 1319, 1268, 1224, 1196, 1167, 1110, 1082, 1038, 992, 938 cm-1; HRMS 
(MM: ESI-APCI) m/z calculated for [C11H16O4] [M+H]+: 213.1121, found 213.1119. 
 
 
(R)-2-allyl-2-hydroxycycloheptan-1-one (A7.7c). Following general procedure C, 
alcohol A7.6c (20 mg, 0.094 mmol, 1.0 equiv) in toluene (2.3 mL) was added to a 
solution of [Pd2(pmdba)3] (4.1 mg, 0.0038 mmol, 4 mol %) and (S)-(CF3)3-t-BuPHOX 
(5.6 mg, 0.0094 mmol, 10 mol %) in toluene (0.5 mL). Purification by flash 
chromatography (10% EtOAc/hexanes) gave alcohol A7.7c as a clear oil (12 mg, 75% 
yield, 78% ee): 1H NMR (400 MHz, CDCl3) δ 5.73 (ddt, J = 17.0, 10.3, 7.3 Hz, 1H), 
5.19 – 4.95 (m, 2H), 3.83 (d, J = 1.5 Hz, 1H), 2.74 – 2.63 (m, 1H), 2.50 – 2.29 (m, 3H), 
2.07 – 1.93 (m, 2H), 1.91 – 1.81 (m, 1H), 1.81 – 1.71 (m, 1H), 1.67 (ddt, J = 14.9, 10.8, 
1.3 Hz, 1H), 1.51 – 1.31 (m, 2H), 1.31 – 1.17 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 
215.6, 132.2, 118.9, 81.4, 44.7, 39.0, 36.8, 30.6, 27.4, 23.6; IR (Neat Film, NaCl) 3481, 
3076, 2928, 2858, 2357, 1703, 1639, 1506, 1453, 1379, 1341, 1320, 1232, 1174, 1141, 
OHO
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1103, 1076, 1062,1043, 996, 947, 918, 839, 789, 671, 633 cm-1; HRMS (MM: ESI-
APCI): m/z calc’d for [C10H17O2] [M+H]+: 169.1223, found 169.1224; [α]D23.8 –53.3 (c 
1.0, CHCl3); Chiral GC conditions: Astec® CHIRALDEX G-TA column, 100 °C 






allyl 1-hydroxy-2-oxocyclopentane-1-carboxylate A7.6d. Following general procedure 
B, to a solution of iodine (15 mg, 0.06 mmol, 0.02 equiv) and samarium (III) triflate (89 
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oxocyclopentane-1-carboxylate (500 mg, 2.97 mmol, 1 equiv). The reaction was stirred 
for 72 h. Purification by silica gel flash chromatography (20% EtOAc/hexanes) afforded 
alcohol A7.6d as a clear oil (200 mg, 36% yield): 1H NMR (400 MHz, CDCl3) δ 5.86 
(ddt, J = 17.2, 10.4, 5.7 Hz, 1H), 5.34 – 5.21 (m, 2H), 4.66 (ddt, J = 5.6, 2.7, 1.4 Hz, 2H), 
3.74 (s, 1H), 2.56 – 2.35 (m, 3H), 2.09 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 213.3, 
171.4, 131.1, 119.3, 79.9, 66.9, 35.9, 34.9, 18.5; IR (Neat Film, NaCl) 3473, 3088, 
2965, 2893, 1758, 1737, 1649, 1447, 1403, 1363,1258, 1169, 1097, 1051, 982, 939,850, 
817, 788, 649, 618 cm-1; HRMS (MM: ESI-APCI) m/z calculated for [C9H16NO4] 
[M+NH4]+: 202.1074, found 202.1069. 
 
 
(R)-2-allyl-2-hydroxycyclopentan-1-one (A7.7d). Following general procedure C, 
alcohol A7.6d (40 mg, 0.22 mmol, 1.0 equiv) in toluene (4.5 mL) was added to a solution 
of [Pd2(dba)3] (7.7 mg, 0.0087 mmol, 4 mol %) and (S)-(CF3)3-t-BuPHOX (12.8 mg, 
0.022 mmol, 10 mol %) in toluene (2.1 mL). Purification by flash chromatography (15 → 
20% EtOAc/hexanes) gave alcohol A7.7d as a yellow oil (22 mg, 73% yield, 30% ee): 1H 
NMR (400 MHz, CDCl3) δ 5.79 (dddd, J = 16.9, 10.2, 8.1, 6.6 Hz, 1H), 5.31 – 5.08 (m, 
2H), 2.46 (s, 1H), 2.41 – 2.17 (m, 4H), 2.17 – 2.06 (m, 1H), 2.06 – 1.75 (m, 3H); 13C 
NMR (101 MHz, CDCl3) δ 219.4, 131.7, 120.1, 78.6, 40.4, 34.8, 34.6, 17.2; IR (Neat 
Film, NaCl) 3448, 3077, 2968, 2923, 2361, 1745, 1639, 1434, 1403, 1323, 1245, 1167, 
1132, 1064, 1036, 998, 919, 839, 819, 752, 705, 630 cm-1; HRMS (MM: ESI-APCI): 
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CHCl3); Chiral GC conditions: Astec® CHIRALDEX G-TA column, 100 °C isotherm, 





allyl 1-benzoyl-3-hydroxy-2-oxopiperidine-3-carboxylate (A7.6e). Following general 
procedure B: to a solution of iodine (6.7 mg, 0.026 mmol, 0.02 equiv) and samarium (III) 
triflate (40 mg, 0.066 mmol, 0.05 equiv) in a 1:5 mixture of H2O/THF (15 mL) was 
added allyl 1-benzoyl-2-oxopiperidine-3-carboxylate (380 mg, 1.32 mmol, 1.0 equiv). 
The reaction was stirred for 6 days. Purification with silica gel flash chromatography (3:1 
hexanes/EtOAc) afforded A7.6e as an off-white solid (243 mg, 61% yield); 1H NMR 
(400 MHz, CDCl3) δ 7.72 – 7.65 (m, 2H), 7.53 – 7.46 (m, 1H), 7.42 – 7.35 (m, 2H), 5.96 
(ddt, J = 17.3, 10.4, 6.0 Hz, 1H), 5.39 (dq, J = 17.1, 1.4 Hz, 1H), 5.33 (dq, J = 10.3, 1.2 
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1H), 2.61 – 2.47 (m, 1H), 2.22 – 2.01 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 174.0, 
172.1, 170.7, 134.9, 132.2, 130.9, 128.3, 128.2, 119.9, 76.9, 67.3, 46.7, 32.4, 19.3; IR 
(Neat Film, NaCl) 3459, 2954, 1747, 1682, 1600, 1478, 1450, 1393, 1270, 1178, 1141, 
992, 947, 796, 727, 694, 662 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for 
C16H18NO5 [M+H]+: 304.1179, found 304.1182; 
 
 
(R)-3-allyl-1-benzoyl-3-hydroxypiperidin-2-one (7e). Following general procedure C, 
α-hydroxylated allyl ester A7.6e (10 mg, 0.033 mmol, 1.0 equiv) in toluene (0.5 mL) was 
added to a solution of [Pd2(dba)3] (1.2 mg, 1.3 µmol, 0.040 equiv) and (S)-(CF3)3-t-Bu-
PHOX (2.0 mg, 3.3 µmol, 0.10 equiv) in toluene (0.5 mL). The reaction was stirred at 40 
°C for 16 h. Purification by flash chromatography (15% EtOAc/hexanes) gave α-hydroxy 
piperidinone A7.7e as a colorless oil (6.8 mg, 79% yield, 92% ee): 1H NMR (400 MHz, 
CDCl3) δ 7.59 – 7.54 (m, 2H), 7.52 – 7.48 (m, 1H), 7.40 (t, J = 7.5 Hz, 2H), 5.87 (ddt, J 
= 17.4, 10.4, 7.1 Hz, 1H), 5.31 – 5.20 (m, 2H), 3.88 (dtd, J = 12.8, 4.7, 1.6 Hz, 1H), 3.84 
– 3.74 (m, 1H), 3.31 (s, 1H), 2.66 (d, J = 7.2 Hz, 2H), 2.27 – 2.17 (m, 1H), 2.10 – 1.98 
(m, 2H), 2.01 – 1.89 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 178.9, 174.6, 135.6, 132.1, 
131.4, 128.5, 127.9, 120.3, 74.2, 47.4, 44.1, 33.1, 20.0; IR (Neat Film, NaCl) 3478, 
2953, 1682, 1450, 1391, 1286, 1149, 1072, 998, 928, 795, 726, 694, 662 cm-1; HRMS 
(MM: ESI-APCI): m/z calc’d for C15H18NO3 [M+H]+: 260.1281, found 260.1278; 
[α]D23.1 +9.7 (c 0.64, CHCl3); SFC conditions: 20% IPA, 2.5 mL/min, Chiralpak OD-H 













Allyl 2-(hydroxymethyl)-1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate (A7.8). 
To a solution of allyl 1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate (200 mg, 0.87 
mmol, 1.0 equiv) in THF (1.6 mL) at 0 °C was added potassium bicarbonate (261 mg, 
2.61 mmol, 3.0 equiv) and aqueous 37% formaldehyde (420 uL, 5.65 mmol, 6.5 equiv). 
The mixture was allowed to warm to room temperature and stirred for 3 h. Water (2 mL) 
was added and the mixture was extracted with CH2Cl2 (4 x 2 mL). The combined organic 
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residue was taken up in THF and 1 drop of 1 M aqueous HCl was added. The solution 
was stirred for 20 minutes before being concentrated under reduced pressure onto silica 
gel and then purified by silica gel flash chromatography (20 → 25% EtOAc/hexanes) to 
give alcohol A7.8 as a clear oil (195 mg, 86% yield): 1H NMR (400 MHz, CDCl3) δ 
8.06 (dd, J = 8.0, 1.6 Hz, 1H), 7.49 (td, J = 7.5, 1.4 Hz, 1H), 7.33 (t, J = 7.6 Hz, 1H), 7.28 
– 7.17 (m, 1H), 5.88 – 5.68 (m, 1H), 5.22 – 5.08 (m, 2H), 4.62 (ddd, J = 5.3, 3.5, 1.6 Hz, 
2H), 4.11 – 3.98 (m, 1H), 3.91 (dd, J = 11.4, 9.9 Hz, 1H), 3.42 – 3.28 (m, 1H), 3.10 – 
2.89 (m, 2H), 2.45 (dt, J = 13.6, 4.4 Hz, 1H), 2.18 (ddd, J = 13.5, 10.9, 5.2 Hz, 1H); 13C 
NMR (101 MHz, CDCl3) δ 197.3, 171.0, 143.3, 134.2, 132.0, 131.4, 128.9, 127.9, 127.1, 
118.4, 66.4, 66.0, 59.3, 29.2, 26.0; IR (Neat Film, NaCl) 3521, 3071, 3024, 2940,2881, 
1731, 1681, 1650, 1600, 1455, 1414, 1354, 1315, 1268, 1239, 1185, 1137, 1086, 1048, 
942, 805,787, 745, 689, 654 cm-1; HRMS (MM: ESI-APCI): m/z calc’d for [C15H17O4] 
[M+H]+: 261.1121, found 261.1117. 
 
 
Following general procedure C, alcohol A7.8 (52 mg, 0.20 mmol, 1.0 equiv) in toluene 
(4.0 mL) was added to a solution of [Pd2(dba)3] (7.3 mg, 0.008 mmol, 4 mol %) and 
(S,S)- ANDEN (L3) (16 mg, 0.02 mmol, 10 mol %) in toluene (2.0 mL). The reaction 
was stirred at ambient temperature for 16 h. Purification by flash chromatography (20 → 
25% EtOAc/hexanes) gave primary alcohol A7.9 as a clear oil (27 mg, 63% yield, 92% 
ee): 1H NMR (400 MHz, CDCl3) δ 8.02 (dd, J = 8.0, 1.4 Hz, 1H), 7.50 (td, J = 7.5, 1.5 
Hz, 1H), 7.32 (tdd, J = 7.8, 1.6, 0.9 Hz, 1H), 7.26 (m, 1H), 5.89 – 5.73 (m, 1H), 5.21 – 
O OH
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5.09 (m, 2H), 3.77 – 3.63 (m, 2H), 3.20 – 3.07 (m, 1H), 2.92 (dt, J = 17.4, 4.6 Hz, 1H), 
2.85 (dd, J = 8.5, 4.9 Hz, 1H), 2.58 – 2.46 (m, 1H), 2.35 (ddt, J = 13.9, 8.1, 1.1 Hz, 1H), 
2.05 (ddd, J = 13.7, 11.5, 5.1 Hz, 1H), 1.93 (ddd, J = 13.8, 5.1, 3.9 Hz, 1H); 13C NMR 
(101 MHz, CDCl3) δ 204.0, 143.6, 133.9, 132.9, 131.6, 129.0, 127.9, 127.0, 119.2, 66.5, 
49.2, 34.8, 28.0, 24.9. IR (Neat Film, NaCl) 3459, 3072, 2928, 1673, 1600, 1454, 1357, 
1287, 1229, 1156, 1043, 997, 919, 793, 741 cm-1; HRMS (MM: ESI-APCI): m/z calc’d 
for [C14H17O4 ] [M+H]+: 217.1223, found 217.1214; [α]D22.9 +39.1 (c 1.00, CHCl3); 
SFC conditions: 3% IPA, 2.5 mL/min, Chiralpak OJ–H column, λ = 210 nm, tR (min): 
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Figure A8.2 Infrared spectrum (Thin Film, NaCl) of compound A7.1. 
 
Figure A8.3 13C NMR (101 MHz, CDCl3) of compound A7.1. 
 





































Figure A8.5 Infrared spectrum (Thin Film, NaCl) of compound A7.2. 
 
 Figure A8.6 13C NMR (101 MHz, CDCl3) of compound A7.2. 
 





































Figure A8.8 Infrared spectrum (Thin Film, NaCl) of compound A7.3. 
 
Figure A8.9  13C NMR (101 MHz, CDCl3) of compound A7.3. 
 






































Figure A8.11 Infrared spectrum (Thin Film, NaCl) of compound A7.5. 
 
Figure A8.12 13C NMR (101 MHz, CDCl3) of compound A7.5. 
 






































Figure A8.14 Infrared spectrum (Thin Film, NaCl) of compound A7.6a. 
 
Figure A8.15 13C NMR (101 MHz, CDCl3) of compound A7.6a. 
 






































Figure A8.17 Infrared spectrum (Thin Film, NaCl) of compound A7.6b. 
 
Figure A8.18 13C NMR (101 MHz, CDCl3) of compound A7.6b. 
 






































Figure A8.20 Infrared spectrum (Thin Film, NaCl) of compound A7.6c. 
 
Figure A8.21 13C NMR (126 MHz, CDCl3) of compound A7.6c. 
 






































Figure A8.23 Infrared spectrum (Thin Film, NaCl) of compound A7.6d. 
 
Figure A8.24 13C NMR (126 MHz, CDCl3) of compound A7.6d. 
 






































Figure A8.26 Infrared spectrum (Thin Film, NaCl) of compound 
A7.6d. 
Figure A8.27  13C NMR (101 MHz, CDCl3) of compound A7.6d. 
 






































Figure A8.29 Infrared spectrum (Thin Film, NaCl) of compound A7.6e. 
 
Figure A8.30  13C NMR (101 MHz, CDCl3) of compound A7.6e. 
 






































Figure A8.32 Infrared spectrum (Thin Film, NaCl) of compound A7.7a. 
 
Figure A8.33  13C NMR (101 MHz, CDCl3) of compound A7.7a. 
 






































Figure A8.35  Infrared spectrum (Thin Film, NaCl) of compound A7.7b. 
 
Figure A8.36   13C NMR (101 MHz, CDCl3) of compound A7.7a. 
 






































Figure A8.38 Infrared spectrum (Thin Film, NaCl) of compound A7.7c. 
 
Figure A8.39  13C NMR (101 MHz, CDCl3) of compound A7.7c. 
 






































Figure A8.41 Infrared spectrum (Thin Film, NaCl) of compound 
A7.7d. 
Figure A8.42 13C NMR (101 MHz, CDCl3) of compound A7.7d. 
 






































Figure A8.44 Infrared spectrum (Thin Film, NaCl) of compound 
A7.7e. 
 Figure A8.45 13C NMR (101 MHz, CDCl3) of compound A7.7e. 
 








































Figure A8.47 Infrared spectrum (Thin Film, NaCl) of compound A7.8. 
 
Figure A8.48 13C NMR (101 MHz, CDCl3) of compound A7.8. 
 







































Figure A8.50 Infrared spectrum (Thin Film, NaCl) of compound A7.9. 
 
Figure A8.51 13C NMR (101 MHz, CDCl3) of compound A7.9. 
 







































Figure A8.53 Infrared spectrum (Thin Film, NaCl) of compound A7.11. 
 
Figure A8.54 13C NMR (101 MHz, CDCl3) of compound A7.11. 
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